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Chapter 1 
1. INTRODUCTION 
 
1.1 Aim of the study 
According to the literature radioactive iodine 131I has been used for many years to treat benign thyroid 
disease. Also, treatment of thyroid cancer with Na131I is the most common application of radionuclide 
therapy in nuclear medicine and has been in use for many decades. At the Institute of 
pathophysiology and nuclear medicine this kind of radiotherapy is performed since 1956 y [1].  
Whenever radiation is used in the treatment of the benign or cancer diseases, dosimetry is essential. 
The treatment must deliver the right dose to the target tissue of thyroid gland in the case of 
hyperthyroidism or residual thyroid volume in the case of the thyroid cancer patients, without harming 
other organs.  
The main aim of this study is to simulate dosimetry of internal organs and risk assessment using 
MCNP 4b code in the case of performing radioiodine therapy either for hyperthyroid or thyroid cancer 
patients [2]. To search a safety optimization in this kind of therapy, it was recognized the necessity of 
more accurate knowledge of dose levels received by stomach and other organs. The study is focused 
on the dose determination due to 131I administration in thyroid treatment in internal organs. Very 
important is to know the effective dose that will be reached in gastric. The main aims of this thesis 
are: 
1. To calculate dose equivalents, effective doses for internal organs under the risk during 
therapy application of radioiodine using numerical simulations and to confirm all introduced 
assumptions.  
2. To perform external measurement of dose rates (µSv/h) of thyroid cancer and hyperthyroid 
patients at 0.25 m, 0.5 m, 1.0 m and 2.0 m different distances. 
3. To estimate with TLD’s effective dose at the surface of the skin above region of gastric for 15 
minutes after administration and during three days of hospitalization of patients. 
4. To determinate additional risks of lifetime mortality of hyperthyroid and thyroid cancer 
patients. 
An additional aim of this study was to provide information to be used in the improvement of radiation 
therapy, radiation safety practices and improvement of the fundamentals of radiation protection as 
defined by International Commission on Radiological Protection (ICRP): justification, optimization and 
application of dose limits. 
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1.2. Significance of the research 
1.2.1 Objectives 
The objective of this research was to determine the radiation – absorbed dose to the organs that were 
likely to receive significant doses from the capsule 131I or in the form of capsule or solution for 
treatment of hyperthyroid and thyroid cancer patient. This was achieved by using computer codes that 
were executed with Monte Carlo N-particle-4b to calculate the doses to organs of interest [2].  
 
1.2.2 Practical dosimetry: Benefits vs. risks 
For many decades, radiation has been beneficial in both diagnostic and therapeutic nuclear medicine. 
Radiation was used to diagnose and treat the cancer with processes such as ablation as in 131I 
therapy to treat thyroid cancer.  
The long-term benefit of undergoing this treatment is the minimized probability of reoccurring tumors, 
adding years to the patient’s lives and allowing them to proceed with their regular daily activities. 
Although there are significant benefits to undergoing this therapy, there are also certain issues that 
must be considered. These issues include side effects and radiation safety. The focus of this research 
is to the dose delivered to the stomach and other organs while undergoing this therapy since the 
capsule is dissolved and start absorption process. The dose delivered to the thyroid gland is expected 
to be high in these typical treatments. This research is important because, since the radiation dose to 
the thyroid gland should be large, the other organs and stomach are at risk of receiving high radiation 
doses. 
As we study the details of dose calculations, it is possible to develop carefully the minimum 
requirements for performing an adequate calculation of radiation dose. With more and more data, 
constantly gathered the quality of the results and approaches will improve. The data analysis requires 
the time and attention of skilled professionals. 
When only fixed dosages of radiopharmaceuticals are administered to all patients with no study 
whatsoever of radiation doses received, it is impossible to optimize individual subjects’ therapies or to 
advance our understanding of dose–effect relationships and how to provide the best treatments for 
our patients. Although, gathering data and dosimetry modeling requires significantly more efforts and 
is difficult to implement day to day practice, it is worthwhile in providing the patient with a better quality 
of care and expectancy for a positive outcome from therapy [3].  
The significance of this research is that the doses to internal organs can be determined and it worth to 
mention that such internal dosimetry calculation has been performed rare in the field of nuclear 
medicine.  
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We hope that in accordance with the calculations carried out during this study and reference available 
in the literature that we will improve therapy practice at Institute of pathophysiology and nuclear 
medicine, Faculty of medicine, “Ss. Cyril and Methodius” University, Skopje, Macedonia. 
Designed quality programs will be useful also for regulatory and accreditation bodies in the process of 
accreditation and radiation protection strategy. The results of this investigation will improve safety 
culture in the health care system and also among authorities who make regulatory decisions.  
 
1.2.3 Summary of this dissertation 
This work is divided into interconnected chapters. Chapters 2 to 4 contain the literature review, history 
and theoretical background to the study. The basic physics and dosimetry theory applied in beta 
radiation, particularly to the 131I are also discussed in chapter 2. Chapter 3 covers material and 
methods and aspects of the Monte Carlo transport code and focuses on the MCNP4b code which was 
used in this study. Chapter 4 provides the results and the discussion of the findings. Finally, the 
conclusions and recommendations and future research are discussed in Chapter 5.  
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Chapter 2 
2. BASIC PHYSICS AND DOSIMETRY THEORY                                                                                                                  
 
2.1 Introduction 
The physics of the interaction of radiation with matter is used in nuclear medicine, radiation therapy, 
diagnostic radiology and other areas of medical physics. In order to optimize treatment in 
radiotherapy, the way in which radiation energy is transferred to and absorbed by the patient’s body 
must be investigated [4]. The main subject of interest in dosimetry is the mechanism of energy 
deposition in the matter by radiation [5]. 
Photons require an intermediate interaction stage of transferring energy first to atomic electrons 
before any transfer of energy to the medium can take the place since charged particles lose energy in 
a totally different manner to photons. Electrons start to lose energy immediately to the medium [5]. 
The basic physics of beta (β) particles, photons, dosimetry quantities and radiation dose distributions 
are discussed in the next sections. 
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2.2 Main types of ionizing radiation 
Ionizing radiation can be divided into two categories. The first is called directly ionizing radiation and 
is composed of charged particles. Such charged particles include beta (β) particles, protons and alpha 
(α) particles, which require sufficient kinetic energy to produce collision and radioactive ionization 
when penetrating the absorber. The ionizing particles which are more important biologically are the 
alpha (α) and beta (β) particles [6]. The second category is named indirectly ionizing radiation, which 
is composed of uncharged particles such as neutrons and photons. The latter type of ionizing 
radiation can be detected by determining the ionization effects the charged particles produce during 
their interactions with matter [7, 8, 9, and 10]. As there are so many ionizing particles, only the most 
important will be discussed here. 
 
2.2.1 Beta (β) – particles 
The (β)-particles are fast, energetic electrons (high speed electrons) arising, not from orbital electrons 
but nuclear decay or transformations. They are ejected from the nucleus of unstable radioactive atom, 
with energies ranging from just above 0 MeV to the maximum energy (Eβ max) available for particular 
radionuclide. This range of energies forms a continuous spectrum [10, 11]. The beta (β) particles are 
single, negatively charged and have a small mass. They cause ionization just like the primary 
electrons produced by photons [6]. 
The only difference between (β)-particles and electrons is their energy. The (β)-particles are deflected 
through a rather tortuous path [11], due to the light mass and high speed. They are more penetrating 
than (α)-particles, but can be stopped by a few millimeters of aluminum, so cannot penetrate deeply 
into tissues. 131I is a beta emitter and hence is used for radiotherapy of hyperthyroid and thyroid 
cancer patients. Beta particles lose their energy in four ways: direct ionization, creation of delta rays 
by ionization, the production of Bremsstrahlung and Cerenkov radiation. Although all such 
mechanisms may occur, the most common are direct ionization and Bremsstrahlung production [11].  
 
2.2.1.1 Transformation mode of beta particles   
Radioactive nuclides, either naturally occurring or artificially produced by nuclear reactions, are 
unstable and strive to reach more stable nuclear configuration. These can be achieved through 
various processes of spontaneous radioactive decay. The radioactive transformation is chaotic 
process and defined as spontaneous nuclear transformations those results in the formation of new 
elements. This process is described as a change of radionuclide from one nuclear configuration to 
another [7]. Thus it is a process by which the nucleus attempts to achieve stability, it is not always 
successful at the first attempt and further transformation process may be necessary [4]. The rate of 
transformation is not affected by natural processes, such burning, freezing, solidifying, dilution, etc. 
with the exception of chemical change which can increase the electron density near the nucleus [11].                                                                                                 
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The process of radioactive transformation was first recognized by Rutherford. Commonly the term 
radioactive decay is used, but transformation is more accurate description of what is actually 
happening. Decay suggests a process of disappearance, what in reality happens is an atom with 
excess energy transforms itself to another atom that is either stable or one with more favorable 
conditions to proceed on stability [11]. The radioactive transformation of an atom occurs because of 
the constituents in the nucleus neither is nor arranged in the lowest potential energy state possible. 
Therefore, the rearrangement of the nucleus causes an excess energy to be emitted, and nucleus is 
transformed to an atom of a new isotope. This process may involve the emission of alpha particles, 
beta particles, orbital electron capture, negatrons, positrons , electromagnetic radiation in the form of 
X-rays or gamma rays and to a lesser extend neutrons, protons and fission fragments depending on 
the characteristics of the radionuclide [8.11]. 
In actual fact, the process is characterized by the transformation of an unstable nucleus into a more 
stable isotope that itself may be unstable, and will decay further through a series chain of decays until 
a stable nuclear configuration is reached [12]. In a stable nucleus, no particle ever acquires enough 
energy to escape, however, in radioactive nucleus it is possible for a particle by series of chance 
encounters to gain enough energy to escape from the nucleus. The ejection of a nuclear particle is 
pure chance, and there is no way to decide when any particular nucleus will disintegrate. However, if 
there are many nuclei, a certain percentage will disintegrate in a given time. Nuclei are characterized 
by the number of protons, Z and the number of neutrons in the nucleus. 
(N=A-Z)             (1) 
In such decay sequence, the nuclide which decays is frequently called the parent and its decay 
product the daughter. If both the parent and daughter nuclides are radioactive and the parent has a 
longer half-life than the daughter, the rate of decay of the daughter is determined not only by its own 
half–life but also by the rate at which it is produced. As a first approximation assumes that if the 
activity of the parents remains constant or is constantly replenished, so that the rate of production will 
at first exceed its rate of decay and equilibrium will be reached  when rate of production is just equal 
to the rate of decay [4]. 
Two practical situations should be distinguished [4, 11, 13]: 
1. Secular equilibrium: Occurs when the half-life of a parent is much longer than half life of 
daughter and λd >>λp . Thus daughter is much short lived than parent. In this case the parent 
and daughter activities are equal and both decay with the half life of parent radionuclide. 
A =	 A	
	               (2) 
2. Transient equilibrium: Occurs when half-life of the parent is not that much longer than that of 
the daughter, both are almost equal in terms of activity and parent activity is not constant [14]. 
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
                            (3) 
 
2.2.2 Gamma (γ) – rays 
Gamma (γ) – rays are highly penetrating than (α) or (β) particles; electromagnetic rays (photons) 
emitted from the nucleus of an atom. They are highly energetic photons emitted from a radioactive 
source with a variety of monoenergetic energies, ranging from a low value of 100 keV to as high as 3 
MeV. This means that each gamma ray has a precise energy corresponding to the discrete energy 
transformation within nucleus [15]. 
The energy of these rays is determined by the energy level structure of a particular radionuclide or the 
transition between the energy levels in the nucleus. Therefore, an emitted (Y)-ray is characteristic of 
that particular nucleus found that, in most (α) and (β) transformations, the (Y)-rays are emitted by the 
daughter nucleus during deexcitation and referred as if they were from the parent nucleus [10]. 
Practically, it requires several centimeters of lead to reduce their intensity appreciably. (Y)-rays offer 
the most practical approach to external beam radiotherapy [12].  131I has the yield percentage of 63 % 
for gamma rays with energy of 0,364 MeV. 
 
2.2.3 X – rays 
(X)-rays are electromagnetic radiation like (Y)-rays but are produced during the interaction of incident 
beta-particles with atomic orbital electrons of the target nucleus of interaction with a target nucleus. 
This produces characteristic radiation and “Bremsstrahlung” radiation, respectively. (X)-rays can be 
categorized in terms of their energy or clinical means as follows: 
- Low energy: 0.1 – 20 keV 
- Superficial x – rays: 10 keV – 100 keV 
- Diagnostic range x rays: 10 keV – 150 keV 
- Deep therapy or Orthovoltage X - rays: 100 keV – 500 keV 
- Intermediate X- rays: 300 keV – 1 MeV 
- Megavoltage X-rays: 1 MeV and above. 
(X) – Rays are used mainly in diagnostic radiology for disease diagnosis, and in radiation therapy for 
disease treatment [12]. 
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2.3 Interactions between ionizing radiation and matter 
When a photon beam travels through any material, it interacts with the atoms and atomic electrons of 
this material by transferring some or all of its energy to the material. These photon interactions with 
matter or the absorber can lead to biological, chemical or physical changes, depending on the 
material type and photon beam quality [16]. The number of photons attenuated through matter 
depends on the number of incident photons, the type of material concerned and its density. The 
attenuation of photon beams follows an exponential relationship in a homogenous medium [17]. When 
considering a monoenergetic, narrow photon beam with (N) incident photons and the absorbing 
material of thickness (∆x), with () photons that interact with the attenuator and are removed from the 
beam, then () is expressed by: 
n = μN∆x                                                                    (4) 
The proportionality constant (µ) is called the linear attenuation coefficient with dimensions cm-1. It 
defines the fraction of photons that interact per unit thickness of attenuator (∆x). This coefficient 
depends on the photon and the nature of the material. Thus, this is the probability of whether or not 
particular photon will penetrate a given absorber. By considering the change in the number of photons 
(∆N) in the beam passing through material thickness (∆x), the number of incident photons (N) is 
reduced by one for each interaction,  
∆N = −μN∆x                                                                                                      (5) 
In order to determine the number of transmitted particles, last equation can be solved to 
N = Noe                                                                   (6) 
Equation (4) describes how incident photons (N) change as the beam passes through the attenuator, 
and equation (5) determines the number of interactions in the slab thickness bombarded by (N) 
incident photons. 
The amount of attenuation depends on the number of atoms in any thickness of material which is 
material density. The linear attenuation coefficient divided by material density is referred to as the 
mass attenuation coefficient (µ/ρ) [8, 17]. 
Once a complicated series of processes has taken place, the average energy transferred (Etr) and 
the average energy absorbed (Eab) per interaction can be used to calculate the total energy 
transferred (∆Etr) and the total energy absorbed (∆Eab) in thickness (∆x). These total energies are 
defined by Johns & Cunningham (1983) as follows: 
∆Etr = EtrμN∆x = 	μ $%&'∆Nhυ∆x                                                    (7) 
∆Eab = EabN∆x = 	μ * $+,&'∆-Nhυ∆x                                                   (8) 
Where (Nhυ) is the energy carried by the beam ratios (Etr/hυ) and (Eab/hυ) are energy transferred 
and energy absorbed respectively and (µN∆x) indicates the number of interactions occurring. The 
dimensions of µ(Etr/	hυ) and µ(Eab/	hυ) are the same and provide more fundamental coefficient called 
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transfer (µtr) and absorption (µab) coefficient which can also be used to find total energies transferred 
and absorbed respectively in equation (7) and (8). The coefficients (µtr) and (µab) are used in radiation 
dosimetry since (µ) explains only the local removal of photons from a beam without directly providing 
a measure of the energy transferred to or absorbed around the removal site. 
Other more fundamental attenuation coefficients are electronic coefficient (eµ) and the atomic 
coefficient (aµ) defined by:  
eμ = 	 ./+0                                                                     (9) 
aμ = 	 ./+                                                                    (10) 
Where (µ/ρ) is the mass coefficient which is more fundamental and independent of density. (Na) is the 
Avogadro’s number and (ρ), (Z) and (A) are density, atomic number and atomic mass of attenuating 
material, respectively [8]. 
Since the mass, electronic and atomic coefficients are measured in terms of area per gram, area per 
electron and area per atom, the coefficients are often referred to as cross sections. The cross-section 
can be defined as the ratio of probability of interaction occurring from the photon beam incident on a 
slab of material containing a number of atoms per unit area. 
 
2.3.1 Photon interactions 
Photons are far more penetrating in matter than other known types of radiation. They have no specific 
depth range, and their interaction with matter is based only on cross sections. In a matter, photons 
may undergo scattering or may have no interaction with matter (transmission), or they may be 
completely absorbed (absorption) and disappear. Photons demonstrate five important types of 
interaction which will be dealt with in the following subsections. These interactions are the 
Photoelectric effect, Compton Effect, Thompson scattering, Coherent scattering and Pair production. 
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2.3.1.1 Photoelectric Effect 
The photoelectric effect process, also known as the photo effect is the interaction that might take 
place between an incident photon beam and one of the tightly bound electrons of K, L, M or N atomic 
shells in matter. It occurs mostly in the K-shell as illustrated in Figure 1. 
Figure 1. Illustration of photo effect (Khan 2003) 
 
During the process, the photon disappears, and its energy is absorbed by the atomic electron. The 
requirement for the process to occur is that the incident photon energy (hυ) must be greater but in 
order of binding energy of the orbital electron. In addition, this hυ must be totally absorbed. The 
reason for this is that the electron must first absorb enough energy to overcome the binding energy 
(Eb) of its shell, and remaining photon energy is then given to the electron in the form of kinetic 
energy (Ek). The electron is ejected and is now called a photo-electron, leaving the atom with kinetic 
energy of: 
                                                             Ek = hυ − Eb                                                                (11) 
An atom is left in an ionized state with vacancy created in the shell; thus the atom is left highly 
unstable. Very quickly the vacancy will be filled by one of the outer shell L, M or N orbital electrons. 
During this transition, energy will be released as electromagnetic radiation and this process is known 
as Characteristic radiation. 
This radiation is the binding energy difference between the two shells with the exact specific 
characteristic value which is different for different elements. The energy of characteristic radiation 
depends on the energy of the photon and atomic number (Z) of the material and is found to be very 
low in biological absorbers. 
The atom may also undergo a process known as the Auger effect where the energy released during 
the filling of the vacancy is absorbed by an orbital electron instead of being released from the atom. 
This excited and mono-energetic electron is then emitted from the atom. The emitted electron is 
called an Auger electron. Both Characteristic radiation and Auger electrons are emitted by all 
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elements, but heavy elements are more likely to emit radiation rays (Characteristic radiation) while 
light elements are more likely to emit electrons (Auger electrons).   
The angular distribution of photoelectrons depends on incident photon energy: as the photon energy 
increases the photo-electrons are emitted in a more forward direction although momentum and 
energy are conserved. The photo-electron is quickly brought to rest by surrounding atoms and 
delivers its energy to them in the process. A similar process occurs in Auger electrons. 
The probability of the occurrence of the photoelectric interactions depends on photon energy (hν). 
Also the photoelectric attenuation depends strongly on the binding energy (Eb) of the atomic electrons 
(which is the atomic number Z of absorbing material). The photoelectric attenuation coefficient is zero 
when hν << Eb  and is inversely proportional to (hν). Hence, the following relationship between the 
mass photoelectric attenuation coefficient (σ/ρ), atomic number (Z) and incident photon energy (hν) 
holds true: 
3
. =	
45
&65                                                                   (12) 
The last equation applies to energies up to 200 keV. At higher energies the term hν7	 approximates 
to hν8 and eventually to hν [7, 9].  
 
2.3.1.2 Compton effect 
Compton scattering is an incomplete absorption of a photon’s energy or the scattering of photon 
radiation. It is also defined as incoherent scattering. This process involves the inelastic interaction of 
photons with free or loosely bound outer orbital shell electrons, as shown in Figure 2. 
 
 
Figure 2. Compton effect (Khan 2003) 
 
This interaction is inelastic in that the photon energy is not conserved, although the total energy of the 
interaction is. By free electron, it is meant that the electron has a much smaller binding energy, 
fraction than the incident photon energy [19]. The Compton Effect appears as a collision between a 
photon and a free electron [14]. In the process, some of the incident photon energy (hν0) is absorbed 
while the scattered photon continues with a reduced energy. Then an emission of an electron (recoil 
or Compton electron) from the atom at recoil angle (Θ) occurs. This angle lies between the incident 
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photon direction and the direction of the recoil electron. Thus energy of the incident photon is shared 
between the scattered photon and the Compton electron. The sharing of energy depends on the 
scattering angle (ϕ) and the energy of the incident photon (hν0) relative to the energy equivalent of the 
rest mass of the electron (m<c8) [19]. The energy of scattered photon (hν’) is related to the angle of 
deflection (ϕ) and by applying the laws of conversation of momentum and energy, as expressed in 
Figure 2, the following relationships can be derived: 
     E = hν< >?@ABC?D>?@ABC                                                            (13)                                       
     hνE = hν< ??D>?@ABC                                                           (14) 
Where ϕ is the scattering angle at which the photon scatters which lies between the incident photon 
direction and the scattered photon direction. (E) is the energy of the recoil or Compton electron, which 
may also be expressed by: 
E = hν< − hνE                                                                (15) 
And α = &6GHG@ and m<c8 is the rest mass of the electron. The scattering angle (ϕ) depends greatly on 
the amount of energy received by the scattered photon. For each collision the amount of the energy 
transferred to both recoil electron and scattered photon, depends on the energy of the incident photon 
and scattering angle. For a high energy incident photon the Compton electron acquires most of the 
energy, and the scattered photon will carry away only small fraction of energy. So, most of the energy 
is deposited in forward direction. For low energy incident photon very little energy is transferred to the 
recoil electron, and most is entirely scattered. The probability of photon being scattered forward and 
being scattered backward are almost equal, depending on the amount of incident photon energy. 
Thus, as energy of incident photon increases the greater the energy of scattered photons at all 
scattering angles [8, 9]. The scattering angle determines the decrease in energy of the scattered 
photon thus the amount of energy ejected by the scattering photon depends only on the scattering 
angle. The greater the scattering angle the lower the energy of the photon will be scattered. 
Therefore, the lowest energy scattered photons occurs at 180 degrees, which occurs as a back-
scatter radiation photons. 
If the photons makes a direct hit: the electron will travel straight forward, and the photon will be 
scattered straight back. During this process, the electron receives maximum energy compared to the 
scattered photon. 
If the photon makes a grazing hit: the electron will emerge nearly at right angles and the scattered 
photon will move almost straight forward. During this process, the electron receives almost no energy 
and the scattered photon has essentially the full energy of the incident photon. 
The Compton Effect depends strongly on incident photon energy and is independent of density, 
atomic number or any other property of the absorbing material. Hence it follows that the Compton 
mass attenuation coefficient (σ/ρo) is independent of atomic number and depends only on the total 
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number of electrons in absorbing material. In turn, the Compton mass attenuation coefficient depends 
on material density and the number of electrons per gram. The mass attenuation coefficient (σ/ρo) is 
thus a measure of the total energy removed from the primary beam. 
 
2.3.1.3 Classical scattering (Thomson scattering) 
This process is easily explained by classical electromagnetic theory, which states that when an 
electromagnetic wave passes near a free electron, the electron is sent into vibration and accelerated 
by the electrical field of the wave. The electron will then radiate an electromagnetic wave of the same 
wavelength (λ), and this wave will form the scattered radiation. According to Young et al. the intensity 
of the radiation which is scattered at an angle (Θ to the direction of the incident radiation at a 
distance (r) from an electron of charge (e) and mass (m) is expressed as: 
I
8% k81 + cos8Θ	                                                            (16) 
The (I) denote the incident intensity and k is a constant. 
If the fraction of the incident energy scattered by an electron into the solid angle dΩ = 	 ?% at an angle 
Θ is denoted by dσP, then it follows that: 
3Q
R =	
S
8 	1 +	cos8Θ                                                          (17) 
Where (dσP/	dΩ) is called differential electronic cross section for classical scattering. This can be 
defined as a classical scattering coefficient per electron and per unit solid angle. The later is the 
function that allows the correct amount to be scattered for zero energy photons. During this process 
no energy is transferred to the electron since the frequency as well as the wavelength of the scattered 
radiation is the same as that of the incident radiation. 
Since	dΩ = 2π sin sinθdθ	between cone of θ and (θ + dθ, equation (17) becomes 
 
3
X =	
S
8?D@ABX8Y BZ[ X                                                           (18) 
By integrating equation (18) over all values of θ that is from zero to 180 degrees, the total cross 
section (σe), defined as the Thomson classical scattering coefficient for free electrons can be obtained 
[8,19] as: 
dσP =	 \7YS = 66.525 ∙ 	107<	m8                                                  (19) 
This process occurs when the binding energy of the electrons is high which means that the atomic 
number of scattering material is high, while the quantum energy of the incident photon is relatively 
low. 
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2.3.1.4 Coherent Scattering (Rayleigh scattering) 
In coherent (Rayleigh) scattering or elastic scattering the photon interacts with a bound orbital 
electron, i.e., with the combined action of the whole atom. The event is elastic in the sense that the 
photon loses essentially none of its energy and is scattered through only a small angle. Since no 
energy transfer occurs from the photon to charged particles, Rayleigh scattering plays no role in the 
energy transfer coefficient; however, it contributes to the attenuation coefficient [10]. The probability of 
coherent scattering occurring depends on the incident photon energy (hν) and the atomic number (Z) 
of the material. The cross section of coherent scattering decreases rapidly with the increase in photon 
energy, and is negligibly small for energy greater than about 100 keV in low atomic number materials. 
Hence the following relationship applies:   
3bcd
. =	
4
&6                                                                  (20) 
Where (σcoh/ρ) is the mass attenuation coefficient or cross section resulting from elastic scattering. 
Elastic scattering may occur as a result of a photon interacting with the nucleus of an atom of the 
attenuator. But the effect is even less and so may safely be ignored in medical radiography or 
imaging. This process has an effect in slightly broadening the angular width of the beam [7, 8]. From 
the equation (20), it is clear that coherent scattering occurs mainly at low energies (about 50 keV) for 
larger atomic number values. 
 
2.3.1.5 Pair production 
When the gamma photon energy is greater than 1.02 MeV the photon interacts with the nucleus of the 
absorber atom during its passage through it, and a positive electron and negative electron are 
produced at the expense of photon. The energy in excess of 1.02 MeV appears as the kinetic energy 
of two particles. The process is called pair production. It varies almost linearly with Z2 of the absorber 
and increases slowly with the energy of the photon. Positive electrons created by pair production are 
annihilated to produce two 0.511 MeV photons identical to those produced by positrons from 
radioactive decay. 
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2.4 Electron interactions 
All radiation particles or ionizing radiations (α-particles, β-particles, γ-rays and X-rays) interact 
differently with matter or tissue, since they have different characters. As a high energetic particle such 
as a β-particle transverses matter, it interacts with matter through coulomb interactions with atomic 
orbital electrons and atomic nuclei. Through these collisions, these β-particles may lose their kinetic 
energy (collision and radiative losses) or change their direction of travel scattering [12], slowing down 
as they pass through matter as a result of these collisions with atoms and molecules. High energy 
electrons, which are also charged particles, are a by-product of these collisions. The energy losses, 
whereas those occurring in a charged particle, in ionization and excitation events, are called collision 
losses, whereas those occurring in nuclear encounters resulting in Bremsstrahlung production are 
called radiation losses. 
The parameters used to describe the gradual loss of energy of a charged particle as it penetrates an 
absorbing medium are called stopping powers. Such parameters may be collisional (ionization) or 
radiative stopping powers. These parameters play an important role in radiation dosimetry and are 
dependent on properties of the charged particle such as mass, charge, velocity and energy as well as 
on the absorbing medium’s properties, such as density and atomic number [9]. 
Energy losses are described in terms of stopping powers, while scattering is described in scattering 
powers [12]. When attenuation is focused on the absorbing medium, we are interested in the linear 
rate of energy absorption, linear energy transfer (LET) by the absorbing medium as the ionizing 
particle transverses the medium distance (dl). It is important to show the specific point at which the 
energy is absorbed. The energy transfer from the charged particle to matter in each atomic interaction 
is generally small, and the particle undergoes a large number of interactions before its kinetic energy 
is spent. The kinetic energy gained by the electron may be lost through the following processes: 
- Bremsstrahlung (inelastic collision as the electron nears the nucleus) 
- Ionization and excitation (inelastic collision with atomic electrons) 
- Elastic collision in which the electron may lose a maximum of half its original energy 
- Violent electron-electron interaction causing delta ray. 
As a result of the above mentioned processes, electron tracks are tortuous, and their exact shape and 
length are unpredictable. 
A given kinetic energy electron travels at a much higher speed than a heavy particle with similar 
energy. Such an electron thus spends a briefer time in the vicinity of an atom than a heavier particle 
and therefore less likely to interact with the atom. Such an electron also carries only one unit of 
electrical charge and thus exerts weaker forces on orbital electrons. These electrons experience less 
frequent interactions than heavy particles and lose their energy more slowly than heavy particles. 
Electrons are much less densely ionizing, and they travel further before they are stopped, compared 
with heavy particles of similar energy [13]. Transfer from the energy of a photon beam to the medium 
take places in two stages: 
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- First involves the interaction of the photon with the atom, causing an electron or electrons to 
be set in motion 
- The second stage involves transfer of energy from the high energy electron to the medium 
through excitation and ionization [8]. 
 
2.4.1 Collision interaction 
The collision that occurs between a charged (β)-particle and atoms involves electric forces of 
attraction or repulsion, rather than actual mechanical contact. In close encounters, the strength of 
coulomb forces may be sufficient to cause orbital electrons to separate from the atom during the 
interaction of (β)-particle with atom, thus causing ionization. The ionization interaction appears as a 
collision between the (β)-particle and an orbital electron, and the (β)-particle losses energy in the 
process. Part of this energy is used to overcome the binding energy of the electron from the atom and 
what remains is given to the ejected secondary electron as kinetic energy. Thus ionization involves 
the ejection of an individual electron to a higher energy orbital after gaining energy from a (β)-particle. 
The ejected electron may be sufficiently energetic to cause secondary ionizations on its own. Such an 
ejected secondary electron is called a delta (δ) ray and occasionally causes longer side tracks when it 
is energetic enough. The effects of delta ray are accounted for by using the energy limit ∆, below 
which the energy transfer is considered dissipative. Ionization, involving an inner shell electron, leads 
to the emission of characteristic x-ray or Auger electrons, as described in the photoelectric effect 
process. However, these effects are generally small since most ionization interactions involve outer 
shell electrons. 
If the energy lost by the incident (β)-particle is not enough to eject an electron from the atom, it is 
used to raise the electron to a higher level by a process known as excitation, thus causing atomic or 
molecular excitation. These interactions result in smaller energy losses than in ionization events. The 
energy transferred to an atom in an excitation interaction is dissipated in molecular vibrations, atomic 
emissions of infrared, visible, ultraviolet light and so forth.  
The inelastic collisions responsible for energy deposition locally in the irradiated medium result in 
excitation or ionization of an atom. The probability of their occurrence depends on the energy of the 
passing electron, the distance of closest approach and the atomic number (Z) of the medium [5]. 
 
2.4.2 Radiative interaction  
Radiative interaction occurs when the high speed β-particle penetrates the orbital electron cloud of an 
atom and interacts with its nucleus. The particle is rapidly decelerated and may be deflected from its 
original path and through the process it loses energy. The energy appears as a photon of 
electromagnetic radiation, called Bremsstrahlung. The energy of Bremsstrahlung photon can range 
anywhere from nearly zero to maximum equal to the full energy of the incident particle. 
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Bremsstrahlung depends on the atomic number of the absorber and the energy of the beta particle. 
These photons are governed by the Larmor relationship [12], which is expressed by: 
P = 	 f+gYhG@5                                                                  (21) 
P is the power in the emitted photon, (q is the electronic charge, a is the acceleration of the(β)-
particle, ε< the permittivity of free space and (c) the speed of light in free space. 
Radiation losses through Bremsstrahlung increase with increasing - particle energy, and with 
increasing atomic number z of absorbing medium. Hence, low atom number materials like plastic 
and aluminum are more efficient as protective shields for beta particle emitters such as 131I. This is 
because they are poor Bremsstrahlung radiation emitters and at the same time, they are good 
absorbers of beta particles. This type of energy loss is characterized by radiative stopping power [12, 
13]. An approximation of percentage radiation losses for beta-particles having maximum energy 
ElH+ (MeV) is:  
   Percentage	radiation	losses = *4$opqr7<<< - ∙ 100%        (22) 
z is the atomic number of the absorbing material. The approximation is accurate to within about 
30%. The total kinetic energy KE loss by the beta particle per unit length (x) can be described as the 
total mass stopping power given by combination of collisional and radiative interactions as follows: 
                                           *B.- 	tot =
?
. 	
u$
 =	*
B
.- col + 	*
B
.- rad       (23) 
Where *B.- col is the mass collision stopping power resulting from β-particle and orbital electron 
interactions (atomic excitation and ionizations) and *B.- rad is the mass radiative Stopping power 
resulting from beta particle and nucleus interactions (Bremsstrahlung). 
 
2.4.3 Continuous Slowing Down Range (CSDR) 
As a beam of (β)-particles passes through the matter, the interaction causes the particles to slow 
down and change direction. Eventually, particles will lose all their kinetic energy and come to rest. 
There will be a finite distance beyond which there will be no particles, and this distance is called the 
particle range. This gradual and continuous loss of kinetic energy is often referred to as the 
continuous slowing down approximation (CSDA). The CSDA is used to obtain the actual range 
covered by the particle, taking into consideration the variation of the total mass stopping power with 
respect to the energy. The path of the beta particle is tortuous or zigzag. The charge and small mass 
may easily be deflected from a straight line path. This deviation will lead to variations in actual 
penetration of beta particles into the absorbing medium depending on the initial energy of beta 
particles. Thus beta particles do not have a well defined range [20]. In CSDA energy loss fluctuation 
are neglected, and the beta particles are assumed to lose energy along its track according to the 
mean energy loss per unit path length given by stopping power. That is inelastic energy losses by 
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beta particles moving through a medium with density ρ are described by the total mass energy 
stopping power (S/ρ)tot (in MeVcm
2/g). Stopping power defines the effect of material in beta dosimetry 
[5]. The range of beta particle with initial energy E< is given in following relation 
R@B+ = w *x$. -A
? dE$G<                                       (24) 
and *x$. -A
?
 is the total mass stopping power with respect to energy, specifically total unrestricted 
mass stopping power. In the restricted collision stopping power it is, generally accepted that beta 
particles lose their energy in a large number of interactions with small energy losses. Thus, during 
CSDA the energy transferred to the medium may be assumed to be absorbed locally in a small 
volume close to the point of interaction [5]. 
 
2.4.4 Mass scattering power 
Collisions that occur between (β)-particles themselves, between (β)-particles and electrons or 
between (β)-particles and a nucleus not only contribute to the energy absorbed but also increase the 
scatter of beam of (β)-particles. The energy loss and change of direction by the (β)-particle as it 
passes through a medium are described respectively by the stopping and scattering power ratios. The 
scattering angle depends on the atomic number (Z) of the medium, as well as on the cross section of 
radiation loss of the (β)-particles. The mean square angle of scattering related to the mass of 
scattering material is recommended for characterizing the “angular scattering power” of a given 
medium. Multiple scattering of (β)-particles as they traverse a path length (l) of the absorbing medium 
is commonly described by the mean square angle of scattering (Θ2) which is the proportional to the 
mass thickness (ρl) of the absorber. The mass scattering power (T/ρ) expresses the increase in the 
mean square angle of scattering (dθ8) per unit mass thickness (ρl) and can be defined as follows [5, 
12]. 
                                            

. =	
?
.
X
y =	
X
y                                         (25) 
This equation emphasizes that the scattering power is analogous to stopping power in a given 
medium [12). Khan (2003) observed that scattering power varies approximately as the square of 
kinetic energy (KE) of the incident electron (β)-particle [9]. 
 

. =	
z
u$Q                  (26) 
  
  28 
 
2.5 Thyroid gland 
The thyroid is the largest endocrine gland and its function is to synthesize, store and secrete iodinated 
hormones. The thyroid cells both collect and transport iodine for synthesis of the hormones and 
release the thyroid hormones T3 (triiodothyronine) and T4 (tetraiodothyronine) into blood circulation. 
Smaller quantities of several other closely related iodinated hormones that have a profound effect on 
the metabolism of the body are produced by thyroid gland.  
 
 
 
 
 
 
 
 
Figure 3. The Thyroid gland 
 
The first step in the synthesis of thyroid hormones is the organification of iodine.  Iodide is taken up, 
converted to iodine, and then condensed onto tyrosine residues which reside along the polypeptide 
backbone of a protein molecule called thyroglobulin. This reaction results in either a mono-iodinated 
tyrosine (MIT) or di-iodinated tyrosine (DIT) being incorporated into the thyroglobulin. This newly 
formed iodothyroglobulin forms one of the most important constituents of the colloid material, present 
in the follicle of the thyroid unit. The other synthetic reaction that is closely linked to organification is a 
coupling reaction, where iodotyrosine molecules are coupled together. If two di-iodotyrosine 
molecules couple together, the result is the formation of thyroxin (T4). If a di-iodotyrosine and a mono-
iodotyrosine are coupled together, the result is the formation of triiodothyronine (T3). 
From the perspective of the formation of thyroid hormone, the major coupling reaction is the di-
iodotyrosine coupling to produce T4.  Although T3 is more biologically active than T4, the major 
production of T3 actually occurs outside of the thyroid gland.  The majority of T3 is produced by 
peripheral conversion from T4 in a deiodination reaction involving a specific enzyme which removes 
one iodine from the outer ring of T4. The T3 and T4 released from the thyroid by proteolysis reach the 
bloodstream where they are bound to thyroid hormone binding proteins. The major thyroid hormone 
binding protein is thyroxin binding globulin (TBG) which accounts for about 75% of the bound 
hormone. 
In order to attain normal levels of thyroid hormone synthesis, an adequate supply of iodine is 
essential. The recommended minimum intake of iodine is 150 micrograms a day.  Intake of less than 
50 micrograms a day is associated with goiter. High iodine levels inhibit iodide oxidation and 
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organification. Additionally, iodine excess inhibits thyroglobulin proteolysis (this is the principal 
mechanism for the antithyroid effect of inorganic iodine in patients with thyrotoxicosis). 
 
2.5.1 Hyperthyroidism 
In hyperthyroidism, the level of thyroid hormones in the blood is increased while the level of TSH is 
depressed, and the thyroglobulin production is increased. The thyroid is depleted of iodine because of 
the hormones that are rapidly eliminated from the thyroid gland. The most common causes for 
hyperthyroidism are diffuse toxic goiter, also called Graves’ disease, toxic multi nodular goiter and 
toxic adenoma (4) (Fig 4). The classic symptoms are weight loss, increase in appetite, weakness, 
palpitations, sweating, heat intolerance, tremor and irritability. 
                                           
 
            a                               b                   c 
Figure 4.  Examples of scintigrams after administration of 131I-iodide showing the diagnosis a) Graves’ disease; 
b) Multinodular goiter and c) Autonomous adenoma 
 
Graves’ disease (Figure 4-a) is caused by antibodies (IgG), which stimulate the TSH receptor. The 
cause of the disease is unknown, but stressful events in the life, like the death in the family or 
separation could trigger the disease [21]. A gamma camera image usually shows an enlarged thyroid 
and an uptake measurement of 131I reveals a raised uptake of iodide.  
The multi nodular goiter (Figure 4-b) is enlarged and has multiple nodules of various sizes. The 
growth of the nodules is often a slow process during several years. The gamma camera image will 
show an enlarged goiter with nodule-hot areas of different sizes. A nodular goiter is common in areas 
with iodine deficiency. 
Autonomous adenoma (Figure 4-c) is functioning autonomously, and the rest of the normal thyroid 
tissue is suppressed. In gamma camera image, the nodule will show clearly, and the rest of the 
thyroid tissue will not be visible in the image. The frequency of the autonomous adenoma is higher in 
iodine – deficient areas then in iodine – sufficient areas [22]. 
 
2.5.2 Thyroid carcinoma 
Although benign disease of the thyroid is relatively common, malignancy occurs relatively 
infrequently. Carcinoma of the thyroid represents approximately 1% of newly diagnosed cancers each 
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year and is the most common endocrine malignancy. Fortunately, for most individuals, the prognosis 
is excellent, and the most common types of thyroid cancer can be completely removed by surgical 
resection. There are four main varieties of thyroid cancer (papillary, follicular, medullary, and 
anaplastic).  
Papillary Carcinoma representing approximately 65 % of cases, and are the most common thyroid 
malignancy. Papillary carcinomas are solitary or multifocal, slow growing tumors that arise from the 
thyroxin and thyroglobulin producing follicular cells of the thyroid. They typically present as 
asymptomatic thyroid nodules, however, the first manifestation may be enlargement of cervical lymph 
node, where metastases travel primarily. Distant spread of papillary carcinoma typically occurs to the 
lungs and bone. Approximately 5 % - 10 % of patients will develop distant metastases. These tumors 
are highly likely to take up radioiodine [22]. 
Follicular carcinoma is the second most common thyroid malignancy, constituting 20 % - 25 % of 
cases. They similarly arise from the follicular cells of the thyroid and present as slowly enlarging, 
painless masses. In contrast to papillary carcinoma, the rate of metastasis is somewhat higher (about 
20%). Fortunately, well-differentiated metastases usually take up radioactive iodine, which can aid in 
identifying and ablating such lesions. Thyroid  lobotomy and isthmusectomy or total thyroidectomy is 
both surgical options with very good prognoses.   
Radioiodine is used for diagnostic, ablation and treatment. The initial diagnostic approach at thyroid 
cancer patients is the demonstration of residual normal thyroid tissue following removal of the tumor. 
At hyperthyroid patients, the diagnostic approach is to evaluate the size of thyroid tissue. The routine 
protocol in the treatment of thyroid cancer patients is if any thyroid tissue is visualized after removal of 
cancerous thyroid gland, ablation with radioiodine should be performed. After ten days from therapy, a 
whole body imaging is also performed. 
 
2.5.3 Iodine 
131
 I 
2.5.3.1 History 
The first studies of iodide metabolism in thyrotoxicosis were made in 1927 when stable iodide was 
administered orally and the iodine in the urine determined after different intervals. It was found that 
most patients with thyrotoxicosis excreted less iodine than normal subjects and this method became 
one of the most frequently used diagnostic procedures, before production of radioiodine. The 
radioactive iodine was first produced in atomic-bomb experiments in USA, in the 1930’s.The first 
production of radioiodine for clinical application was made by Robley Evans in 1937 [24]. He 
produced 128I by the neutron irradiation of ethyl iodide. Evans administered an intravenous injection of 
128I into rabbits and demonstrated for the first time the rapid accumulation of radioiodine in the thyroid 
gland [25]. Radioactive iodine-131 was discovered by Glenn T Seaborg and John Livingood at the 
University of California-Berkeley [26] reported on the first use of 131I in human subjects with thyroid 
disease. Some years later in 1940 it was introduced in the medical field. Hertz et al. (1940) introduced 
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the possibilities of radioactive isotope technique into the study of thyroid physiology and the 
investigations concerning thyroid diseases and iodide metabolism were enormously increased. Even 
though Fermi produced radioiodine already in 1934 by neutron bombardment of stable iodine, it was 
not made available until 1946 by actions of the United States Atomic Energy Commission, and 131I 
became first available from a nuclear reactor at Oak Ridge, Tennessee [27]. The first report of the use 
of radioactive iodine for treatment of metastatic thyroid cancer was published by Seidlin et al. in 1946 
[28]. 131I was administered to a patient who was clinically hyperthyroid despite having had a 
thyroidectomy for thyroid cancer. A scan after therapy revealed uptake in pulmonary metastases. This 
report was followed by many case reports that confirmed that metastatic thyroid cancer lesions could 
concentrate the radioiodine. At Institute of pathophysiology and nuclear medicine131I was used for the 
first time in 1950 when were done first experiments with rats [29.30]. Since then, 131I has been used 
for diagnostic examination of the thyroid gland and became major therapeutic agent for 
hyperthyroidism and thyroid cancer. 
 
2.5.3.2 Metabolism of 
131
I 
Iodine is an essential component of thyroid hormones, so the thyroid gland takes up iodine very 
easily. Normally, iodine is supplied to the body in foodstuffs and drinking water, and a normal dietary 
intake hardly ever results in excessive amounts of iodine intake. After intake, iodine will be 
concentrated in the thyroid tissue and used for the synthesis of hormones. If an additional amount of 
iodine is presented to the body, an average of about 25 % of this intake will be directly taken up by 
the thyroid. This amount is strongly dependent on the normal daily intake through the diet. With a low 
daily intake, the amount of uptake can be easily 50 %. Within daily intake, the uptake may be as little 
as 5 % - 10 %. The rest leaves the body quite quickly, within some days, mostly in the urine but also 
in other excretions, such as feces, sweat, saliva and breath. The iodine used by the gland is slowly 
released from the hormones into the body fluids and can recalculate. It is retained in a thyroid with a 
biological half-life of 120 days in the form of organic iodine. Organic iodine is assumed to be uniformly 
distributed in all organs and tissues of the body except the thyroid, and retained with a biological half-
life of 12 days [31]. The committed dose is significantly reduced due to the short physical half-life of 
131I [31]. 
 
2.5.3.3 Radioactive iodine  
As the body does not differentiate between stable and radioactive iodine -131I, behaves in the same 
manner as stable iodine. This means that a large part of the intake will be concentrated in the thyroid 
within 24 hours to 48 hours. During the initial retention and recycling period that the radioactive iodine 
is in the body, it irradiates the thyroid tissue, resulting in death of tumor cells in the case of thyroid 
cancer or of a substantial amount of normal thyroid cells in the case of benign thyroid diseases. The 
half of the amount of the radioactive iodine will decay within 8 days. The main decay product is 131Xe, 
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which is rapidly washed out of the body. In addition, damaged thyroid cells lose their capacity to 
organify iodine and consequently, the iodine is released back to the blood stream, resulting in 
excretion. Thus, radioactive iodine is removed from the body reasonably quickly, due either to 
radioactive decay or to metabolic excretion. The total amount of radioactive iodine reduces to half its 
original value at a rate which depends on the state of disease: between one day, in the case of thyroid 
cancer and total ablation of thyroid tissue, and seven days for patients with euthyroid goitre. In the 
case of hyperthyroidism, the effective half-life is about four to five days. It is well known that it is 
based on the physical half-life and the biological half-life, dependent on metabolism [32]. 
 
2.5.3.4 Radioactive decay products of 
131
I 
The original 131I radionuclide, employed for studies of iodine metabolism, was produced by 
bombarding stable Tellurium with deuterons. Nowadays, 131I is obtained primarily as a reactor 
byproduct from fission of 235U atoms. Both methods produce 131Te, which decays to 131I according to 
the following [33]. 
  
 
 
The nuclear material is processed to yield sodium iodide as a final chemical form. There are 37 
known isotopes of iodine, and only one 127I is stable. The isotopes of iodine have atomic masses from 
108 to 144. The iodine 131I nucleus is characterized by 53 protons and 78 neutrons, four neutrons 
more than the stable isotope 127I.  
The particles that are emitted as a result of radioactive decay, of an isotope, determine the potential 
usefulness in diagnostic and treatment of disease. The radioiodine 131I fulfills many criteria as a 
radionuclide suitable for therapy. The ideal properties should one radionuclide have are as follows: 
- Effective-half life in the range 5 h – 100 h (half-life should be relevant for the biokinetics 
procedure/treatment). 
- Suitable modality of radiation (beta or alpha for therapy, gamma and other photons for 
imaging). 
- Suitable energy range. 
- Stable chemical bonds. 
- Simple labeling procedure. 
- Suitable metabolism of the radiopharmaceutical.  
235
U (n,f) 
131
Te 
130
Te (n,γ) 
131
Te 
131
I 
30 
Beta 
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The iodine 131I is used for treatment of hyperthyroidism and thyroid cancer as it has suitable physical 
half-life of 8.04 days, which is long enough for uptake by thyroid gland and is used in the metabolism 
and production of thyroid hormones it allows for an assessment of the function. 
The simplified decay scheme is shown on Figure 5. As it is shown 131I decays to stable 131Xe [34], by 
negative beta decay according to the following nuclear transformation equation [35].  
 
        I → Xe + β + γ + ν~?7?7?7?                                                        (27) 
The mechanism of transformation is called “beta decay” because neutron is converted to a proton and 
an electron. In this decay process, an antineutrino is created and carries away part of the energy of 
this reaction. 
                                                               n<? → p +?	? e?< + ϑ                                                             (28) 
                           
   
 
 
 
 
Figure 5. Decay Scheme of 131I 
 
The transition energy between 131I and the 131Xe ground state is 971 keV. The first emission product 
was an electron with a range in energy between 250 keV - 800 keV [35]. It is this product that makes 
131I useful for ablating normal thyroid tissue and treating differentiated thyroid cancers. Electrons in 
this energy range usually travel less than a millimeter before depositing their energy and causing an 
ionization event. This means that most of the damage from the electrons produced from the decay of 
131I occurs in the cells in which the 131I is concentrated. This is the main point what we want to happen 
when we use 131I to treat thyroid disease. The second decay product of 131I is a moderate energy 
photon 364 keV. From the standpoint of treating thyroid disease, this emission product is undesirable 
because it travels far from its source before depositing its energy and thus increases total body dose 
with relatively little impact on thyroid tissue. The value of the 364 keV photon emitted from the decay 
of 131I is that it makes iodine useful for diagnostic studies. In an iodine scan or uptake study it is 
photons that are not attenuated by the patient’s body that are being counted or processed into 
diagnostic images [36]. All iodine decay data is listed in Table 1. 
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  Emissions                              Energy / (MeV)                                      Yield (%) 
 Beta                0.248     2.12 
 “    0.334     7.36 
 “    0.606     89.3 
 Gamma   0.03     4.6 
 “    0.08     2.6 
 “    0.284     5.8 
 “    0.364     63.6 
 “    0.637     6.5 
 “    0.723     2.6 
 X-ray   0.030     3.9 
Table 1.  131I Decay Data (20) 
The beta particles (Emax=0.606 MeV and Y=89.3%) are absorbed within a few millimeters of tissue 
and hence a very high, locally confined dose is delivered. Maximum range of beta in air is 165 cm 
[37]. There are three ways an individual other than the patient can be exposed to 131I, external 
exposure from gamma rays, external beta contamination to the skin and eyes and internal 
contamination through ingestion or inhalation of radionuclide. Gamma emissions (E=0.364MeV, 
Y=82% and E=0.637MeV, Y=7%) can present a penetrating external exposure hazard. It is the 
exposure from these gamma rays that pose a radiation risk to medical staff, close friends, relatives 
and other individuals. 131I is excreted through the urine, sweat, vomit and the saliva of the patient. This 
may pose a risk of external contamination if the patient is incontinent or nauseous as well as a small 
risk of internal contamination if the patient exchanges body fluids through kissing etc. Due to the high 
administered activity and the high energy of the 131I gamma rays, the implementation of radiation 
protection guidelines, to protect the surroundings of the patient, are, therefore, crucial. 
 
2.5.4 The Half life of 
131
I 
It is essential when selecting a therapy radionuclide, to match the physical half-life of the radionuclide 
with its biological half life in vivo. The half-life of the radioactive isotope is the time it takes for the 
isotope to decrease activity by 50%. There are three kinds of half life’s that should be considered 
when radioactive iodine is used to study or treat a hyperthyroid and thyroid cancer patient. The 
physical half-life is the time it takes for the amount of radioiodine to decrease by 50% purely as a 
result of radioactive decay. The biologic half-life is the time it takes, the amount of radioiodine in a 
person’s body to decrease by 50% purely as a result of the excretion of iodine in the sweat, saliva, 
feces and urine. In the thyroid gland or in thyroid cancers, the biologic half-life is mainly determined by 
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the time that the isotope remains in the normal or malignant follicular cell. The effective half-life is the 
combination of the effects of radioactive decay and physiologic excretion. The relationship between 
the three types of half-lives is given in following equation: 
                                                       Te = ,×	,D	                                                                   (29) 
Table 2 presents the physical, biological and effective half life of 131I. The values for biologic and 
effective half- life are different for the thyroid and extra thyroidal compartment because thyroid follicle 
cells normally concentrate iodine to a much greater degree than many other tissues [36]. 
131
I Physical half 
life 
131
I Biologic half-life 
131
I Effective half-life 
normal thyroid 
compartment 
extra thyroid 
compartment 
thyroid 
compartment 
extra thyroid 
compartment 
8.04 days 80 days 12 days 7,3 days 8 hours 
Table 2. Physical, biological and effective half life of 131I 
 
2.5.4.1 Sodium Iodide (Na
131
I) 
Na131I-sodium iodide is available for oral ingestion as sodium iodine of high specific activity as a liquid 
solution or in capsules, for oral ingestion. Sodium iodide (Na131I), therapeutic capsule is prepared by 
absorbing a solution of carrier-free 131I sodium iodide onto an inert filter that is contained within a 
gelatin capsule. Capsules are available from several manufacturers in a range of calibrated activities. 
At IPNM, we use products from CIS with following characteristics, given in Table 3. 
Table 3. Formulation information of therapeutic - Sodium Iodide (Na 131I) 
 
Following oral administration in liquid form, iodine is rapidly and completely absorbed in the upper 
intestine. It is distributed primarily in the body’s extravascular fluid within the first one hour. When 
patient takes a therapy in the form of a capsule Figure 6, it takes some time before absorption starts. 
 
Figure 6. Capsule form of 131I 
Manufacturer Information 
Cis-US,Inc Capsule (gelatin-white opaque): Sodium iodide 131I absorbed onto inert filler. 
Sodium iodide Oral Solution: 0.1% sodium bisulphate and 0.2% edentate 
disodium (stabilizers), 0.5% sodium phosphate (buffer) Sodium hydroxide or 
hydrochloric acid (pH adjustment: 7.5-9.0). 
Cis-US,Inc Sodium Iodide 131I Oral solution: 2.48 mg/ml sodium thiosulfate Antioxidant, 4.2 
mg/ml phosphate buffer, sodium hydroxide (PH adjustment: 7.5-9.0). 
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Although, it is much safer to perform therapy in the form of capsule gastric and other surroundings 
organs receive certain internal absorbed dose. Very rare the intravenous route is used only in patients 
who are unable to ingest the solutions or capsules. From the view of radiation protection capsules are 
safer than liquid solutions, because less radioactivity is released into the air during the handling. We 
recommend to patients to ingest large amounts of water that attenuates the radiation dose that may 
be emitted to the gastric wall before dissolution of the capsule. The functioning thyroid tissue takes up 
part of the dose and is completed by 24 hours [33]. The rest is excreted, primarily in the urine. In 
some thyroid cancer patients, there may be very little uptake and much as 90 % of the dose can be 
excreted in the first 24 hours [34]. Contrary hyperthyroid patients may retain up to 80 % in the thyroid 
gland. A small amount of 131I is present in other body fluids, including sweat and saliva.    
Iodine is a precursor of thyroxine and is taken up into follicular cells of the thyroid where it is rapidly 
converted to protein-bound iodine. Its retention in the follicular cell is dependent on the metabolic 
activity of the cell, and in the thyrotoxic patient the biological half-life of iodine will be shorter than in 
the euthyroid patient. Following oral administration, about 40% of the activity has an effective half – 
life of 0.3 days and 60% has an effective half-life of 7.61 days [33]. In patients with differentiated 
thyroid cancer, the retention of iodine is variable but activity may still be visualized at the site of a 
thyroid tumor a month after treatment has taken place [33]. As the path length of the beta particle is 
about 0.5 mm - 0.8 mm, the toxic effects are limited to the thyroid, with sparing of adjacent tissues. 
The normal biodistribution of iodine includes salivary glands, stomach and renal tract including 
bladder. These organs also receive a radiation dose during therapy with 131I, although this dose may 
be reduced by stimulating salivary flow and maintaining a high urine output during the early treatment 
period. The high-energy gamma emissions also contribute to an unwanted whole body radiation dose 
and also to the radiation protection problems associated with radiation therapy. 
 
2.5.4.2 Organ of interest – Gastric 
When performing radioiodine therapy especially for treatment of thyroid carcinoma a great dose has 
to be delivered to the unhealthy thyroid tissue as a target organ and to avoid or limit the expression 
undesired effects in other normal tissues of the patient. First critical organ during performing this kind 
of therapy is a gastric Figure 7. Of course, most of absorbed dose will be delivered to the thyroid 
tissue but of our interest is the dose that has been delivered to gastric and other organs. One of the 
goals of this thesis is to perform dose calculation and to estimate the absorbed dose to gastric. For 
that purpose, we have used several assumption, but first of interest is the anatomy and form of the 
gastric. 
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Figure 7. Gastric 
 
The stomach is the most dilated part of the digestive tube and is situated between the end of the 
esophagus and the beginning of the small intestine. It lays in the epigastria, umbilical, and the 
hypochondriac regions of the abdomen, and occupies a recess bounded by the upper abdominal 
viscera and completed in front and on the left side by the anterior abdominal wall and the diaphragm. 
The radioiodine therapy is performed orally, and the patients take the therapy in the form of capsules 
or in the form of solution. When the therapy is performed in the form of the capsule, it takes some 
time before absorption start. The dissolving time of the capsule material is about 15 minutes [40]. This 
is long enough to make possible risky exposure to a part of the stomach wall and several surrounding 
organs. These doses are not measurable directly but could be easily estimated using numerical 
experiment as Monte Carlo technique is.  
 
2.5.4.3 Isolation ward 
After performed thyroidectomy, patient has to be treated with radioiodine therapy 131I. Because131I 
emits gamma rays 364 keV the patient’s represents radiation hazard to his surroundings i.e. family 
members and hospital staff. The patient has to be hospitalized in “isolation room” to avoid 
contamination of other persons. This room is specially designed of lead walls to avoid irradiation to 
bystander and allows management of radioactive waste produced by the patient by separate waste 
collection, storage and disposal after complete decay. Hospitalization time can be from three up to 
seven days when release criteria will be reached. Physicist performed every day measurements and 
when dose rate of 7 µSv/h at a distance of two meters will be reached, patient will be released from 
hospital. For his further behavior, written instructions will be given. It is local hospital rule according 
national regulation. 
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Figure 8. Isolation ward for patients 
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2.6 Internal dosimetry and basic dosimetry quantity 
The need for quantitative measurements is necessary for all fields, especially in dosimetry is crucial to 
have understandable and precise quantities and units. Two International organizations are active in 
relation to quantities and units: The International Commission on Radiation Units and Measurements 
(ICRU) which mainly working with the physical aspects of dosimetry and The International 
Commission on Radiological Protection (ICRP) – assessment and quantification of the biological 
effects of radiation and provides recommendations and guidance on all aspects of radiation protection 
against ionizing radiation. The goal of current systems of a units is to assess the biological effects 
resulting from external and internal exposure to ionizing radiation in terms of stochastic (cancer 
induction, genetic effects) as well deterministic effects (tissue effects) in order to have sufficient 
mechanisms to control these effects [41].  
 
2.6.1 Biologic effects of ionizing radiation 
It is well known that the interaction between ionizing radiation and human tissues result in biological 
damage. The damage to tissues is primarily due to secondary charged particles, usually energetic 
electrons that result when the tissues are exposed to ionize radiation. The secondary ionizing 
particles yield highly reactive free radicals that interact with molecules in the tissue breaking chemical 
bonds and causing a variety of chemical changes. Most of the resulting damage is subsequently 
repaired, but some is not. There are two broad categories of radiation related effects in humans: 
stochastic and nonstochastic.  
Nonstochastic effects, (now deterministic effect, previously acute effects) are effects that are 
generally observed soon after exposure to radiation. The major characteristics of nonstochastic 
effects are: 
- There is a threshold of dose below which effects will not be observed  
- Above this threshold, the magnitude of the effect increases with dose 
- The effect is clearly associated with the radiation exposure. 
The amount of radiation required to produce these deterministic effects has been derived from studies 
in experimental cell cultures and animal studies as well as human epidemiology studies. From these 
studies, the dose thresholds have been established where the effect is observed in 1% of population 
(Table 4).  This means these values represent the amount of radiation energy absorbed by the tissue 
where if 100 people were exposed to this level of radiation, only a single individual would experience 
this effect. 
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Tissue Total acute dose threshold (Gy) Time to develop effect 
Lens of eye   
Detectable opacities 0.5-2 > 1 year 
Cataract formation 5.0 > 1 year 
Skin   
Skin reddening 3-6 1 - 4 weeks 
Temporary hair loss 4 2 - 3 weeks 
Skin death and scarring 5-10 1- 4 weeks 
Testes   
Temporary sterility 0.15 3 - 9 weeks 
Permanent sterility 3.5 - 6 3 weeks 
Ovaries   
Permanent sterility 2.5 - 6 < 1 week 
Gastrointestinal   
Mucosa lining loss 6 6 - 9 days 
Bone marrow   
Reduction of blood cell production 0.5 1- 2 months 
1% incidence level based on ICRP publication 103 (2007) 
Table 4. Dose Threshold for Deterministic Effects 
Reviews of biological and clinical studies have shown that, below 0.1 Gy, no deterministic effects from 
radiation exposure have been proven. This is primarily that the cellular repair mechanisms occur 
continuously, and this prevents deterministic effects at low radiation exposure levels. Examples of 
these effects are erythematic, epilating, depression of bone marrow cell division central nervous 
system damage, damage to the unborn child etc. Some organs are more radiosensitive than others. 
The law of Bergonie Tribondeau [42], states that cells tend to be radiosensitive if they have three 
properties: high division rate, long dividing future, the type of cell is unspecialized. In other words, the 
law states that the radiosensitivity of a cell type is proportional to its rate of division and inversely 
proportional to its degree of especially. So, rapidly dividing and unspecialized cells as a rule are the 
most radiosensitive. One important no stochastic effect is death. This results from damage to the 
bone marrow, then to the gastrointestinal tract than to the nervous system. 
Stochastic effects (earlier called late effects) are effects that are probabilistic. They may or may not 
occur in any given exposed individual. These effects generally manifest many years, even decades, 
after radiation exposure. Their major characteristics, in direct contrast with those for nonstochastic 
effects, are: 
- Threshold may not be observed 
- The probability of the effect increases with dose 
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- We cannot definitively associate the effect with radiation exposure. 
Examples of this effect are cancer induction and genetic effects.  
 
2.6.1.1 Cancer induction 
The fact that ionizing radiation causes cancer is well established. At high enough doses, the rate of 
production clearly increases with increasing the dose. Radiation-induced cancer is indistinguishable 
from a “spontaneous” cancer. In the populations that have been studied to establish relationships 
between dose and risk, in most cases, the radiation doses them and the rates of cancer are subject to 
considerable uncertainty. For different types of cancer if we plot the cancer rate against the dose 
received; the data will show an upward trend Graph 1. The question that none of the data sets clearly 
answers is that of the shape of the curve at low doses and dose rates. The controversy continues to 
rage over whether the relationship between dose and the absolute or relative number of induced 
cancer should be extrapolated to zero dose. That means all exposure to radiation, no matter how 
small, is associated with some risk of cancer, or if there is a threshold.  
 
 
Graph 1.  Possible dose-response curves describing the excess risk of stochastic  
health effects at low doses of radiation 
 
There is evidence to support both views, even controversial theory of hormesis. According this theory 
exposure to low levels of radiation is associated with less cancer induction than in systems deprived 
of all radiation exposure. The possible mechanism here is that exposure to radiation stimulates 
cellular repair mechanism so called adaptive response. In individual, experiments, hormetic and 
adaptive response mechanisms have been demonstrated [43]. Very recent research has profoundly 
challenged conventional notions of the relationship between radiation dose and observed effects. In a 
report by the American Association of Physicists in Medicine, (AAPM) [44], it is noted that various 
cellular and organ studies have shown that low LET type effects have been seen when Auger emitters 
are present only in the cytoplasm of cells, whereas when Auger emitters may be incorporated into the 
DNA of cells. In that case, the resulting survival cells curves are similar to those seen for high-LET 
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alpha particles. The committee concludes that the absorbed dose from Auger emitters must be 
calculated at a level suited to the biological system employed. For that purpose, the target volume 
must be determined on a case by case basis. 
Brooks point out that absorbed dose is often used too liberally as a direct indicator of radiation risk 
[45]. The simple concept of energy absorbed per unit mass of tissue has good predictive value at 
some dose levels, and if the activity is uniformly distributed throughout the organ, it is clearly not a 
good predictor of biological response when activity is not uniformly distributed and when energy 
deposited by high LET particles occurs in regions where it is difficult to distribute the energy over the 
appropriate target mass. The experimental evidence has shown that in some condition cells with no 
direct energy deposition from radiation may demonstrate a response so-called bystander effect. 
The data available concerning the bystander effect fall into two quite separate categories, and it is not 
certain that the two groups of experiments are addressing the same phenomenon. First, there are 
experiments involving the transfer of medium from irradiated cells, which results in a biological effect 
in unirradiated cells. Second, there is the use of sophisticated single particle micro beams, which 
allow specific cells to be irradiated and biological effects studied in their neighbors; in this case 
communication is by gap junction. Medium transfer experiments have shown a bystander effect for 
cell lethality, chromosomal aberrations and cell cycle delay. The type of cell, epithelial vs. fibroblast, 
appears to be important. Experiments suggest that the effect is due to a molecule secreted by 
irradiated cells, which is capable of transferring damage to distant cells. Use of a single microbeam 
has allowed the demonstration of a bystander effect for chromosomal aberrations, cell lethality, 
mutation, and oncogenic transformation. When cells are in close contact, allowing gap junction 
communication, the bystander effect is much larger magnitude than the phenomenon demonstrated in 
medium transfer experiments. A bystander effect has been demonstrated for both high and low-LET 
radiations, but it is usually larger for densely ionizing radiation such as alpha particles. Experiments 
have not yet been devised to demonstrate a comparable bystander effect on a three-dimensional 
normal tissue. Bystander studies imply that the target for the biological effects of radiation is larger 
than the cell, and this could make a simple linear extrapolation of radiation risks from high to low 
doses of questionable validity [46]. 
Another mechanism called genomic instability also suggests that the effects from radiation may be felt 
in cells other than those directly irradiated. Cells irradiated with radiation have been shown to not 
have observable radiation damage, but subsequent generations of these cells may show DNA 
damage 
In the scientific world, there is still no agreement concerning this issue. Most regulatory bodies in the 
United States and elsewhere follow and use the Linear No Threshold Model (LNT). LNT model of 
cancer risk prediction was validated by (Biological Effects of Ionizing Radiation) BEIR VII Committee, 
and still it is best working model. The problem arises when this model is used for scientific 
conclusions [47]. 
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It is very important to notice that radiation induced cancer in a population and the cancers are always 
expressed at some long time after the exposure. This period of time between exposure and the 
expression of the disease is called the latent period. Large populations have to be considered to 
perform statistically valid studies. Leukemia has the shortest latency period before expression, (5 -15 
years) after exposure. With most solid cancers, the latent period is more like 20 years. Late effects of 
radiation also occur due to environmental radiation. Since accurate information is lacking on the 
natural frequency of these effects, it is difficult to estimate the influence of low radiation doses on this 
increase. In addition sex, age, genetic history, geography and other socio-economic factors influence 
the frequency of natural occurrence. Therefore, it is very difficult to prove that a cancer is directly 
related to earlier radiation exposure, because the other factors encountered during the latency period 
may be the actual cause of the cancer.  
An estimation of risks to a person at low radiation doses has been made from following sources: 
- Human exposures – medical, occupational, military and accidental 
- Experimental animal studies 
- Experiments on mammalian cell cultures 
- Prospective studies of the victims of the atomic bomb explosions in Nagasaki and Hiroshima 
- The inhabitants of Bikini and other Pacific island who were exposed to radiation as a result of 
fall-out. 
In the Table, 5 are presented the risk of the cancer as deducted from the currently available 
information. 
 
Type Male 
(rad per 106 persons) 
Female 
(rad per 106 persons) 
Leukemia 660 730 
Nonleukemia 110 80 
Total 770 810 
Table 5. Excess cancer mortality-life time risk, single exposure (Chandra 1992) 
 
2.6.1.2 Type of radiation, Amount of Tissue and Biological Variation 
Even for the same absorbed dose, different type of radiation, have different abilities to damage tissue. 
A weighting factor (quality factor, ωR) is introduced which represents the relative amount of damage 
likely to be caused to live cells by the same amount of different radiation types. Higher linear energy 
transfer (LET) is produced by alpha particles, protons and neutrons as a result of the production of 
recoil protons. Lower LET radiations are electrons and gamma rays and x-rays as a result of Compton 
and photoelectric interaction. High LET produces greater damage in a biological system than low 
LET. The relative biological effectiveness (RBE) of a radiation for producing a given biological effect is 
defined as follows [48]. 
RBE = D/D’                                                         (30) 
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D - Dose of standard (x-ray) radiation needed to produce a biological effect. 
D’ - Dose of a second radiation needed to produce the same biological effect.   
The biological response depends on the type of tissue (ex: thyroid, ovaries, testes, bone marrow, or 
nerve tissue) involved. All cells are not equally sensitive to radiation damage. In general, cells which 
divide rapidly and/or are relatively non-specialized tend to show effects at lower doses of radiation 
than those which are less rapidly dividing and more especially. Examples of the more sensitive cells 
are those which produce blood. This system (called the hemopoietic system) is the most sensitive 
biological indicator of radiation exposure. The risk of malignancy per Sv is different for various tissues 
of the body. Given the same radiation dose and dose rate, bone marrow is much more sensitive than 
nerve tissue to certain types of radiation damage. Biological factors like species, individual and cell 
sensitivity and the recipient’s age are important. Injury to a biological system also depends upon the 
amount of tissue irradiated. 
 
2.6.2 Internal radiation dosimetry 
2.6.2.1 Dose Calculation 
The radiation absorbed dose depends on several factors: 
1. The amount of radioactivity administered  
2. The physical and biological half-lives of the radioactivity 
3. The fractional abundance of the radiation in question from the radionuclides 
4. The biodistribution of radioactivity in the body 
5. The fraction of energy released from the source organ that is absorbed in the target volume, 
which is related to the shape, composition and the location of the target.  
The physical characteristics of a radionuclide are well established. Information about the 
biodistribution of the ingested radioactivity can be obtained from various experimental studies in 
humans and animals. Factors 4 and 5 vary from one individual to another and therefore they are 
approximated for a “standard” or “average” 70-kg man. Radiopharmaceuticals administered to 
patients are distributed in a different region of the body. The region of interest for which absorbed 
dose is to be calculated is considered the “target”, whereas all other regions contributing to the 
radiation dose to the target are considered”sources”. The source and the target become the same 
when the radiation dose due to the radioactivity in the target is calculated [49].  
 
2.6.2.2 Absorbed dose  
All dose quantities are based on the fundamental definition of absorbed dose in a point [50] as the 
quotient of  by	, where  the mean energy is imparted to matter in an infinite volume (dV) 
at a point of interest in a material of density (ρ) during a certain period of time by ionizing radiation 
and  is the mass in (dV) 
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The absorbed dose (D) is defined as the statistical average of the energy (E) imparted per unit mass 
at a point: 
D = dε/dm                                                          (31) 
The unit of absorbed dose is the Gray (Gy) and one Gy is equal to 1 joule of energy absorbed per 
kilogram of matter (1J/kg) [51]. The concept of absorbed dose applies to all categories of ionizing 
radiation dosimetry, to all materials, and to all forms of ionizing radiation.  
Absorbed dose can be measured absolutely or relatively using advanced equipment, not at all 
suitable for daily radiation protection work. In all fields of radiation protection, there is an interest to 
estimate the risk to the individual or to a group of individuals of the exposure which they have 
undergone. Together with the basic quantity absorbed dose, there are two types of quantities defined 
for specific use in radiological protection: protection quantities (defined by the ICRP and used for 
assessing the exposure limits) and operational quantities (defined by ICRU and intended to provide a 
reasonable estimate for the protection quantities). The relationship between physical protection and 
operational quantities are given in the following Figure 9. 
Figure 9. Relationship between physical protection and operational quantities (S.Mattsson 2013) 
 
2.6.3 Protection Quantities 
The protection quantities are mean absorbed dose to an organ or tissue (DT), equivalent dose in 
tissues or organs (HT) and effective dose (E). 
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2.6.3.1 Calculation of mean absorbed dose 
 To assess radiation exposure to humans and correlate it with the risk of exposure, mean absorbed 
dose in tissues or organ is used. The mean absorbed dose, to an organ from internally administered 
radiopharmaceuticals is dependent on the characteristics of both the radionuclide and pharmaceutical 
in terms of the type of radiation emitted and spatial and temporal distribution of the radionuclide in the 
body. The mean absorbed dose, DT (Gy) averaged over the tissue or organ (T) is defined as: 
 
DT = εT/mT                                     (32) 
Where (εT) is the mean total energy imparted in a tissue or organ (T) and (mT) is the mass of that 
tissue or organ. 
 
2.6.3.2 Equivalent dose 
In 1973, ICRU [52] defined equivalent dose H, which is used to take into account the fact that 
different particle types have biological effects that are enhanced per given absorbed dose. The 
absorbed dose can, however, result in different biological effects depending upon the type and energy 
of radiation causing the dose. The equivalent dose is expressed in a unit named the Sievert (Sv). 
Equivalent dose is equal to the absorbed dose multiplied by a factor that takes account of the way a 
particular radiation distributes energy in tissue, thus influencing its effectiveness in causing harm. The 
concept of equivalent dose is applied only to radiation exposures received by human beings. The 
dose equivalent (HT) at a point of interest in tissue or organ (T) is given by the equation: 
 
   	H = ∑w D,                                      (33) 
 The w is the radiation weighting factor for radiation (R) and D  is the mean absorbed dose in 
organ or tissue (T) from radiation (R). For gamma rays, X-rays and beta particles, the factor is set at 
1, therefore the absorbed dose and equivalent doses are numerically equal. For alpha particles, the 
factor is 20, so that an absorbed dose of 1 Gy from alpha radiation corresponds to a dose equivalent 
of 20 Sv, [53].The factor (ωR) is defined to be a function of linear energy transfer (LET). LET is the 
radiation energy lost per unit length of path through a material. Different types of radiation have 
different LET. X-rays, gamma rays and electrons are known as low LET radiation. Higher LET is more 
destructive to biological material than low LET radiation at same dose. The radiation used in nuclear 
medicine is typically low LET radiation. LET is approximately equivalent to the stopping power for 
charged particles and is expressed in units of keV µm-1. All of the radiation ultimately manifests itself 
through charged particles, so LET is a good measure of localized radiation damage to materials not 
limited to biological structures. For the common situation where a spectrum of energies and a mixture 
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of particle types are present, the value of (ωR) for the complete radiation field is an average over 
spectrum of LET present weighted by the absorbed dose as a function of LET, D (LET). 
The values of the new radiation weighting factors (ωR) compared with previously recommended are 
given in the following Table 6. 
 
Radiation type Radiation weighting factors (ωR) 
ICRP 1990 ICRP 2007 
Photons, electrons and muons of all 
energies 
1 1 
Protons and charged pions 5* 2 
Alpha particles and heavy ions 20 20 
Neutrons Step and continuous 
function of neutron 
energy 
Revised continuous 
function of neutron 
energy 
*Pions were not considered   
Table 6. ICRP recommended radiation weighting factors (ICRP1990, 2007) 
In general, the values of (ωR) in the 1990 ICRP system are larger than those of (ωR) used in 1973 
system. The latest guidance found in ICRP publication 103 [54] has reduced the size of this increase 
in (ωR) for neutrons in some energy intervals. Generally more serious effects are produced by high 
doses rather than low doses. Also, it is generally assumed that the dose and effect are linearly related 
even at low doses. There is no threshold radiation dose below which the two important effects – 
(production of genetic damage and the induction of cancer) are not produced [53]. 
 
2.6.3.3 Effective dose  
When the body is irradiated after administration of radiopharmaceuticals, individual organs and 
tissues are likely to receive different equivalent doses. Since various tissues and organs have 
different radiation sensitivity, the quantity effective dose E is introduced, providing the possibility to 
express the radiation risk to patients undergoing different radio diagnostic procedures by means of a 
single figure. The effective dose is a revision of the effective dose equivalent (He) [55] which initially, 
was developed for occupationally exposed persons, and is defined as the sum of the equivalent 
doses H weighted by the tissue weighting factor	w. Effective dose	E, obtained as the sum of 
equivalent doses to each organ or tissue, weighted using defined tissue weighting factors	w, to 
take account of the contribution of the individual organs and tissues to overall detriment from cancer 
and hereditary effects is given by 
 
     E = 	∑w H =	∑w ∑wD,                                    (35) 
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The unit for effective dose is Sievert, Sv (J/kg). The basis for the weighting factors is the relative 
contribution of the organ to the total detriment, based on probability of fatal cancer; relative length of 
life lost; relative non fatal contribution and severe genetic effects [56, 37]. The (ωT) values have been 
developed from the reference population of the equal number of both sexes and the wide range of 
ages. On the Graph 2 are presented the comparison between changing values of ICRP 26, ICRP 60 
and ICRP 103. 
Graph 2. Tissue weighting factors according ICRP26, ICRP 60 and ICRP 103 
 
The organ doses that are needed for calculation of effective dose are calculated for reference male 
and female persons using a family or reference phantoms of which the adult male and adult female 
phantom is already published [38]. Using the reference phantoms, dose conversion coefficients for 
external and internal exposure are calculated for reference conditions: 
- Standard irradiation geometries for external radiations [39]. 
- Standard (ICRP) biokinetics models for internal emitters [40]. 
 
Tissue  	 
Bone marrow, breast, colon, lung, stomach and remainder tissues (13*) 0.12 0.72 
Gonads 0.08 0.08 
Bladder, esophagus, liver and thyroid 0.04 0.16 
Bone surface, brain, salivary glands and skin 0.01 0.04 
*Reminder tissues: adrenals, extra thoracic (ET) region, gall bladder, heart, kidneys, 
lymphatic nodes, muscle, oral mucosa, pancreas, prostate (male), small intestine, spleen, 
thymus and uterus/cervix (female). 
Table 7. ICRP recommended tissue weighting tissue factors, ICRP 2007 [36] 
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Effective dose is not based on data from any one individual person and does not provide individual 
specific dose but rather that for a reference person under a given exposure situation. Effective dose 
because of underlying approximations and simplifications is not suitable for risk assessment for 
individuals. It is, however, of practical value for comparing the relative doses related to stochastic 
effects from different diagnostic examinations, the use of different technologies for the same medical 
examination provided that the representative patients or patient populations for which the effective 
doses are derived are similar with regard to age and gender.  
 
2.6.3.4 Absorbed dose rate 
According to the publication ICRU No67 (2002) [57] when a radionuclide decays by emitting only one 
type of radiation the average absorbed dose rate in the target volume for the transformation volume 
source is given by: 
      D= ∆ ÃΦ/m            (36) 
Where (∆) is the mean energy emitted per nuclear transformation, (Ã) is the accumulated activity of 
the source volume, (m) is the mass of the target volume, and (Φ) is the fraction of energy absorbed by 
mass of the target volume. Volume settings source and target volume are illustrated in Figure 10 
 
 
 
 
Figure 10. Representation of source and target volume 
 
Depending on the metabolism they are associated to the incorporated radionuclides could decay in 
lungs, in gastrointestinal (GI) tract or other specific organs: these are known as source organs. The 
tissues in which energy is deposited following a nuclear decay are known as target organs. In the 
ICRP publication there are as many as 23 target organs listed. 
 
2.6.3.5 Energy emitted per disintegration 
This term is known as the mean energy emitted by nuclear transformation of a radionuclide. It is 
expresses by: 
    ∆i = KnZEi           (37) 
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(Ei) is the average energy of the (i) type of radiation, (ni) is the average number of the (i
th) type of 
radiation emitted by nuclear transformation and (K) is a constant that depends on the chosen 
system.  Generally this term is tabulated according to the type emission of radiation. 
 
2.6.3.6 Absorbed fraction 
According Sgouros [58] the absorbed fraction is the fraction of the energy emitted by the source 
volume which is absorbed in the target volume, according. The flux (Φ), equals the energy absorbed 
in the target volume for the ith type radiation emitted by the source volume divided by the energy of the 
ith type of radiation emitted by the source volume. 
If the source volume emits electrons, alpha particles it is generally that these particles are completely 
absorbed by the tissue volume source. 
Electron                Assume (AFT ← T = 1 elsewhere = 0 
 Alpha                           Assume (AFT ← T = 1 elsewhere = 0 
If the volume source emit photons depending on its energy, it will be absorbed not only the volume of 
tissue source as well as other organ tissues adjacent to the volume source. Photon data are found in 
Reference Man (MIRD Pamphlet). In this work, it was considered only the transport photon irradiation 
scenarios. Figure 11. 
 
 
Figure 11. Different tissue absorption properties of photos versus electron or  
α- particle emissions of radio nuclide 
 
Additional considerations are required for wall organs and bone. The computation of the values of 
	 ←  for each combination source to target organ is performed by means of Monte Carlo 
radiation transport calculations on anthropomorphic numerical phantoms.  
 
2.6.3.7 Accumulated activity 
Activity located in the source organ and the time that remains in this region depends on the properties 
and biological characteristics of the radiopharmaceutical and individual metabolism as well as the 
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physics half-life of the radionuclide. The total number of disintegration is the sum of all nuclear 
transformations in this organ within a time interval of interest is accumulated activity Ã and is defined 
as: 
   Ã = 	w Atdtt2t1             (38) 
 
Where A (t) is defined as activity function which is integrated in time interval interest. According 
Zanzonico et al. [59] measures of activity versus time are illustrated as shown in Graph 3. 
 
 
 
 
Graph 3. Time activity curve 
 
The function activity can usually be described using a sum of exponentials, as can be seen from the 
following equation: 
 
   At = ∑ AH+ ∗ eD
∗ = ∑ AH+ ∗	eQ∗                                 (39) 
where (Amax) is the maximum activity in the organ, (λ) is the physical decay constant corresponding to 
the physical half-life of the radionuclide, (λj) is the elimination constant biological component of the 
exponential, (λef)j is the effective constant decay for the j-
th component of the exponential, (t) is the 
total time radionuclide in a particular organ. The maximum activity captured by the residual thyroid 
tissue can be expressed by: 
    AH+ = f ∗ AA                                 (40) 
Where (f) is the maximum activity fraction captured by the residual thyroid tissue from administered 
activity to patient. For a simple model which considers only one compartment accumulated biological 
activity can be calculated by the following equation [60]. 
 
A = w AH+ ∗ eQ∗dtE = AH+ ∗ 1 − eQ∗
/λP¡<                      (41) 
Where λef = ln(2)/T1/2ef. As the accumulated activity until the complete elimination the radionuclide is 
obtained when the integral is calculated in the range of zero to infinity, the radionuclide is obtained 
when the integral is calculated in the range of zero to infinity, it has been: 
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A =	AH+ AP¡ = AH+ ∗ T?/8P¡ ln2 = 1,443 ∗ AH+ ∗⁄ T?/8P¡⁄               (42) 
 
2.6.3.8 Residence time 
If the accumulated activity (A) is normalized by the administered activity (Ao), the activity units are 
canceled and new parameter residence time (Ʈ) is obtained [57]. 
 
          Ʈ = A/Ao                                  (43) 
 
2.6.3.9 Specific absorbed fraction 
It is defined as the fraction of energy by the radionuclide in the volume-source that is absorbed per 
unit mass of the target volume: 
    Φ = Φ/m                                    (44) 
This equation can be used to specific target volume and surface [118]. The values of SAF’s have 
been calculated and revised on the basis of the Oak Ridge series of analytical anthropomorphic 
phantoms. Recently new sets of data have been extensively calculated using “voxel” phantoms. 
 
2.6.3.10 Average absorbed dose per unit accumulated activity "S" values 
 “S”-values are defined as average absorbed dose per unit cumulative activity. The physical aspects 
can be combined within magnitude in volume source, according to following equation: 
 
                 S = 	∆ ∗ Φ =	 ∆∗§H                                                (45) 
This equation contains information regarding the radiation emitted by volume source, the geometry 
and composition of the source volume and target volume. Thus average absorbed dose can be 
simplified to the following equation: 
     D¨ = 	A ∗ S                                              (46) 
Equation (46) is considered only for radiation from a volume type source. When considering different 
source volumes, various types of radiation and various target volumes can be used another equation: 
 
    Du = ∑ A&& SrS ← r&                  (47) 
Where Srk ←	 rh	 indicates the average absorbed dose per unit accumulated activity of the target 
volume of the volume source, rS, r&.		The subscript “h” represents the number of volumes source. 
When the target volume is a source volume, the dose is known as self-dose, when the source volume 
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is a target volume dose is known as cross-dose. Average absorbed dose per unit accumulated activity 
is given by: 
   SrS ← r& = ∑ ∆ZΦZrS ← r& = ∑ ∆©§©%ª←%dHªZ               (48) 
The “S” values can be calculated from MIRD phantom as it was done in this work.  
 
2.6.4 Anthropomorphic model 
The evaluation of the dose in organs and tissues of the human body for various conditions of 
exposure to ionizing radiation has a very important role for radiation protection. However, due to the 
inability of the positioning of dosimeters in many cases is not feasible to measure the dose in organs 
and tissues of interest. To solve this problem, there is the possibility to use simulation models of 
human body, which aim is to represent, as best as possible external and internal structures enabling 
evaluation by the simulation of dose, irradiation conditions and exposure of individuals to external 
sources [61]. 
The anthropomorphic models used to evaluate the dose can be classified into three different types: 
• Physical models constructed in whole layers, using materials presenting properties of 
interaction with matter similar to human tissues. In this type of model there are holes where it is 
possible to place dosimeters; 
• Using mathematical models equations for the representation of several organs and tissues of a 
human body. These equations describe organs on geometric way as ellipsoids, cubes etc. 
• The models based on images of the external and internal components of the human body of 
real people, mainly obtained through medical imaging techniques such as Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI).This model is known as voxel 
simulator. The voxel is defined as an elementary unit of volumetric digital image, or three 
dimensional pixel, which make up the structure of the simulator. These models are more realistic 
because they represent individual anatomical structures more faithfully in a computational 
context than the other models; therefore provide a better estimation of dose.   
 
 
 
 
 
 
 
 
 
Figure 12. Differences between a mathematical simulator and a simulator voxel 
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The most popular analytical phantom is the so called MIRD phantom, which consists of three types of 
tissues: lung, skeletal and soft tissue (red bone marrow). Such phantoms are used in Monte Carlo 
radiation transport simulations where the source is usually located within each source organ. Models 
have been extended to take into account age groups other than adults. 
Figure13. The adult human phantom external dimensions (MCNP model of ADAM) 
 
 
 
Figure 14. The adult human phantom  
GI tract (an MCNP model of the sigma (Courtesy L. Casalini)) 
 
The model used in this work and data for the creation of this model was taken from MIRD and is 
explained in details in material and methods part. There are developed voxel models which are 
presented on Figure 15. Also, there are developed software’s which might be used for dosimetry, but 
with well known individual based input data: MIRDOSE, OLINDA, RADAR etc. 
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Figure 15. Voxel based phantoms: Golem, Holga, Donna and Irene Radiat. Env. Biophys (2001) 
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2.7 Monte Carlo Method 
 
The Monte Carlo (MC) method was invented by Jon von Neumann, Stanislaw Ulam and Nicholas 
Metropolis, who gave it its name, and independently by Enrico Fermi. Originally it was not simulation 
method, but a mathematical approach aimed at solving a multidimensional integrodifferential equation 
by means of the stochastic process. When the method is applied to physical stochastic process, such 
as neutron diffusion, the model (in this case a random walk) could be identified with the process itself. 
Under those circumstances, the Monte Carlo method represents a simulation technique since every 
step of the model is aimed at mimicking an identical step physical process. Particle transport and 
interaction represent a typical stochastic process and is, therefore, perfectly suitable for Monte Carlo 
simulation. Many applications in high energy physics and medicine are based on Monte Carlo 
simulation in which the history of each particle (trajectory, interactions) is reproduced in detail. An 
important and useful feature of MC simulations is the possibility of studying parameters that cannot be 
measured experimentally. While, before 1990, the typical Monte Carlo approach was to simplify 
problems as much as possible, the modern Monte Carlo codes instead require fewer approximations 
and provide more accurate solutions [62]. 
 
2.7.1 Phase space 
The concept of phase space is central to the understanding of the Monte Carlo method. Phase space 
is a concept of classical statistical mechanics. Each phase space dimension corresponds to a particle 
degree of freedom: three dimensions correspond to the position in real space (x, y, z), and three other 
dimensions correspond to the momentum: px, py, pz, or to energy (E, Θ, Φ). More dimensions may 
correspond to other possible degrees of freedom: quantum numbers, particle type and so on.  Each 
particle is represented by a point in phase space. Time can also be considered a coordinate, or it can 
be considered an independent variable. The variation of other phase space coordinates as a function 
of time constitutes a particle “history” [62]. 
 
2.7.1.1 Phase Space Density 
The basic quantity describing a population of particles is the phase space density n (t, x, y, z, px, py, 
pz), which is the number of particles in an infinitesimal volume of phase space. The product (nv) of the 
space phase density and the particle velocity are important because they represents the rate of the 
path length density and therefore relates to the particle interaction rate with matter. The quantity        
Ψ = nv is called angular flux and is the most general radiometric quantity. (Ψ) Can also be defined as 
the derivative of the fluence (Φ) with respect to all phase space coordinates time, energy and solid 
angle (direction vector). 
   Ψ =	 ¬§¬¬$¬R­­®	 = Φ¯$R­­°                  (49) 
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The angular flux is a fully differential quantity, but most Monte Carlo solutions are integrals of (Ψ) over 
one or more phase space dimensions: coordinates, time, energy, angle. Fluency (Φ) on the other 
hand is the most integral radiometric quantity:  
  Φ = w$wR­­°wΦ¯$R­­°dEdΩ­­°dt                    (50) 
Often in Monte Carlo calculations the time dependence is not explicitly followed and the fluency 
differential with respect to energy Φ (E) = dΦ/dE  is the quantity of interest [62]. 
 
2.7.1.2 Physical meaning of the elements of Boltzmann equation 
Calculation using Monte Carlo method is different from the calculations based on deterministic 
methods [63]. When it is desired to describe the radiation transport using the deterministic method, it 
solves the Boltzmann transport equation which is balance equation in phase space. At any phase 
space point, the increment of particle density (n) in an infinitesimal phase space volume is equal to 
the sum of all “production terms” minus the sum of all “destruction terms”. 
?
'
¬±
¬ + Ω­­° ∙ ∇Ψx + ΣΨx − Sx = wRw$ΨxΣBx′ → xdx                   (51) 
where (x) represents all phase space coordinates: µ­°,  Ω­­­°, E, t. The various elements of the Boltzmann 
equation have the following physical meaning: 
• The 	1v
∂Ψx
∂t    term represents the time dependent change of angular flux, due to particle decay 
• Ω­­° ∙ ∇Ψx is the change due to translational movement without change of energy and 
direction. 
• ΣΨxWhere Σ	the total is macroscopic cross section, is a term representing absorption. 
• Sx represents the particle sources 
• The double integral, where Σ¸ is the macroscopic scattering cross section, refers to scattering, 
change in angular flux due to direction change without a change of particle position. 
All Monte Carlo particle transport calculations are attempts to solve the Boltzmann equation in its 
integral form, carrying out the integration over all possible particle histories. According to the order 
described in the text, the Boltzmann equation has no analytical solution. In Monte Carlo 
calculations transport equations are not solved analytically, but to simulate processes of 
interaction of individual particles and record up some aspects of their behavior. The behavior 
medium is then inferred from the Central Limit Theorem and the average behavior of individual 
particles as described in Annex 1. The Monte Carlo method can in principle, simulate any problem 
particle transport in any geometry. The technique simulates the physical laws that acting on the 
particles. The accuracy of the results depends only on the approximation of physical theories with 
the “reality” of interactions, and the number of “stories” executed. Monitoring of the particle from 
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its creation until the end of his life is defined as “history”. According Laurel et al. main components 
of a Monte Carlo algorithm are described as follows:   
• Probability distribution: This method simulates the physical laws that act on the 
particles. These laws can be described by one or more distributions probability and the 
accuracy of the results depends only on the approximation of physical theories with the 
“reality” of interactions, and the number of “histories” executed. In other word, the 
physical system must be described by a set of pdf’s. 
• Random Number Generator: The Monte Carlo method is based on randomness of 
physical processes. To provide this simulation process of randomness, random number 
generator was used. This generator should be capable of providing the random values, 
numbers, uniformly distributed between 0 and 1, short run time (speed of the algorithm) 
and period (sequence of random numbers) which produces numbers apparently 
independent, similar to figures from truly random occurrences. 
• Marking, counting or scoring: The results of each simulation must be accumulated. 
Counters are used to accumulate the number of attempts and successes. The outcomes 
must be accumulated into overall tallies or scores for the quantities of interest. 
• Error estimation: an estimate of the statistical error (variance) as the function of the 
number of trials and other quantities must be determined 
• Variance reduction techniques: methods for reducing the variance in the estimated 
solution to reduce computational time for Monte Carlo simulation. 
• Parallelization and vectorization algorithms to allow. 
To perform the transport simulation of radiation that defines the probability of interaction of a particle 
per unit distance is	Σ¸. The probability that an interaction occurs between x + dx follow the Poisson 
distribution, given by: 
                                         pxdx = e¹∑ dx                          (52) 
For each random number uniformly distributed in the interval 0 ≤ η < 1 there is a variable x, a 
cumulative distribution function, which obeys the following relationship: 
 
     η = w px?dx?<                            (53) 
Substituting the value of p(x), and performing the integration  
     η = 1 − e¹                              (54) 
And 
½ =  y[?¾
Σ¿
                        (55) 
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Since (1- η) is also uniformly distributed in the interval (0, 1) then value coincidence with the (η) and 
will result in the following equation: 
       ½ =  y[¾
Σ¿
                       (56) 
 
The distance between interactions, (S) is derived by the following equation (57) where 
                                 = −À lnÁ                         (57) 
 
À = ?
Σ¿
	is the mean free path. The probability of interaction can be defined with attenuation coefficient 
being the same and may vary depending on the power photon, the composition and density of the 
medium in which it moves.  
 
2.7.2 Determination of errors in the Monte Carlo technique 
The result of a calculation using the Monte Carlo method is the average number of “histories” 
performed during the simulation (BRIEMEISTER et al 1986). The histories are generated by random 
sampling and a value of the quantity studied is allocated to each “history”. Let p(x) be the probability 
function of a “history” of value x. Mx variable is given by p(x). 
 Mx = w x	px	dx,+                                  (58) 
The values of p(x) and thus Mx are not known exactly, but the true mean; (x) can be estimated using 
the Monte Carlo method (59). 
      ` xÃ = ?/∑ xZ/ZÄ?                           (59) 
where xi value of corresponding to the “history” (i), and (N) is the total number of “histories”. The 
variance (σ2) can be estimated using following formula (60). 
    σ8 = ?/?∑ xZ − xÃ8/ZÄ?                                                  (60) 
The square root of (σ2) is defined as the standard deviation of the population½Å  obtained using the 
values ½Å that were generated by random sampling. For (N) large, the variance of the distribution 
averages of Æ½¨2 can be calculated by the equation:  (61) 
      σÃ8 = 3

/                     (61) 
Thus 
    σÃ = 3√/        (62) 
  
To reduce ÆÈ̅ 	half is the need to run four times the number of “histories” which is the problem inherent 
in the Monte Carlo method. Using Central Limit Theorem, when N>>1: 
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A) xÃ − σÃ < Mx < xÃ + σÃ, interval of confidence is 68%. 
B) xÃ − 2σÃ < Mx < xÃ + 2σÃ, interval of confidence is 95%. 
C) xÃ − 3σÃ < Mx < xÃ + 3σÃ, interval of confidence is 99.7%. 
If we associate the greatness absorbed dose to be allocated to each “history” we can calculate the 
standard deviation SD of the absorbed dose in each organ using equation (62) where N is the number 
of simulated photons, (Di) is the dose absorbed by the i-th photon, (D) is the average absorbed dose 
deposited in each organ. Then calculated coefficient of variation (CV) is given by (63). 
SÊ¨8 = ∑ DZ − D¨8/ZÄ? /NN − 1                         (63) 
  CV = xÍ¨Ê¨                                  (64) 
BRIESMEISTER 1986 presented a way to verify the degree of reliability of the radiation transport 
calculations using the method of Monte Carlo, as it is shown in Table 8. 
 
Coefficient of variation (CV) values Rating the calculated magnitude 
0.5 to 1 Disposable 
0.2 to 0.5 Unreliable 
0.1 to 0.2 Questionable 
<0.10 Generally trustworthy, except for point detectors 
<0.05 Generally trustworthy 
Table 8. Values of coefficients of variation (CV) provided by BRIESMEISTER (1986) 
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2.8 Risk assessment of the nuclear medicine patient  
 
Diagnostic and therapeutic applications of radioiodine in hospitals worldwide have continued to grow, 
so the general public awareness of the hazards of ionizing radiation and their tendency to question 
clinical management has increased. Recent recommendations have identified an increased risk from 
radiation and contain reduced occupational and public dose limits [56, 64]. Therefore, a key factor in 
sustaining this growth in clinical activity while retaining the confidence of the referring clinician, the 
patient and the public, is for nuclear medicine practitioners to maintain and up-to-date knowledge of 
the radiation risks associated with their procedures. The need to understand the methodology used to 
assess these risks and to appreciate the associated limitations is of great importance. Two types of 
risk are identified following the administration of radiopharmaceutical to the patient: the risk to the 
patient and risk to critical groups exposed to the patient. Administered radioactivity presents a risk to 
the patient who should be balanced against the benefit from obtaining a diagnosis or carrying out the 
treatment. A method for quantifying the risk to the patient is described in terms of estimating the 
effective dose. The main limitations in these estimates are uncertainties in the biokinetics data and 
the assumption of a uniform distribution of activity in each organ. Contact with radioactive tissue from 
the patient or exposure to radiation emitted from radioactivity retained by the patient presents a risk to 
hospital staff and to members of the public. Also, member’s of patient’s family, particularly young 
children and breast-fed infants, are of particular concern, and their associated risks require careful 
assessment [65]. 
 
2.8.1 Risk evaluation 
It is essential to explain the patient which sets out to evaluate the risk associated with nuclear 
medicine procedure; it is also essential to advise the patient of the risk associated with not carrying 
out the procedure.  
 
2.8.2 Relative risk 
A very simple method of explaining the risk associated with the procedure is to compare the effective 
dose with that from a more familiar radiation source such as diagnostic X-ray procedures Table 9 [64]. 
Comparison with the average dose from background radiation or with the dose from a change in 
lifestyle yielding a background dose higher than the average value can also provide a simple way of 
placing the nuclear medicine risk into a meaningful context. For example in Macedonia, the average 
dose from natural background radiation is 2.0 mSv/y.  
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Procedure Effective dose (mSv) 
Plain film  
Chest 0.04 
Skull 0.1 
Pelvis 1.0 
Thoracic spine 1.1 
Abdomen 1.4 
Lumbar spine 2.2 
Intravenous 
urogram 
4.6 
Barium enema 8.7 
Ctomography  
Head 1.8 
Cervical spine 2.9 
Thoracic spine 5.8 
Pelvis 7.3 
Chest 8.3 
Table 9. Effective dose 
 
2.8.3 Absolute risk 
Expressing the risk in absolute terms not only allows an estimate to be made of the probability of 
radiation induced injury. It allows comparison with the risks associated with the natural occurrence of 
these effects and with risks associated with occupational, personal and recreational activities. ICRP 
gives a risk for severe hereditary effects, the fatal cancer and non-fatal cancer of 1.3, 5 and 1.0x10-2 
Sv-1 respectively (total 7.3x10-2 Sv-1) for the whole population [63]. These values correspond to the 
risk for each effect of 1 in 77 000, 1 in 20 000 and 1 in 100 000, respectively, for an ED of 1 mSv, 
which is the annual limit for members of the public recommended by ICRP. These risks can be 
compared with an estimated natural frequency of 1-3 in 100 for genetic diseases manifesting at birth, 
and a cumulative risk of 1 in 1300 for fatal childhood cancer up to the age of 15 years [64]. 
In the Table 10. are given examples of occupational, personal and recreational activities carrying a 
fatal risk of 1 in 20 000 [46].  
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Activities carrying a fatal risk of 1 in 20 000 
Smoking 75 cigarettes 
Working in a typical factory for 1-2 years 
Travelling 4023 km by motor car 
Travelling 20 116 km by air 
Table 10. Examples of occupational, personal and  
recreational activities carrying a fatal risk 
 
The ICRP risk coefficients are age, and sex averaged for a normal population.  
Exposed population Excess relative risk of cancer (per Sv) 
Entire population 5.5 % - 6.0 % 
Adult only 4.1 % - 4.8 % 
Relative risk values based on ICRP publications 103 (2007) and 60 (1990) 
Table 11. Nominal Risk for Cancer effects 
 
For the age group corresponding to adult workers, the risk is reduced to 80 % of that for the whole 
population. For children, the risk is 2-3 times greater than for adults, and for persons aged over 50 
years, the risk is 10-20% of that for younger adults. Nuclear medicine patients cannot be regarded as 
a normal group, and their skewed age distribution will produce a smaller increase in risk. In a study, in 
the United States, in 1982, one third of nuclear medicine patients were aged over 64 years [66]. The 
age-adjusted incidence rate in the US from 2001 to 2005 was 467 cancers per year per 100 000 men 
and women [68]. Quantifying their fatal risk in terms of loss of life expectancy has been suggested as 
providing a basis for the comparison of different activities [67]. However, it is not generally used as a 
means of explaining the risks of nuclear medicine procedure. It has been pointed out that loss of life 
expectancy does not provide an easy means of comparing the risk of acute death caused by an 
accident with death caused by cancer because of the long latency period associated with the latter 
[69]. 
 
2.8.4 General basis of risk assessment 
2.8.4.1 Internal radiation 
Estimates of organ absorbed doses are the primary basis of any form of internal risk assessment for 
nuclear medicine procedures [70] and are usually required by radiopharmaceutical licensing 
authorities. MIRD Committee has developed the method of estimating organ absorbed dose generally 
referred to as MIRD Shema [71]. Example from MIRDOSE software is given in Figure16. 
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Figure 16. MIRD dose software 
 
The body is considered to consist of source organs which accumulate a significant amount of 
radioactivity, and target organs which are irradiated by activity in the source organs. The calculation of 
mean absorbed dose to a target organ (t) from its exposure to a source organs is simple multiplication 
of the two quantities, cumulated activity (A) and the mean absorbed dose per unit cumulated activity, 
(S) by: 
  Dt ← s = 	∑ASt ← s       (65) 
              
Where (S) is the tissue or organ emitting the energy (source organ) and (t) is the tissue or organ 
where the energy is absorbed (target organ). 
The S-factor involves readily available parameters such as mass of the target tissue, the mean 
energy emitted per nuclear transition and the fraction of energy emitted from the source organ that is 
absorbed in the target organ. Given an appropriate anatomical model and biokinetics data, and by 
adding all the source organ contributory doses, the MIRD schema allows the total absorbed dose to 
every target organ to be derived including the situation of the target organ and source organ being the 
same. The list of organ absorbed dose for radiopharmaceuticals published by (ICRP) has been 
complied by this method [72].                                                                                                                                                                                                                           
ICRP has defined the risk to an irradiated individual as the effective dose (E) expressed in units 
Sievert (Sv). In 2008 Brenner in the study published in BJR proposed to replace effective dose, with 
“effective risk”, where summed organ doses will be replaced each weighted with actual 
epidemiologically-based cancer risks, instead with committee-generated numbers. The effective risk 
is thus a generic lifetime radiation - attributable cancer risk. 
 
                     Effective	Risk = R =	∑ H =	∑wÎÏ 	∑wD,                        (66) 
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Whereµ, lifetime radiation attributable organ specific cancer risks are estimates (per unit equivalent 
dose to tissue T). This equation is the same with Effective dose, the calculation will be no harder and 
any inherent assumptions will be the same for both (e.g. LNT). 
For radiation protection purposes ICRP adopted in its Publication 26 (1977) for whole body 
exposures: 
• Mortality risk factor for radiation-induced cancers: about 10-2 Sv-1 (average for both sexes and all 
ages). 
• Average risk factor for hereditary effects (expressed in the first two generations) 4x10-3Sv-1. 
Calculation of dose limit for occupational exposure was based on judgment of the acceptability of the 
level of risk in radiation work by comparing it with that for other occupations recognized as having 
high standard of safety: average annual mortality due to occupational hazards lower than 10-4 per 
year. It was adopted an annual dose limit of 50 mSv for occupational exposure and the risk of 5x10-5 
per year for fatal cancer and 2x10-5 for hereditary effects. 
For the general public, exposure risk was in range 10-6 to 10-5 per year. Based on detriment of 10-2 Sv-
1 the restriction on the lifetime dose would correspond to a 1mSv per year. Annual dose limit of 5 mSv 
was adopted for public exposure, assuming to result in average dose equivalents of less than 0.5 
mSv. 
The ICRP 60 contains reassessment of the risk according to evolution of the scientific knowledge on 
the follow up of atomic bomb survivors. 
Morbidity and year of life lost are integrated in the calculation of health detriment. Dose limits are 
revised on the basis of the model tolerability of risk – Risk informed approach.  In the Table 12 are 
presented the fatal probability coefficients compared within ICRP 26 and ICRP 60.           
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Fatal probability coefficient (10-4Sv-1) Detriment 
 ICRP 26 ICRP 60 ICRP 60 
Bladder - 30 29.4 
Bone marrow 20 50 104.0 
Bone surface 5 5 6.5 
Breast 25 20 36.4 
Colon - 85 102.7 
Liver - 15 15.8 
Lung 20 85 80.3 
Esophagus - 30 24.2 
Ovary - 10 14.6 
Skin - 2 4.0 
Stomach - 110 100.0 
Thyroid 5 8 15.2 
Remainder 50 50 58.9 
Gonads   133.3 
Total 125 500 725.3 
Table 12. Evolution of risk estimates for fatal cancer 
 
In recent ICRP Publication 103 are evident evolutions of scientific knowledge on cancer incidence that 
lead to base the calculation of the health detriment on incidence. There is the significant reduction of 
the part of severe hereditary effects in health detriment. The reference levels are introduced as 
guideline for managing the different exposure situation with risk consideration. The new formula to 
calculate the health detriment, cancer mortality based from ICRP 60 is changed in cancer incidence 
based. In the Table 13 are presented calculation of the health detriment 
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Health Detriment (10-4Sv-1) 
 ICRP 103 ICRP 60 
Bladder 16.7 29.4 
Bone marrow 61.5 104.0 
Bone surface 5.1 6.5 
Breast 79.8 36.4 
Colon 47.9 102.7 
Liver 26.6 15.8 
Lung 90.3 80.3 
 Esophagus 13.1 24.2 
Ovary 9.9 14.6 
Skin 4.0 4.0 
Stomach 67.7 100.0 
Thyroid 12.7 15.2 
Remainder 113.5 58.9 
Gonads 25.4 133.3 
Total 574.3 500 
Table 13. Detriment 
         
2.8.4.2 External radiation 
After administration of radiopharmaceuticals, the radiation emitted from the patient acts as a potential 
mobile source of exposure to other individuals. Critical groups within the hospital are nuclear medicine 
staff, ward staff and visitors. Exposure of these groups is controlled by the designation of controlled 
areas, local rules and written systems of work. After the patient has left hospital members of the 
public who could be at risk are fellow travelers, colleagues at work and family members. Their 
exposure is controlled by keeping the patient in the hospital for an appropriate period of time, and 
after discharge from hospital by issuing instructions to modify their behavior inside and outside the 
home for a certain period of time. 
To assess the dose to the critical group, from the radiation emitted by a patient, two methods can be 
used. Firstly, direct measurements can be made of the integral dose received by an individual in the 
critical group by securing a thermoluminiscent dosimeter (TLD) to the individual. This method satisfies 
the criteria of being sensitive to a decrease in dose rate with time. The other method that might be 
used is when the dose to an individual in the critical group is estimated by multiplying the dose rates 
measured at different distances from the patient by the times spent at each distance by that 
individual. Both methods have disadvantages but give the idea of approximately estimated dose rate 
at certain distances. The dose rate variations with distance from the patient will depend on the 
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anatomical distribution of the radioactivity and hence on the radiopharmaceutical administered. The 
extrapolations and interpolations will be much easier if the variation of dose rate with distance can be 
described by a simple mathematical function. TLD measurements and Monte Carlo calculations have 
shown that the inverse square law can be used to describe the variation of dose rate with distance 
beyond a distance which increases with the area of the source [73]. 
 
2.8.5 Potential groups exposed to 
131
I patient 
It is well known that patients treated with 131I presents radiation hazard for the people that might come 
in close contact with them.  The exposed groups are members of staff and members of the public. In 
the members of staff are included: nuclear medicine staff (physician, physicist, technologist, nursing 
staff). While in members of the public are included: (parents, children, the breast fed infant and other 
groups that might come in close contact with patient treated with 131I).  
 
2.8.5.1 Nuclear medicine staff 
Nuclear medicine staff is exposed to radiation while performing the treatment to the patient either for 
treatment of hyperthyroidism or thyroid cancer. In both case, the physician and physicist are the most 
exposed staff. The therapy usually and in the most cases is performed with capsules and from 
radiation protection point it is much safer way than solution. Also, technologist is exposed during the 
scanning of patient, but in that case most of activity is gone because, in the case of thyroid cancer 
patients, the imaging is performed after ten days from received therapy [74]. 
 
2.8.5.2 Nursing staff 
An in-patient who is undergoing a therapy procedure should be nursed in an isolation suite 
designated as the controlled area. The risk to staff can be assessed on an individual basis depending 
on measured dose rates and the level of care required. In the literature [75, 76, 77] it has been shown 
that from dose rate and occupancy data that the ward nurse would only exceed the control area limit 
of 60 µSv per day [75] if helping a totally helpless patient that had undergone one of the high activity 
procedure, for example, bone scan. 
 
2.8.5.3 Children exposed to patients treated with radioiodine 
131
I 
When radiopharmaceutical is administered to a breastfeeding mother (Figure 17), radioactivity will be 
secreted into the milk, and the child will be necessary exposed on undesired radiation, and will 
receive certain radioactivity [78]. The activity concentration secreted in milk decreases exponentially 
with time after administration, and therefore assuming the volume per feed (V) and the time between 
feeds (Ð are constant the total activity ingested by infant (I) for all feeds can be calculated from the 
following formula. 
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Ó
H
Ä?
 (67) 
 
Where (m) is its number of exponential components for each of which c is its concentration of 
activity ingested in the first feed and  λ is its effective decay constant. The effective dose (D) to the 
infant is given by: 
D = Ie                                                                     (68) 
Where Ô is effective dose to the infant per unit activity ingested. 
 
 
 
 
Figure 17. Activity in breast feeding woman (IAEA) 
 
2.8.5.4. Parents exposed to child undergone 
131
I therapy. 
A parent looking after young children who have undergone nuclear medicine procedure will receive a 
dose from the radiation emitted from the radioactivity retained by child’s organs. The critical group in 
this case will be the parents of young infants who require extended periods of close contact. 
Estimates of these doses have been made from maximum values of dose rate measured at 0.1 m 
from pediatric patients multiplied by the effective exposure times described in the literature. It was 
estimated that a parent could receive a dose of 1 mSv if the infant had been administered 500 MBq of 
99mTc. It is the case that is based on the maximum dose rate per unit activity observed at 0.1 m (0.5 
µSvh MBq-1) and on the maximum reported period of close contact. For the parents caring for children 
treated as in-patients with 131I-MIBG for neural crest tumors such as neuroblastoma, a thyroid 
blockade is unnecessary because the main risk is from external radiation rather than the ingested 
activity. In the case of thyroid radioiodine therapy, the youngest child in this study is 16 years old, and 
there was no so close contact with parents. Anyway the use of straightforward precautions it should 
be possible to limit the dose to parents from this external radiation to 1 mSv per treatment [79].  
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2.9 Radiation Protection and Regulations during performing therapy with 
131
I 
2.9.1 Dose Limits 
In the context of radiation protection and radiation risk dose limits and reference levels are of 
importance. Dose limits refer to the maximum level of dose that the general public can receive from a 
source other than natural background radiation levels and those received by occupational workers in 
their job. The reference levels reflect the typical dose values expected in the majority of imaging 
studies [55]. 
Limits for exposure to radiation should be at a level below the threshold where deterministic effects 
occur (i.e. below 0.1 Gy) and the limit should exclude exposures from background radiation. Using the 
threshold dose as a starting point, dose limits are detriment using the Principles of Justification and 
Optimization. On the Graph 4 are presented the key elements of the radiation protection system: 
 
 
 
Graph 4. The main elements of the radiation protection 
 
Principle of Justification: Any decision that alters the radiation exposure to an individual or 
population should have an outcome that does better than harm. This means that any radiation source 
should provide a benefit with its use; either to the individual or to society at large and the risk of any 
detrimental effects must be small relative to any benefit. 
Principle of optimization: The application of radiation in any situation should be developed to 
minimize the risk of exposure while maximizing the benefit. When the medical benefit is retained or 
maximized, the risk should be as low as possible. The principle of optimization is analogous to the As 
Low As Reasonably Achievable (ALARA) concept. 
To minimize radiation hazard International and national organizations have been established to set 
guidelines for the safe handling of radioactive materials. The ICRP and IAEA also National Safety 
regulatory authority set guidelines for all radiation workers to follow in handling radiation. According 
National regulations the annual limit of occupational dose to an individual adult is 20 mSv. 
The cardinal principles of radiation protection from external sources are based on four factors: time, 
distance, shielding and activity.  
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Time 
The total radiation exposure to an individual is directly proportional to the time of exposure to a 
radiation source. The longer the exposure, the higher the radiation dose is. Therefore, it is wise to 
spend no more time than necessary near radiation sources. 
Distance 
The intensity of the radiation source and hence the radiation exposure varies inversely as the square 
of the distance from the source to the point of exposure. It is recommended that an individual should 
keep as far away as possible from the radiation source. Procedures and radiation areas should be 
designed so that individuals conducting the procedures or staying in or near the radiation areas 
receive only minimum exposure. 
Shielding 
Various high atomic number (Z) materials that absorb radiations can be used to provide radiation 
protection. Because the ranges of α and β particles are short in a matter, the containers themselves 
act as shields for these radiations. γ – radiations, however, are highly penetrating. Therefore, highly 
absorbing material should be used for shielding of γ-emitting sources. For economic reasons, lead is 
most commonly used for this purpose. Shielding is very important means of protection from radiation. 
Radionuclides should be stored in a shielded area. The radiopharmaceutical dosages for patients 
should be carried in shielded syringes. 
Activity 
It should be obvious that the radiation exposure increases with the intensity of the radioactive source. 
The greater the source strength, the more the radiation exposure is. Therefore, one should not work 
unnecessarily with large quantities of radioactivity. 
 
2.9.2 Personnel monitoring 
Personal dosimeters are devices worn by individuals exposed to ionize radiation to evaluate and 
document their external radiation exposure level. Personnel monitoring usually employs film 
dosimeters, ring dosimeters, thermoluminescent, pocket ionization chambers etc. At the Institute of 
pathophysiology and nuclear medicine monitoring of workers is performed by using TLD’s and ring 
dosimeters. The TLD gives accurate exposure reading and can be reused after proper heating 
(annealing). 
 
2.9.3 Radioactive waste disposal 
Radioactive waste generated in nuclear medicine (syringes, needles, contaminated papers etc.) are 
disposed of by the following methods according to national guidelines: decay in storage, release into 
the sewerage system, transfer to authorized recipient etc. 
Decay in a storage 
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Radionuclides with half-lives less than 65 days usually are disposed of by this method. These 
radionuclides are allowed to decay in storage for a minimum of 10 half-lives and then surveyed. If the 
radioactivity of the waste cannot be distinguished from background, it can be disposed of as normal 
medical waste after removal of all radiation labels. This method is most appropriate for short-lived 
radionuclides. 
Release into sewage system 
Radiation safety directorate permits radioactive waste disposal into the sewage system provided the 
radioactive material is soluble or dispersible in water. Excreta from humans undergoing medical 
diagnosis or treatment with radioactive material are exempted from the limitation. To adopt this 
method of radioactive disposal one must determine the total volume and the flow of the sewer water 
in the institutions and the number of users for specific radionuclide. 
 
2.9.4 Radioactive spill 
Accidental spillage of radioactivity can cause unnecessary radiation exposure to personnel and must 
be treated cautiously and expeditiously. There are two types of spills: major and minor spill. A major 
spill usually occurs when the spilled activity cannot be contained in a normal way and can cause 
undue exposure to personnel. In the case of a major spill, the RSO should be notified immediately. 
Areas, personnel and equipment must be decontaminated. Survey and wipe tests must be performed 
after decontamination.  
 
2.9.5 Record keeping 
Records must be maintained for the receipt, storage and disposal of radioactive materials, as well as 
for various activities performed in the radiation laboratory. These records contain specific information 
and are kept for a period of five years specified by Radiation Safety Directorate.  
 
2.9.6 Transportation of radioactive material 
The radioactive packages must be labeled properly before transportation. There are three types of 
labels according to the exposure reading in µSv/h at 1m from the surface of the package (transport 
index). The transport index must be indicated on the label and the sign “RADIOACTIVE” must be 
placed on the package. The labels must identify the content and amount of radionuclide in 
Becquerels. The package must contain shipping documents inside, bearing the identity, amount and 
chemical form of the radioactive material and TI Figure 18. 
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Figure 18. Form of the package with 131I 
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Chapter 3 
3. MATERIAL AND METHOD OF RESEARCH  
 
3.1 Patients  
In this study were analyzed thyroid cancer and hyperthyroid patients for 5 years period (2007-2011) 
who were treated at the Institute of pathophysiology and nuclear medicine, Faculty of Medicine, Ss. 
Cyril and Methodius University in Skopje, the Republic of Macedonia. The total number of patients 
who were reviewed was 526 (136 male and 390 female) age between (15 and 80). Patients were 
evaluated by ultrasonography, in vivo and in vitro nuclear medicine techniques, and final diagnosis 
was documented by histopathology during or after operation. The demographic findings will be 
presented in the results chapter from this thesis.  
At the group of thirty thyroids cancer and thirty hyperthyroid patients were performed external 
measurements at different distances with dose rate meter, after receiving iodine therapy. 
Estimation of effective dose for different organs using Monte Carlo simulation was performed at 24 
groups of patients divided according given activity. Patients were divided in 24 groups receiving 
average dose per group: 185 MBq; 370 MBq; 555 MBq; 1110 MBq; 1813 MBq; 2423 MBq; 2516 MBq 
2756 MBq; 3009 MBq; 3145 MBq; 3237 MBq; 3349 MBq; 3441 MBq; 3515 MBq; 3614,2 MBq; 3737 
MBq; 3838 MBq; 3959 MBq; 4033 MBq; 4440 MBq; 5106 MBq; 5476 MBq;  5550 MBq; 6105 MBq.  
External measurements over gastric region on the surface of the skin were performed with TLD at 
fifteen patients. 
Environmental release of iodine in the sewage system was performed with environmental radioactivity 
monitoring system. 
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3.2 Survey meter Dose Rate Test 
A survey meter dose rate test was performed to determine if the dose rate measurements are 
consistent at all nominated distances. The aim of the test was to find out that the dose rate 
measurements are in accordance with inverse square law. Mathematically the inverse square law is 
expressed with following equation: 
    I ∝ 	 k
d2
                                                   (69)        
This law states that radiation exposure or intensity (I) at a distance (d) from a radioactive source is 
proportional to the inverse square of the distance and (k) is proportionality constant that depends on 
the type of the radioactive source and its activity. This statement is true for exposure from radioactive 
point source (a source that is very small when compared to the large distances from the source 
involved) which emits radiation that is not absorbed in the distances involved. The exposure from 
radioactive patient does not follow the simple inverse square law, but approximately we can afford to 
take the measurements and account patient as point source.  The purpose was to find out if variations 
in the distance affect dose rate measurements. A syringe with 1100 MBq of 99mTc activity was placed 
at 145 cm height. The height was estimated for a normalized man’s height of 170 cm minus 25 cm for 
thyroid location. Dose rate measurements were taken with the survey meter ”mini-rad” series 1000 at 
0.25 m; 0.5 m; 1.0 m; 2.0 m; at 145 cm height. 
 
Figure 19. Survey meter “mini-rad” series 1000 
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3.3 Patient procedure 
At a group consisted of sixty patients, were performed external dose rate measurements. The patients 
were interviewed and informed on the research aims by medical physicist and physician. They signed 
agreement for receiving a therapy and all patients feel positive about participating in the study. Thirty 
were hyperthyroid patients and thirty were thyroid cancer patients. The patient population consisted of 
25 female and only 5 male at hyperthyroid group and 26 were female and 4 were male at thyroid 
cancer group. Age ranged between 15 years to 80 years old. Hyperthyroid patients were treated with 
185 MBq to 1295 MBq of 131I and thyroid cancer patients were given activities between 3700 MBq and 
5550 MBq. 
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3.4 Radiation Dose Rate Measurement 
The dose rate from the patient was monitored with external survey monitor “mini-rad” Series 1000 at 
horizontal distances of 0.25 m; 0.5 m; 1.0 m; and 2.0 m for hyperthyroid patient and 0.25 m; 0.5 m; 
1.0 m; 2.0 m; and for thyroid cancer patients. The survey meter was calibrated by The Service from 
Public Health Protection Institution, Skopje, and the Republic of Macedonia using the known exposure 
rate from 740 GBq 137Cs source primary gamma energy of 0.66 MeV. The distances from the source 
were 4.0 m; 2.0 m; 1.0 m and 0.5 m in order to obtain different exposure rates. The errors in all cases 
were 15%. The effective point of the patient measurements was taken to be in the centre of the 
detector. Vertical movement of the survey meter was utilized to obtain the maximum reading each 
time. The highest dose rate measurement depends on closest position of the survey meter to residual 
extra thyroidal functioning tissue, which retains radioactive radioiodine. A standard height was not 
used in order to reduce the error originating from variations in the patients’ heights and the locations 
of the target organ (thyroid). 
The initial measurements were performed within 15 minutes following administration of the131I dose. 
Thyroid cancer patients were measured during three very rare four days (every day at same time) 
until the measured level fall down to permitted limit (2.0 m – 8 µSv/h). The dose rate was determined 
at different distances: 0.25 m; 0.5 m; 1.0 m and 2.0 m from the patient. Distance 0.5 m, is relevant 
distance for partner sharing the same bed; 1.0 m is relevant distance for people who have their meal 
at the same table, watching television and being around the same house. The 1.0 m and 2.0 m 
distances would be relevant for people sharing the same office. The assumptions for distances were 
based on the previously published works of Culver et al and Barrington et al. The authors of this 
publication assumed that the dose received at a distance greater than 1.0 m was negligible. Author 
Babicheva in her work included a distance of 2.0 m in the patients survey form rather than make the 
same assumptions. I have also included the 2.0 m for thyroid cancer patients expecting that it would 
be the safe distance for first day measurement for thyroid cancer patients. For hyperthyroid patients, 
the measurements were performed within 15 minutes after administration of the dose at distances 
0.25 m; 0.5 m; 1.0 m; and 2.0 m. Inverse square law ratios of dose rate were calculated for both 
groups of patients in order to assess consistency of the measurements at varying distances. The 
patient instructions form about therapy, and written following instructions were given to patients and 
also they have signed an agreement for therapy with radioiodine 131I. Thyroid cancer patients stayed 
at hospital for three days. Medical physicist has done measurements every day until the dose rate of 
8 µSv/h at 2.0 m was reached. That means that the residual activity is less than 800 MBq when 
patients were released to go home with orally given and written instructions for their further behavior 
in home conditions. 
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3.5 External measurements over gastric region using TLD 
Effective dose measurements were done with thermoluminiscent dosimeters which contains hot 
pressed chips from phosphors or lithium fluoride (LiF) with property of thermal luminescence. TLDs 
were most appropriate to estimate radiation because the amount of ionizing radiation is directly 
proportional to the effective dose. The principle of thermo luminescence dosimetry is often described 
as a two step process: ionization of atoms into a metastable state and then recombination of the 
electron hole pair with the resulting emission of photons. When TLD material is irradiated an electron 
is excited to the conduction band creating a hole in the valence band. These electrons and holes are 
free to migrate and can also be trapped in shallow energy levels from which they can later decay 
without the TLD material being heated (fading). If the energy levels are deep enough (deep trap), then 
the electron or hole can remain in the trap for a long time. The number of electrons trapped in 
metastable level is proportional to the absorbed energy in the TLD material. If the TLD material is 
heated up these electrons may be excited to the conduction band and later recombine with holes 
emitting the excess energy as light (Figure 20). The light is detected by a PM-tube and resulting 
charge is correlated to an absorbed dose in TLD material. 
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Figure 20. Process of thermoluminiscence 
 
Used TLD’s were type TLD 100 Thermo Fisher Scientific Inc. square shape dimensions   3 mm2. 
LiF:Mg and Ti is approximately tissue-equivalent (Zeff = 8.2 ) and has an photon energy response for 
gamma-rays that ranges from 15 keV - 3 MeV (IEC 1066). A detection threshold of the dosimetry 
system is 30,689 µSv, according ISO/12794 (S.5) Figure 21. 
 
Figure 21. TLD 
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The controlled TLD was kept separately to measure background. The background readings were 
subtracted from the readings of estimated effective doses at surface of the skin above gastric region. 
The TLDs were prepared with standard instructions. TTP recommendation for Teflon card 
configuration for chip TLD type (TLD 100, LiF: Mg,Ti) for hot gas reader type for 6600 plus automatic 
are given in following Table 14. 
Description Settings 
Preheat temperature 50 o C 
Preheat time 0 s 
Temperature rate 25 o C/s 
Maximum temperature 300 o C 
Acquire time 13 1/3 s 
Annealing temperature 0 o C 
Annealing time 0 s 
Table 14. TTP 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 5. Heating cycle 
The heating cycle normally consist of preheat, acquisition, anneal and cool segments. Preheat is 
applied to segregate the light generated from low energy traps to minimize fade effect. Significant 
dosimetry data are generated and stored during acquisition segment. To ensure current exposures do 
not contribute to subsequent measurements, the anneal cycle is applied. This has the effect of 
removing signal residual. The heating cycle applied helps to establish the reproducibility of the 
dosimeter. The combined standard uncertainty of a dosimetry system is less than 15 %.  An 
automatic TLD reader (Thermo Harshaw 6600 plus) was used to evaluate the TLD chips Figure 22. 
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Figure 22. TLD Reader Thermo Harshaw 6600 
The system uses Nitrogen gas to heat TLD pellets rather than a heater plate. The Win REMS System 
Software running on a Windows platform is used to analyze the read data. After annealing the TLD 
can be used again.  
At fifteen, patients were performed external dose rate measurements at the surface (skin) over gastric 
region. Actually in these cases it was estimated Hp (0.07).These measurements were performed for a 
limited time of fifteen minutes and total time of three days until the patient left the hospital. The results 
will be presented in the next chapter.  
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3.6 Environmental measurements of released concentration of iodine in sewage system  
Patients treated with ablation doses of 131I are confined in the hospital for a few days to allow external 
radiation levels to decline to acceptable levels before release. Activity declines rapidly due to the 
biological elimination of 131I from the body. As a result of this elimination, considerable amounts of 
radioactive 131I are discharged within patient excreta into the local municipal sewer. The 
environmental network monitoring system was installed in the sewage system, to evaluate the 
concentration of 131I during hospitalization of the patient. The measurement station consists of: 
- an acquisition and processing board (PCB) allowing the connection of the detection probe, 
and the other optional measurement instruments, 
- the gamma ray detection probe, 
- the power supply and the telecommunication devices. 
The gamma ray detection probe (Figure 23) has the following characteristics: 
- 1 NaI(Tl) detector, 
o Energy resolution at 662 keV: ±7% 
o Energy measurement range: 80-2000 keV, 
o Impermeable casing made of 316 l stainless steel or corrosion resistant HDPE, 
o 1 multi-channel analyzer (1024 channels). 
The probe was installed by and calibrated at National Institute of Radioelements, Fleurus, Belgium.  
The estimation of discharged levels was performed over five patients during their hospitalization at 
isolated room.  The measurement was performed when there was treated one patient with 3700 MBq  
and two patient at the same time each of them treated with 3700 MBq. The results will be presented 
in the next chapter. 
  
Figure 23. Monitoring system 
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3.7 Sampling 
3.7.1 Radiopharmaceutical 
131
I 
Radioactive material in the form of 131INa is purchased from CIS Biointernational, France (Figure 24). 
Usual radioiodine concentration supplied by the manufacturer is 1110 MBq/ml on the date of 
calibration. In the hospital measured the activity of the capsule is in the process of 
radiopharmaceutical preparation for administration. Activity was measured using dose calibrator Atom 
lab 100 (Figure 24) based on pressurized well type ionization chamber (14 bar Argon, inside well 
diameter 57 mm and length 270 mm). Energy range of the dose calibrator was between 25 keV and 3 
MeV with resolution of 1 kBq. Electrometer accuracy was declared as ±1% while chamber standard 
uncertainty for activity determination was estimated at less than ±3%. Considering the data on the 
measurement uncertainties obtained from the manufacturer and our own measurements we can state 
that expanded uncertainty of radioiodine activity in solution is less than ±10% (k=2) assuming a 
normal distribution for uncertainty Type B.  
 
Figure 24. Dose calibrator Atom lab 100, Biodex 
 
Radionuclide purity of Na131I is not less than 99.9% (total radioactivity is due to 131I). Capsule material 
and additional elements in the solution are not relevant for the purpose of these investigations. 
Volatility of radio pharmacy prepared Na131I is neglected (on the order of 10-5 of the total activity) [81]. 
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Figure 25. Lead container and vial for the capsule 
According to our protocol a first ablation dose for residual thyroid tissue is 3700 MBq. Patients are 
usually administered into designated room with onsite bathroom facilities; visiting time being restricted 
to not more than 10 minutes a day at distance of more than 5.0 m. Daily monitoring and 
measurements were performed until the day of discharged with radiation levels acceptable under 
national regulation. The dose values for several organs of interest were compared for different 
administered doses.   
 
3.7.2 Application of Monte Carlo software package 
The use of Monte Carlo method to simulate radiation transport has become the most accurate means 
of predicting absorbed dose distributions and other quantities of interest in radiation treatments of 
cancer patients using either external or radionuclide therapy. The general idea of Monte Carlo 
analysis is to create a model, which is similar as possible to the real physical system of interest and to 
create interactions within that system based on known probabilities of occurrence with random 
sampling of the probability density functions (PDFs). As the number of individual events (histories) is 
increased, the quality of the reported average behavior of the system improves meaning that the 
statistical uncertainty decreases. 
 
3.7.3 Estimation of effective dose for different organs using Monte Carlo simulation 
General method for determination of effective dose in different organs and for estimation of additional 
risks is presented as three steps procedure: 
- Dose equivalents in tissues or organs are calculated by appropriate radiation transport codes 
using a suitable mathematical anthropomorphic phantom; 
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- The effective doses E, on the basis of tissue weighting factors, has been calculated and 
- Additional risks of lifetime mortality were assessed. 
Geometry 
The used radiation transport code MCNP4b [91] is appropriate for various complex geometries. The 
geometry is arranged in two major parts: surfaces and cells. Each surface is a two-dimensional plane 
with given parameters that are created for cell boundaries. These planes have many shapes including 
spheres, cylinders and spheroids, elliptical and curved plane. 
Tallies 
MCNP provides seven standard neutron tallies, six standard photon tallies and four standard electron 
tallies. The basic tallies can be modified by the user in many ways. Proper tally specification is very 
important in MCNP calculations. In the case of dose distribution calculation in different organs for 
gamma rays the tallies *F8 and F6 are applicable and therefore used. For beta particles, only *F8 can 
be used. These tallies give the absorbed energy in organs in units MeVg-1 per disintegration. In the 
case of calculation of local dose distribution in the stomach wall, beside F6 and *F8 tallies just for 
gamma rays, F2 tally has been used to. Because this tally represents flux average over the surface, 
flux dose rate conversion coefficients have been used [80].  
The basic concept of dose estimation using Monte Carlo calculations starts from input data and 
presumptions introduced into consideration. Input data are data determining the source (nuclear, 
radiological and shielding data), geometry and materials [81]. 
 
3.7.3.1 Source data 
Iodine 131I is boson with 53 p and 78 n. It is beta emitting radionuclide with complex beta decay 
scheme, a principal gamma ray of 364 keV and a principle beta particle with maximum energy of 0.61 
MeV, an average energy of 0.192 MeV and a range in tissue of 0.8 mm. Each beta minus emission 
for 131I has one or more corresponding gamma emissions. Reaction energy is Q = 0.97 MeV. Specific 
activity is 4600 TBq /g. In the case of 131I beta particles and gamma ray transport should be taken into 
account. For the energies less than 2.5 MeV the range of beta particle is approximated by the 
following equation: 
   R = 	 <.?8. 	E?.8g<.<× y[ $                               (70) 
Where (R) is range expressed in cm, (E) is the beta particle energy in MeV, (ρ) is material density in 
gcm3. Conversion factors for radiation absorbed dose from Na 131I are well known and are given in 
numerous literatures. In Table 15 there are given tabulate values from ICRP 53 [82], used in the 
simulation. 
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Organ Conversion factor  (mGy/MBq) 
0% uptake 55% uptake 
Bladder wall 0.610 0.290 
Colon wall 0.043 0.058 
Kidneys 0.065  
Ovaries 0.042 0.041 
Testes 0.037 0.026 
Stomach 0.034  
Thyroid  790.00 
 
Table 15. ICRP conversion coefficient  
 
3.7.3.2 Geometry and materials 
The source of 131I was considered as a point source placed in the middle of the soft tissue sphere. It 
was reasonable to presume the point source geometry as the small dried drop was deposited on the 
capsule holder. Self-absorption in such source should not be significant. The calculations performed 
during this study used a few various anthropomorphic organs due to the presence of the source in 
some other organ [85]. 
For our purposes, we used the new MIRD model. The phantom consists of three major sections: 
- An elliptical cylinder representing the trunk and arms 
- Two truncated circular cones representing the legs and feet 
- A circular cylinder on which sits an elliptical cylinder capped by half an ellipsoid representing 
the neck and head. 
The other organs are modeled by appropriate geometrical figures. The stomach wall is represented 
by the volume between two concentric ellipsoids and contents within the inner ellipsoid. Average 
stomach masses in grams are between 150 g for wall and 250 g for contents if it is not empty. The 
stomach is represented as the mass between two ellipsoids 
*È\ -
8 + *ØD7 -
8 + *Ù7\ -
8 ≤ 1                    (71) 
* È\7.7\Ú-
8 + * ØD8.7\Ú-
8 + *Ù7Ú.7\Ú-
8 ≥ 1    (72) 
  86 
In the case of adult male the parameters in former equation have the next values: a=4.00, b=3.00, 
c=8.00, d=0.613, x0=8.00, y0= -4.00, z0=35.00 [85]. 
The axes are in cm; stomach volume is 151.9 cm3 and the mass is 150 g. The thickness of the 
stomach wall is assumed to be about 0.613 cm. Only the case of the empty stomach is considered; 
therefore, we didn’t put into calculation the stomach contents. This consideration is based upon 
clinical practice in our hospitals that all therapy procedures are given “at the empty stomach”. 
According to this presumption the iodine capsule is at the bottom of the stomach lying at the stomach 
wall. The highest doses are delivered to an empty stomach because beta particles are absorbed in 
stomach content if present. Three phantom tissue types are recognized as skeletal, lung and all other 
tissue (soft tissue). The densities of those tissues are: 1.4 gcm-3, 0.296 gcm-3 and 1.04 gcm-3 
respectively. The exact compositions of each tissue type are given in ICRP reports 70 and ICRP 89 
and ICRU-46, [86, 87, 88]. The soft tissue composition used is presented as 
10.6%H+11.5%C+2.2%N+75.1%O+0.1%Na+0.1%P+0.1%S+0.2%Cl+0.1%K. 
For organs with walls and with contents as a source (even the very small one) it can be considered 
that  
    ΦZrS ← r& = ?8Hd                     (73) 
The (mh) is the mass of the source organ. Thus the dose to the wall sections of the gastrointestinal 
tract and to the urinary bladder from sources in the corresponding contents represents a surface dose 
for electrons and beta particles. 
 
Figure 26. Elipsoid gastric model 
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3.7.3.3 Modeling of energy distributions of beta particles 
Beta decay spectra which included internal conversion electrons were calculated using the Fermi 
model of beta decay with a relativistic correction for Coulomb Forces and the spectral factor 
correction for “forbidden” transitions was a set of polynomial function [89]. End point energies and 
activity data were acquired from Evaluated Nuclear Structure Data File (ENSDF) database at 
Brookhaven National Laboratory [90]. On Graph 6 is presented beta spectra of iodine 131. 
 
Graph 6.  Beta spectra of 131I 
 
In the process of beta decay, either an electron or positron is emitted as well; there is a spectrum of 
energies for the electron or positron depending upon what fraction of the reaction energy (Q) is 
carried by the massive particle. The shape of this energy curve can be predicted from the Fermi 
theory of beta decay. Treating the beta decay as a transition that depended upon the strength of the 
coupling between the initial and final states, Fermi developed a relationship which is now referred to 
as Fermi, golden rule [89], where the transition probability is given by: 
   λZ¡ = 8YÜ |MZ¡|8ρ¡                                                      (74) 
Where (Mif ) is the matrix element for the interaction and (ρf) is the density of the final states. A 
transition will proceed rapidly if the coupling between the initial (i) and the final (f) states is stronger. 
The matrix element can be expressed as integral final (f) and initial (i)  
     MZ¡ = wφ¡∗VφZdv                                             (75) 
The (V) is operator for the physical interaction which couples initial and final states of the system. And 
(φ) is the wave function for final (f) and initial state (i). The transition probability is proportional to the 
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square of the integral of this interaction over all of the space appropriate to the problem. From the 
Fermi theory of beta decay the shape of distributions for the transitions is given approximately by the 
expression: 
NKEP = CàKEP8 + 2KEPmPc8Q − KEP8KEP +mPc8FZE, KEP                        (76) 
Where F (Z”,KEe) is called Fermi function. It accounts for nuclear coulomb interaction which shifts the 
distribution toward lower energies because of the Coulomb attraction between the daughter nucleus 
and the emitted electron. It shifts the distribution upward for positrons. Q represents the energy yield 
of the transition and as such is the upper bound on the kinetic energy of the electron, KEe. The 
relativistic momentum for the electron apparent complexity of the expression is partly because it is 
necessary to use relativistic momentum for the electron.  
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Chapter 4 
4. RESULTS AND DISCUSSION 
 
4.1 Five years follow up 
In the thesis are presented the results for five year period (2007 - 2011) of patients treated with 
radioiodine 131, either for hyperthyroidism or thyroid cancer, at the Institute of pathophysiology and 
nuclear medicine in Skopje, Macedonia. The statistical analysis was performed by using SPSS 12.0 
version. Proportions, means, medians etc. were calculated, and suitable tests of significance carried 
out. 
Total number of treated patients in this period was 527 (329 hyperthyroidism and 198 thyroid cancer). 
Graph 7. 
 
Graph 7. Treated patients for 5 years 
 
The number of female patients was 391 (234 hyper and 157 cancer) and male 136 (95 hyper and 41 
cancer). Our findings show that the number of the female population was more affected with thyroid 
diseases than a male population for both groups (hyperthyroid and thyroid cancer) or in percents 
(71.1% female and 28.9% male) for hyperthyroid and (79.3% female and 20.7% male) for thyroid 
cancer Graph 8. Total male to female ratio was 1:2.8. Mortality rate during these five years at thyroid 
cancer patients was 2%.  
  
329; 62%
198; 38%
Treated patients with 131I for 5 y 
Hyperthyroid
Thyroid cancer
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Graph 8. Treated patients by sex 
 
Our findings are in good agreement with findings from the published results in the world literature. The 
gender distribution in this thesis is similar to that reported from other studies. 
Tzavara et al. [97] have published a study in which the number of analyzed thyroid cancer patients 
was 677 during the period of 30 years. In that study 75% were female, 81% were with papillary and 
22% had follicular thyroid carcinoma. 
Another study by R. Sciuto et al. [98] followed cohort of 1503 patients with differentiated thyroid 
carcinoma. Median age at diagnosis was 46. Papillary cancer represented > 80% of cases, follicular 
cancer 14.7%. The female patients were 78.6% and male 21.4%. The age less than 45 were 49.6% 
and > 45 were 50.4%.     
A study by Brig SS Anand et al. [99] reports retrospective analysis of 70 patients. Papillary 
carcinomas constituted 88% followed by follicular cancers at 9% of all cancers. Females were 
affected more than males in the ratio 2.2:1. Mean age of presentation for papillary cancer was 39 
years and for follicular 50 years.                                                                                                                                      
Totally administered activity for five years was 894 GBq. For hyperthyroid patients, the administered 
dose was 148 GBq, and for treatment of thyroid cancer 746 GBq Graph 9. Most of the delivered 
therapy was performed in the form of capsules, but there were a certain number of patients that 
received the therapy in the form of solution.   
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Graph 9. Administered activity per years 
 
In the Table, 16 are presented administered activity during five years period. In the group of 
hyperthyroid patients the ratio male : female was 1 : 2,5. It is obvious that the number of patients is 
decreasing in the last years. It is the result of the changes in the public health system or better and 
improved triage of the patients before they have to be sent at tertiary institution. 
Hyperthyroid patients 
Year 
Number of 
patients 
male female ratio MBq 
2007 90 21 69 3,3 42661 
2008 91 26 65 2,5 37037 
2009 70 18 52 2,9 31228 
2010 45 18 27 1,5 23051 
2011 33 12 21 1,8 14060 
Total 329 95 234 2,5 148037 
 
Table 16. Hyperthyroid patients 
 
For the thyroid carcinoma patients the total male : female ratio is 1 : 5,0 and there is no evidence of 
decreased number of patients treated with radioiodine. The majority of well differentiated 
malignancies manifested between third and fifth decades of life.  
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Graph 10. Age of papillary patients 
 
Mean age was 44 ± 5 years (median 45, range 17 -74). On the Graph 10, 30.9% of the patients with 
papillary cancer were less than 40 years of age as compared with papillary/follicular cancer the 
percentage was 37.5%. However the difference was not statistically significant (p = 0.983)  
Carcinoma patients 
Year 
Number of 
patients 
male female ratio MBq 
2007 39 12 27 2,3 146520 
2008 40 5 35 7,0 153180 
2009 32 8 24 3,0 116089 
2010 45 9 36 4,0 163573 
2011 42 7 35 5,0 167591 
Total 198 41 157 3,8 746953 
 
Table 17. Carcinoma patients 
 
On the Graph11 are presented the number of patients during five years. 
 
Graph 11. Number of patients  
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Table 18. Shows that papillary carcinoma were the commonest accounting for 79%, followed by 
follicular carcinoma (20%) and medullar carcinoma (1,5%). Table 17 also shows a comparison with 
the world literature [132]. 70.7% males had papillary carcinoma as compared to 80.2% of females. 
The difference between males and females for the type of cancer was not statistically significant (p 
value = 0.84) 
Diagnosis World (%) Results (%) 
Papillary carcinoma 60-80 79 
Follicular carcinoma 5-25 20 
Medullar carcinoma 5-10 1.5 
Anaplastic carcinoma 4-10 1 
 
Table 18. Distribution of malignant thyroid tumors amongst study group  
and the comparison with world literature 
 
Our results are in consonance with that reported on other studies. The most present is papillary 
carcinoma (79%) and it is similar with the worldwide trend as iodine fortification of the salt has 
resulted in decreased prevalence of the iodine deficiency disorders. 
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4.2 Results for external dose rate measurements 
At sixty patients (hyperthyroid and thyroid cancer) were performed dose rate measurements at 
distances 0.25 m; 0.5 m; 1.0 m; and 2.0 m.  
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4.3 Survey Meter Dose Rate  
In order to validate the dose rate results of the survey meter, dose rate test was performed with 
activity of 1100 MBq 99mTc. The results are presented in Table 19 
 
Activity MBq 
Dose rate µSv/h  Dose rate µSv/h  Dose rate µSv/h  Dose rate µSv/h  
0.25 m 0.5 m 1.0 m 2.0 m 
1100 420 110 30 7 
 
Table 19. Dose rate results 
 
The Table 20 and Graph 12 presents evaluation of the survey meter precision in regard to dose rate 
measurements at different distances. Ratio r1 represents the dose rate at 0.25 m divided by the dose 
rate at 0.5 m distance. Ratio r2 represents the dose rate 0.25 m divided by the dose rate at 1.0 m 
distance, and r3 represents the dose rate 0.25 m divided by the dose rate at 2.0 m distance. The 
values R1, R2, R3 are the dose ratios corrected for the inverse square variation. In the best case, the 
results of those calculations should be equal to 1 in all three distances. The gained results in this case 
are all within acceptable limits. 
 
 
r1 r2 r3 R1=r1/4 R2=r2/16 R3=r3/64 
3.82 14.00 60.00 1.0 0.9 0.9 
 
Table 20. Inverse Square Dose Rate Validation 
 
 
Graph 12. Inverse square dose rate validation                                                                                                                             
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4.4 Hyperthyroid patients 
All patients feel positive to participate in the study. Ten patients were with diagnosis Autonomous 
Functioning Thyroid Adenoma. Eight patients were with hyperthyroidism; six were with diagnosis 
SDT; two were with diagnosis SNT and Ca pap-follow up, and one patient was with diagnosis M. 
Basedow (Graph 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 13. Patients by diagnose 
 
 
Only five patients were male, and other twenty-five patients were female or in percent’s 17% were 
male, and 83% were female (Graph 14). 
 
 
 
 
 
 
 
 
 
 
Graph 14. Patients by sex 
 
The activity that was administered to patients was minimum 185 MBq and max 1295 MBq. The mean 
delivered dose was 683 MBq (Graph 15). 
 
  97 
 
Graph 15. Patients by administrated activity 
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4.4.1 Hyperthyroid patient dose rate 
Table 21 presents the measured dose rates on the first day of administered activity (185 MBq – 1295 
MBq) for hyperthyroid patients. 
 
No. MBq 
Dose rate (µSv/h) 
0.25 m 0.5 m 1.0 m 2.0 m 
1 925 380 90 40 15 
2 1110 390 150 50 17 
3 185 60 20 10 3 
4 370 120 60 20 6 
5 407 120 50 20 6 
6 370 115 50 18 5 
7 370 115 40 15 5 
8 370 130 40 15 5 
9 370 115 30 12 4 
10 555 130 60 25 8 
11 370 120 50 25 5 
12 370 110 50 20 5 
13 370 115 60 20 7 
14 1110 420 150 50 15 
15 1110 410 150 80 20 
16 1110 400 100 50 15 
17 296 100 50 20 4 
18 1295 450 200 70 20 
19 296 110 40 15 4 
20 925 390 100 40 15 
21 444 120 70 30 6 
22 444 120 40 20 6 
23 1110 400 130 50 20 
24 296 110 40 20 7 
25 370 120 40 20 6 
26 1110 390 100 50 15 
27 1110 400 100 60 17 
28 1110 410 100 50 15 
29 1110 420 100 60 20 
30 1110 420 100 55 18 
 
Table 21. Dose rates 
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The results for dose rate from Table 21 are shown on Graph 16. 
 
 
Graph 16. Dose rate of hyperthyroid patients 
 
Table 22 Present the correlation between dose rate and administered activities for hyperthyroid 
patients on the first day. The correlation coefficients were positive and in the range from 0.30 to 0.44.  
Coeficients at distances (m) 
0.25 m 0.5 m 1.0 m 2.0 m 
0,34 0,36 0,44 0,30 
Table 22. Coefficients at distances (m)   
 
A linear correlation coefficient has an absolute value between 0 and 1. With one is indicated a perfect 
linear relationship exists, and zero means that no linear relationship exists. Generally, unless the 
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absolute value of the correlation is greater than 0.5 the relationship between two variables is not 
considered of importance unless the sample is large (45). In our case, there is a positive correlation of 
less than 0.5, and this is not significant (Graph 17).  
 
 
 
 
 
Graph 17. Coefficients at distances 
Distance (m) 
Mean dose rate 
(µSv/h) 
Standard  
deviation 
Dose rate range 
(µSv/h) 
0.25 240 148.41 60 - 450 
0.5 79 43.92 20 - 200 
1.0 34 19.43 10 - 80 
2.0 10 6.14 3 - 20 
Table 23. Dose rate vs. distance for Hyperthyroid patients at time of treatment 
 
Table 23 and Graph 18 presents the mean dose rate for hyperthyroid patients at the time of treatment 
for all 30 patients. The patients were treated with 185 MBq – 1295 MBq of 131I activity on an outpatient 
basis. The maximum dose rate at the time of treatment was 450 µSv/h at a distance of 0.25 m and 
minimum was measured at 2.0 m only 3 µSv/h up to 20 µSv/h. The following Graph 18 presents the 
values of standard deviation, mean dose rate, minimum and maximum dose rate range. 
 
 
 
 
 
 
 
Graph 18. Standard deviation vs. Dose rate range 
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Graph 19. Dose rate measurements 
 
 
The Graph 19 presents dose rate measurements for all thirty patients. With the red line is marked 
standard deviation, max and min.  
The next Table 24 presents inverse square law validation for all patients at the day of administration. 
The given readings for dose rate at different distances should follow the inverse square law. Ratios 
were calculated with respect to that at 0.25 m. These then were divided by the value to allow 
variations to be seen. Overall the results followed the expected pattern of course there were 
exceptions, which are commented in the discussion part. 
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No. 
Dose rate µSv/h Ratio Inverse square 
A B C D r
1
 r
2
 r
3
 R1 R2 R3 
0.25m 0.5m 1.0m 2.0m A/B A/C A/D r
1
/4 r
2
/16 r
3
/64 
1 380 90 40 15 4,2 9,5 25,3 1,1 0,6 0,4 
2 390 150 50 17 2,6 7,8 22,9 0,7 0,5 0,4 
3 60 20 10 3 3,0 6,0 20,0 0,8 0,4 0,3 
4 120 60 20 6 2,0 6,0 20,0 0,5 0,4 0,3 
5 120 50 20 6 2,4 6,0 20,0 0,6 0,4 0,3 
6 115 50 18 5 2,3 6,4 23,0 0,6 0,4 0,4 
7 115 40 15 5 2,9 7,7 23,0 0,7 0,5 0,4 
8 130 40 15 5 3,3 8,7 26,0 0,8 0,5 0,4 
9 115 30 12 4 3,8 9,6 28,8 1,0 0,6 0,4 
10 130 60 25 8 2,2 5,2 16,3 0,5 0,3 0,3 
11 120 50 25 5 2,4 4,8 24,0 0,6 0,3 0,4 
12 110 50 20 5 2,2 5,5 22,0 0,6 0,3 0,3 
13 115 60 20 7 1,9 5,8 16,4 0,5 0,4 0,3 
14 420 150 50 15 2,8 8,4 28,0 0,7 0,5 0,4 
15 410 150 80 20 2,7 5,1 20,5 0,7 0,3 0,3 
16 400 100 50 15 4,0 8,0 26,7 1,0 0,5 0,4 
17 100 50 20 4 2,0 5,0 25,0 0,5 0,3 0,4 
18 450 200 70 20 2,3 6,4 22,5 0,6 0,4 0,4 
19 110 40 15 4 2,8 7,3 27,5 0,7 0,5 0,4 
20 390 100 40 15 3,9 9,8 26,0 1,0 0,6 0,4 
21 120 70 30 6 1,7 4,0 20,0 0,4 0,3 0,3 
22 120 40 20 6 3,0 6,0 20,0 0,8 0,4 0,3 
23 400 130 50 20 3,1 8,0 20,0 0,8 0,5 0,3 
24 110 40 20 7 2,8 5,5 15,7 0,7 0,3 0,2 
25 120 40 20 6 3,0 6,0 20,0 0,8 0,4 0,3 
26 390 100 50 15 3,9 7,8 26,0 1,0 0,5 0,4 
27 400 100 60 17 4,0 6,7 23,5 1,0 0,4 0,4 
28 410 100 50 15 4,1 8,2 27,3 1,0 0,5 0,4 
29 420 100 60 20 4,2 7,0 21,0 1,1 0,4 0,3 
30 420 100 55 18 4,2 7,6 23,3 1,1 0,5 0,4 
mean 240,3 78,7 34,3 10,5 3,0 6,9 22,7 0,7 0,4 0,4 
Table 24. Inverse square ratio 
 
The mean value of dose rate at 0.25 m, 0.5 m, 1.0 m, 2.0 m was 240.3 µSv/h, 78.7 µSv/h, 34.3 µSv/h, 
and 10.5 µSv/h respectively. 
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Graph 20. Inverse Square Law Validation for Hyperthyroid Patients 
 
Graph 20 demonstrates inverse square law validation of dose rate for hyperthyroid patients. The 
mean value for dose rate at 0.25 m is very close (0.7) to the ideal value (1) given by theory for the 
inverse square law.  Changing the distance to 0.5 m, 1.0 m, and 2.0 m the values for dose rates differ 
much more than proposed value by theory. The explanation is given in the part of the discussion, and 
it refers to that we treat patient as a point source in approximation which is very conservative, but in 
reality, the situation is very different and many other factors affect the results.  Further measurements 
in the future can be made more realistic by using patient-specific parameters that are based on direct 
measurements and the modeling of the patient’s lifestyle. 
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4.5 Thyroid cancer patients 
4.5.1 Thyroid Cancer Patients Dose Rate 
The group of thyroid cancer patients consisted of 30 patients. From thirty patients, 23 were with 
diagnosis Ca papillarae, three patients were with Ca follicular, the same number with Ca 
papillary/follicular and only one patient was with diagnosis Ca medullary. Graph 21 summarizes 
patients by diagnose. 
 
 
 
Graph 21. Patients by diagnose 
 
Twenty six of patients were female, and only four were male (Graph 22). 
 
Graph 22. Patients by sex 
 
 
Graph 23. Patients by administrated activity 
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The administered activity varied between 3700 MBq to 5550 MBq (Graph 23). The meanly 
administered dose was 3539 MBq. The most of thyroid cancer patients stayed in the hospital for three 
days. There were 3 follow up patients who had received a second administration dose since the 
adequate ablation had not been achieved on the first treatment. A regularly calibrated sodium iodide 
scintillation survey meter was used. All dose rate measurements were made at anterior midline of the 
patients at about 15 min after radiopharmaceutical administration. The dose rate was determined 
every day during the stay at hospital at distance of 0.25 m; 0.5 m; 1.0 m and 2.0 m. The results are 
presented in the following Table 25. 
No. Dg. Sex Age MBq 
Dose rate (µSv/h) 
day 1 (m) day 2 (m) day 3 (m) 
0.25 0.5 1 2 0.25 0.5 1 2 0.25 0.5 1 2 
1 pap f 26 3700 450 200 100 40 300 90 50 15 170 60 20 7 
2 pap f 70 3700 440 180 100 50 270 80 40 15 90 12 8 3 
3 pap f 29 4440 470 220 150 50 310 120 90 25 240 50 30 8 
4 pap m 41 3700 420 220 150 50 310 100 80 21 280 90 70 15 
5 pap f 43 3700 410 230 150 40 300 100 50 15 250 50 15 6 
6 p/f f 33 3700 400 190 100 30 280 80 30 15 250 50 14 6 
7 pap m 35 3700 440 190 150 50 310 120 60 15 240 60 20 7 
8 pap f 15 3700 450 210 100 50 260 150 60 20 250 70 30 12 
9 pap m 35 3700 420 220 150 40 280 100 40 15 180 30 15 5 
10 pap m 75 3700 470 180 100 60 300 100 50 20 220 60 40 8 
11 pap f 30 3700 480 210 150 60 290 100 50 15 240 70 30 10 
12 pap f 73 5550 490 220 150 80 290 100 70 25 300 65 25 7 
13 foll m 66 5550 500 230 200 50 300 100 70 30 250 70 50 15 
14 pap f 42 3700 440 180 120 40 290 100 50 20 200 100 30 10 
15 pap f 21 3700 450 210 150 50 290 100 70 25 230 60 30 10 
16 med f 43 3700 460 220 150 50 290 90 40 15 240 50 25 8 
17 foll f 68 3700 420 250 200 50 300 110 60 20 190 40 15 7 
18 pap f 18 3700 430 260 200 50 290 100 50 15 200 50 20 8 
19 p/f f 25 3700 430 220 150 50 310 120 70 30 260 90 50 15 
20 pap f 39 3700 480 260 200 50 310 125 70 30 180 40 25 10 
21 pap m 61 4440 470 250 200 60 300 115 70 30 200 50 30 15 
22 foll f 40 3700 460 240 200 40 250 80 30 10 100 30 10 3 
23 pap f 62 3700 450 210 150 50 250 80 40 10 175 40 20 6 
24 pap f 45 3700 430 200 150 60 320 120 70 20 230 70 30 7 
25 p/f f 50 3700 490 220 160 80 240 70 50 20 170 30 5 2 
26 pap f 60 3700 470 240 150 60 240 70 45 20 140 20 8 4 
27 pap f 55 3700 420 190 140 50 310 120 50 15 150 25 12 8 
28 pap f 42 3700 430 210 140 45 300 110 55 20 190 30 15 7 
29 pap f 44 3700 410 200 140 40 280 110 55 20 170 20 10 6 
30 pap f 50 3700 430 210 160 50 270 100 50 15 180 40 12 7 
 
Table 25. Dose rate 
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On the Graph 24 are presented the individual dose rates as measured at 0.5 m distance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 24. Dose rate of Thyroid cancer patients 
 
Coefficients for three days were calculated at distance of 0.25 m and 0.50 m (Table 26, 27). The 
coefficients for 0.25 m were positive for all three days and ranged from 0.05 and 0.12. For the 
distance of 0.5 m, the coefficients were 0.24 for day 3 and 0.48 for the first day. 
Coefficients, n=30, 
at distance of 0.25 m 
day 1 day 2 day 3 
0,12 0,08 0,05 
Table 26. Coefficients for 0.25 m 
Coefficients, n=30, 
at distance of 0.50 m 
day 1 day 2 day 3 
0,48 0,35 0,24 
Table 27. Coefficients for 0.50 m 
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The mean dose rate was calculated for day 1, day 2 and day 3 and the values are given in following 
Tables 28, 29 and 30.  In the same tables are given dose rate ranges for the distance 0.25 m, 1.5 m, 
1.0 m and 2.0 m for thyroid cancer patients. 
Day 1 
Distance (m) 
Mean dose  
rate (µSv/h) 
Standard 
deviation 
Dose rate  
range(µSv/h) 
0.25 m 447 27 410 - 500 
0.50 m 198 29 150 - 200 
1.00 m 150 31 100 - 200 
2.00 m 51 11 40 - 80 
Table 28. Mean dose rate 
Day 2 
Distance (m) 
Mean dose  
rate (µ Sv/h) 
Standard 
deviation 
Dose rate  
range (µ Sv/h) 
0.25 m 288 22 250 - 320 
0.50 m 102 18 70 - 125 
1.00 m 56 14 30 - 90 
2.00 m 19 6 10 - 30 
Table 29. Mean dose rate 
Day 3 
Distance (m) 
Mean dose  
rate (µSv/h) 
Standard 
deviation 
Dose rate  
range (µSv/h) 
0.25 m 206 49 90 - 280 
0.50 m 50 23 12 - 100 
1.00 m 24 14 5 - 50 
2.00 m 8 3,5 2 - 15 
Table 30. Mean dose rate 
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Graph 25. Standard deviation vs. Dose rate range 
 
The maximum dose rate for day one was between 410 µSv/h - 500 µSv/h at 0.25 m and the minimum 
dose rate was between 90 µSv/h - 280 µSv/h at 0.25 m and from 2 µSv/h – 15 µSv/h at 2.0 m 
distance on day three. On Graph 25 are presented, the mean dose rates at day three.  Compared 
with the values from the day one dose rates at day 3 are decreased from 447 µSv/h at 0.25 m to a 
mean dose rate 206  µSv/h, or from 52 µSv/h to 8 µSv/h at 2.0 m.    
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No. 
Dose rate (day 3) Ratio Inverse square 
A B C D r
1
 r
2
 r
3
 R1 R2 R3 
0.25 m 0.5 m 1.0 m 2.0 m A/B A/C A/D r
1
/4 r
2
/16 r
3
/64 
1 170 60 20 7 2,8 8,5 24,3 0,7 0,5 0,4 
2 90 12 8 3 7,5 11,3 30,0 1,9 0,7 0,5 
3 240 50 30 8 4,8 8,0 30,0 1,2 0,5 0,5 
4 280 90 70 15 3,1 4,0 18,7 0,8 0,3 0,3 
5 250 50 15 6 5,0 16,7 41,7 1,3 1,0 0,7 
6 250 50 14 6 5,0 17,9 41,7 1,3 1,1 0,7 
7 240 60 20 7 4,0 12,0 34,3 1,0 0,8 0,5 
8 250 70 30 12 3,6 8,3 20,8 0,9 0,5 0,3 
9 180 30 15 5 6,0 12,0 36,0 1,5 0,8 0,6 
10 220 60 40 8 3,7 5,5 27,5 0,9 0,3 0,4 
11 240 70 30 10 3,4 8,0 24,0 0,9 0,5 0,4 
12 300 65 25 7 4,6 12,0 42,9 1,2 0,8 0,7 
13 250 70 50 15 3,6 5,0 16,7 0,9 0,3 0,3 
14 200 100 30 10 2,0 6,7 20,0 0,5 0,4 0,3 
15 230 60 30 10 3,8 7,7 23,0 1,0 0,5 0,4 
16 240 50 25 8 4,8 9,6 30,0 1,2 0,6 0,5 
17 190 40 15 7 4,8 12,7 27,1 1,2 0,8 0,4 
18 200 50 20 8 4,0 10,0 25,0 1,0 0,6 0,4 
19 260 90 50 15 2,9 5,2 17,3 0,7 0,3 0,3 
20 180 40 25 10 4,5 7,2 18,0 1,1 0,5 0,3 
21 200 50 30 15 4,0 6,7 13,3 1,0 0,4 0,2 
22 100 30 10 3 3,3 10,0 33,3 0,8 0,6 0,5 
23 175 40 20 6 4,4 8,8 29,2 1,1 0,5 0,5 
24 230 70 30 7 3,3 7,7 32,9 0,8 0,5 0,5 
25 170 30 5 2 5,7 34,0 85,0 1,4 2,1 1,3 
26 140 20 8 4 7,0 17,5 35,0 1,8 1,1 0,5 
27 150 25 12 8 6,0 12,5 18,8 1,5 0,8 0,3 
28 190 30 15 7 6,3 12,7 27,1 1,6 0,8 0,4 
29 170 20 10 6 8,5 17,0 28,3 2,1 1,1 0,4 
30 180 40 12 7 4,5 15,0 25,7 1,1 0,9 0,4 
mean 205,5 50,7 23,8 8,1 4,6 11,0 29,3 1,1 0,7 0,5 
Table 31. Inverse square law validation 
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The Table 31 presents inverse square law validation for all patients at the day of discharge from 
hospital. Ratios were calculated with respect to that at 0.25 m.  
Graph 26. Inverse square law validation of dose rate for thyroid cancer patients 
 
The mean value of dose rate at 0.25 m, 0.5 m, 1.0 m and 2.0 m was 205 µSv/h, 50.7 µSv/h, 23.8 
µSv/h and 8.1 µSv/h.  
Very little data has been published regarding the exposure rates near patients receiving diagnostic 
levels of radiopharmaceuticals, as concerns are generally lower. There are also not so many 
publications about dose rates from radioiodine therapy and other used radiopharmaceuticals. From 
the several published papers the findings confirm that calculated values from nuclear medicine 
patients produces significantly overestimated of real dose rates.  
A study by author Yanling Yi et al. [94], from 2013 confirm the findings to others that the use of an 
unshielded point source method to model exposure rates near nuclear medicine patients produces 
significant overestimates of the real dose rates. For 131I cancer patients, who typically have very small 
thyroid remnant uptakes and thus activity mostly distributed uniformly throughout the body, the 
exposure rates are overestimated by a factor of about three at 0.3 m and about two at 1.0 m. When 
using point source model with the appropriate factor, the model provides reasonable data for 
determining patient release criteria. 
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4.6 Results of calculated values of dose equivalent rate, effective dose and risk for different 
organs using MCNP 4b 
By application of MCNP4b software, the absorbed energy in the most exposed organs as a 
consequence of 131I solution/capsule retaining in the stomach has been calculated.  Calculated values 
for imported energy per transformation for different organs are given in Table 32 
 
Organ 
Imparted energy (MeV) 
Gamma Beta Gamma-Beta 
Bone surface 6.02 × 10-3 0 6.02 × 10-3 
Stomach 11.48 × 10-5 2.59 × 10-1 2.59 × 10-1 
Colon 8.35 × 10-3 6.25 × 10-6 8.35 × 10-3 
Kidneys 2.26 × 10-4 0 2.26 × 10-4 
Liver 5.94 × 10-4 8.88 × 10-7 5.95 × 10-4 
Lungs 6.53 × 10-5 2.48 × 10-7 6.56 × 10-5 
Testes 2.02 × 10-4 0 2.02 × 10-4 
Bladder 12.82 × 10-4 0 12.82 × 10-4 
Skin 4.52 × 10-4 0 4.52 × 10-4 
Table 32. Imparted energy per transformation for different organs 
 
The dose equivalent – (radiation weighting factor equal unity) in different organs are calculated and 
presented in the Annex 3. for the capsule and solution activity of 185 MBq up to 6 105 MBq during 15 
min of retaining in the stomach. 
Using the tissue weighting factors, wT [56], and calculated dose equivalent, the effective dose for 
different organs has been calculated and the results are presented in the following Table 33. 
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Organ Quantity 
 Density(g/cm2) Volume (cm3) Dose per transformation (Gy) 
Bone surface 1.40 2500 2.75 × 10-16 
Stomach 1.04 130 3.07 × 10-13 
Colon 1.04 331 3.88× 10-15 
Kidneys 1.04 260 1.34 × 10-16 
Liver 1.04 1300 5.73 × 10-17 
Lungs 0.30 2800 1.25 × 10-17 
Testes 1.04 26 1.19 × 10-15 
Bladder 1.04 40 4.93 × 10-15 
Skin 1.04 1058 6.57 × 10-17 
Table 33. Calculated values of dose equivalent in different organs 
 
The calculations were performed for all activities used in radioiodine diagnostic and therapy. The 
lowest value was 185 MBq; activity used for whole body scan, and the maximums delivered dose was 
6105 MBq for thyroid cancer therapy. The values of effective doses for stomach and other organs 
around the stomach such as skin, lungs, liver, colon, bladder and ovary, gonads are presented in 
Graph 27. In the Graph 28 are given the compared values for 1 minute and 15 minutes for ovary, 
gonads.  
 
Graph 27. Effective doses 
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Graph 28. Comparison of effective doses for given activity for one and 15 minutes 
 
 
The calculated results are for administered activity from 185 MBq up to 6105 MBq, and for the time of 
absorption of 1 minute and 15 minutes. The total number of histories during the simulation was one 
million. Due to sphere symmetry estimated uncertainties for calculation of local stomach doses are 
less than 0.1%, and they are negligible. The relative uncertainty of simulation for all results was not 
higher than 5%. The normal Gaussian probability distribution is applied on uncertainty determination. 
Considering the number of histories obtained uncertainties of Monte Carlo calculations of energy 
imparted in organs (MeV per disintegration) are acceptable.  
The lowest effective dose is received by Skin, Lungs and Liver. The results are given in Table 32  and 
on the Graph 29, also the results are presented in Annex 2. 
 
 
Graph 29. Effective doses for Skin, Lungs and Liver 
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Graph 30. Effective doses for Ovary, gonads, bladder and colon 
 
The Graph 30 shows that ovary and bladder receive approximately the same effective doses, while 
from this group the effective dose for colon is much higher., For the maximum, given activity 6105 
MBq, colon receives maximum effective dose. 
 
 
Graph 31. Effective doses for stomach 
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these cases the absorbed dose due to iodide taken up in the stomach may be of more interest. A 
0,000
200,000
400,000
600,000
800,000
1000,000
1200,000
1400,000
1600,000
1800,000
1
8
5
3
7
0
5
5
5
1
1
1
0
1
8
1
3
2
4
2
3
2
5
1
6
2
7
5
6
3
0
0
9
3
1
4
5
3
2
3
7
3
3
4
9
3
4
4
1
3
5
1
5
3
6
1
4
3
7
3
7
3
8
3
8
3
9
5
9
4
0
3
3
4
4
4
0
5
1
0
6
5
4
7
6
5
5
5
0
6
1
0
5
E
 (
µ
S
v
)
Administrated activity (MBq)
Comparison between Colon, Bladder and Ovary
Ovary, gonads
Bladder
Colon
0,000
20000,000
40000,000
60000,000
80000,000
100000,000
120000,000
140000,000
1
8
5
3
7
0
5
5
5
1
1
1
0
1
8
1
3
2
4
2
3
2
5
1
6
2
7
5
6
3
0
0
9
3
1
4
5
3
2
3
7
3
3
4
9
3
4
4
1
3
5
1
5
3
6
1
4
3
7
3
7
3
8
3
8
3
9
5
9
4
0
3
3
4
4
4
0
5
1
0
6
5
4
7
6
5
5
5
0
6
1
0
5
Stomach
Stomac
h
E
Administrated activity (MBq)
  115 
diminished thyroid uptake may be e.g. a result of thyroid blocking or surgical removal of the gland. 
Recent biokinetics models for radioiodine [100, 72,101] include the stomach wall as a compartment 
where an increased concentration of iodine can be seen shortly after intake. Assuming that the 
residence time in the stomach is 15 to 30 minutes, the absorbed dose to the stomach increases by at 
least 30% for 131I [102]. The dose to the stomach wall is a factor of 2-3 higher if the source is located 
entirely within the wall itself compared to when it is found only in the contents. Assuming that the 
uptake in the stomach is located to the wall, we performed all calculations using Monte Carlo 
simulation as an input parameter. We simulate the situation in the very first one minute and 15 
minutes after radioiodine administration when the thyroid uptake has not yet started. 
 
 
 
 
                
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                  
 
 
Graph 32. Compared values for 1 and 15 minutes, stomach 
 
The highest stomach doses were expected concerning the beta-gamma nature of 131I decay. The beta 
particles and secondary electrons created into interaction of gamma rays deposit their energies in 
short path-lengths. These energy depositions result in absorbed doses to the stomach in which the 
radionuclide is localized and to organs in its vicinity. Taking into account all of these we performed the 
calculation for both beta and gamma emission [102]. The investigation and calculations were started 
with the assumption that the values of additional effective doses of risks during the 15 min of 131I 
capsules retaining in the stomach before their absorption are not negligible neither for stomach wall 
neither surrounding organs. This fact was the main reason for our prediction about the necessity of a 
precise dose and additional risk estimation. Obtained results indicate that the values of local doses in 
the stomach wall could not be ignored.   
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4.6.1 Calculated risk  
From clinical practice, it is obvious that radioiodine therapy is safe and that the level of risk is smaller 
than that of other therapeutic modalities routinely used in oncology (external beam radiotherapy and 
chemotherapy). But also it is very important to support this impression with indisputable data. While 
the risk is obviously small, fear of the unknown is the worst enemy of the medical use of 
radionuclides. The accurate and objective evaluation of risk is thus an important primary task of 
nuclear medicine community. The most common acute complications of 131I therapy radiation 
thyroiditis, gastrointestinal discomfort and nausea, xerostomia are usually mild and self-limiting. 
Among the late effects permanent myelosuppression and pulmonary radiation fibrosis are dose 
dependent, and thus only the minority of patients treated with very high cumulative doses is at risk. In 
contrast to these risks, the potential hazards from 131I therapy which have the greatest impact on the 
decision to utilize this modality are the induction of second tumors [103, 104] and genetic damage 
[105]. These are considered to be stochastic effects with no threshold; virtually every patient treated 
with any dose of 131I is exposed to some potential risk. In such cases, it is necessary to ensure that 
the risks of the radiation are less than from the disease itself [102]. For stochastic effects, the 
probability of their occurrence is believed to be proportional to the dose (linear dose effect relationship 
in the low dose/low dose rate range). Therefore, the probability of their induction should be reduced 
as far as possible by keeping the dose as low as possible. Epidemiological studies report a higher 
incidence of stomach cancer in patients receiving 131I. After higher activities, typically those used in 
the treatment of thyroid malignancies, an increased incidence of leukemia has been observed. There 
may also be a small increase in bladder and breast cancers. Radiation doses to specific organs which 
may not be the target organ of therapy can be influenced significantly by the pathophysiological 
changes induced by the disease process. 
Incidence of secondary malignancies and leukemia might increase with higher doses. A Swedish 
report found that organs that were estimated to have received more than 1 Gy had a significantly 
increased risk of subsequent malignancy [104]. They studied a cancer risk for 834 patients with an 
average dose of 4551 MBq. A dose related increased risk of cancer was observed. For patients 
receiving the dose of less than 1850 MBq, there was no significantly elevated risk of subsequent 
malignancy [104].  
From this aspect, it was very important to compare the effective doses for stomach and surrounding 
organs for different nine values of administered activities. In the Table 34, are presented calculated 
risks for bladder, colon and ovary compared with the risk for stomach. The risk is calculated for one 
and fifteen minutes and forgiven different activities. Our results show that the stomach has the highest 
risk among the other organs. From statistical analysis the correlation coefficient (r) among the 
estimated risk was found to be very significant (p<0,00001) for stomach-bladder, stomach-colon and 
stomach-ovary.  
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The study from Ahmed S. et al. indicates that the significant uptake of radioiodine by stomach of 
thyroid cancer patients carries additional risks of probabilistic fatal occurrence in this organ compare 
to other organs. These warrants long-term follow up of thyroid carcinoma patients. 
 
MBq  Time (min)   Bladder Colon 
Ovary, 
gonads Stomach 
185 
1 min 1.00×10-9 0.90×10-7  0.80×10-8  0.024×10-3  
15 min 0.149×10-7 0.131×10-5 0.120×10-6 0.340×10-3  
555 
1 min 3.01×10-9 2.64×10-7 2.43×10-8 0.08×10-3 
15 min 0.448×10-7 0.396×10-5 0.362×10-6 1.022×10-3 
1813 
1 min 1.007×10-7 7.54×10-7 7.92×10-8 0.24×10-3 
15 min 1.465×10-7 1.112×10-5 1.176×10-6 3.337×10-3 
2423 
1 min 0.14×10-7 0.11×10-5 0.11×10-6 0.31×10-3 
15 min 1.959×10-7 1.487×10-5 1.572×10-6 4.461×10-3 
2516 
1 min 0.14×10-7 0.11×10-5 0.12×10-6 0.32×10-3 
15 min 2.033×10-7 1.544×10-5 1.632×10-6 4.631×10-3 
3515 
1 min 0.21×10-7 0.16×10-5 0.16×10-6 0.46×10-3 
15 min 2.841×10-7 2.157×10-5 2.281×10-6 6.471×10-3 
4440 
1 min 0.25×10-7 0.19×10-5 0.25×10-6 0.58×10-3 
15 min 3.588×10-7 2.724×10-5 2.880×10-6 8.172×10-3 
5476 
1 min 0.31×10-7 0.23×10-5 0.24×10-6 0.74×10-3 
15 min 4.385×10-7 3.309×10-5  3.470×10-6 10.079×10-3  
6105 
1 min 0.34×10-7 0.26×10-5 0.27×10-6  0.76×10-3  
15 min 4.934×10-7 3.746×10-5 3.960×10-6 11.237×10-3 
 
Table 34. Total risk 
 
In general there are no reports of an increased risk of neoplasias, genetic damage or infertility with 
the doses used in hyperthyroidism. Doses obtained for 1813 MBq do not have a significant impact in 
risk assessment. Also calculated risk for one minute even for higher values of administered activity 
also are not significant. Since 1946, millions of adults have been treated with 131I, without an increase 
in cases of leukemia or other forms of cancer. In addition, no increased risks of congenital 
malformations in children of treated parents have been reported.  
ICRP 60 suggests that, in the case of internal exposure, the annual limits on intake based on a 
committed effective dose equivalent of 20 mSv will be ensured so that the lifetime dose equivalent in 
any single organ must not exceed 20 Sv, which is sufficient to avoid deterministic effects in 
unspecified tissues and organs [125]. 
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From the distribution of probabilities of fatal sites, specific cancers for male and female over age 0-90 
y for four countries (Japan, US, UK and Puerto Rico) the average factor was found to be maximum for 
stomach (0.225) over other organs [ICRP 60].  
The risk coefficients are presented in Table 35 
 
Organ Risk coefficient 
[10
-2
Sv
-1
] 
Bladder 0.30 
Bone surface 0.05 
Colon 0.80 
Liver 0.15 
Lungs 0.85 
Ovary, gonads 0.10 
Skin 0.02 
Stomach 1.10 
Table 35. Risk coefficient 
 
 
The use of Monte Carlo calculations allowed this task to be completed successfully, which have been 
extremely complicated with conventional mathematics due to the complex geometries.  
Even though these doses were representative, there are some factors that must be considered. The 
approximate model of gastric, the time of 15 minutes for dissolving the capsule, biokinetics of 
radioiodine and determination of effective half life is individual and different for every patient. Than the 
size and shape of residual tissue of the thyroid also affects the absorbed dose to other organs. 
                        
 
Graph 33. Risk according administered activity 
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Presently, health effects are neither a concern to the patients, nor to the physicians because of the 
overall effect in treating tumors. Although there may be a risk of getting secondary cancers over many 
decades, this therapy is generally preferred over the certainty of dying from thyroid cancer. If thyroid 
cancer occurs during the later years of individual’s life, the probability of adverse health effects from 
this treatment would not be a major concern for the patients, especially because the treatment is very 
effective, and it will increase the years of life of the patients. But in the latest years our findings are 
that thyroid cancer occurs at very young population aged below 16. So in these cases it is of great 
importance to estimate the risk of getting fatal cancer.  However, risk assessment can be performed 
by considering the risk of getting secondary cancer and risk coefficients provided by the International 
Commission on Radiation Protection (ICRP 1990). Using these coefficients and the calculated doses 
to each of the organs, the risk of getting fatal cancer can be calculated for each organ as well as for 
the individual. Because the energies emitted were due to photons, the dose is equal to the dose 
equivalent. The radiation weighting factor is one, so one Gray equals 1Sievert (Sv). 
There are several epidemiological studies that reports that it appears to be no risk of cancer from 
radioiodine therapy [118]. There are factors in the studies that might have an effect on the results: 
- The patients were followed less than 15 years, which might not be long enough to develop 
cancer. 
- The absorbed dose calculations were based upon the model, usually ICRP Publication 53, 
and not the individual biokinetics data. For example, the absorbed dose to the red marrow is 
50 % overestimated in average, using ICRP Publication 53. 
- The age limit for radioiodine treatment is lowered. More young people, women of 
childbearing age and even children are prescribed radioiodine therapy today [119]. 
In a study by Franklyn et al. [118] the relative cancer mortality was decreased after radioiodine 
therapy, but there was a significant increase and mortality for cancer in the small intestine and a 
positive association between bladder cancer incidence and cumulatively administered activity 131I.   
In another study by Holm et al.1991 [111], an elevated risk for stomach, kidney and brain cancer was 
seen. The risk for stomach cancer increased with dose although it was not statistically significant. 
These findings are in accordance with our investigations. The incident of thyroid carcinoma is higher 
in patients with Graves’ disease treated with antithyroid drugs than in patients treated with radioiodine 
or surgery. The explanation might be that more thyroid tissue is persistent after drug treatment than 
after radioiodine treatment or surgery [108]. 
The cancer risk has also been estimated using biological dosimetry [120]. Micronuclei originate when 
radiation disrupts the DNA and chromosome fragments fail to incorporate in the nucleus during next 
cellular division. The number of micronuclei in blood lymphocytes after 131I-iodide therapy was 
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studied, and the cancer mortality was estimated to less than 1%. The patients studied though were all 
over 40 years. 
Thirty years ago radioiodine therapy was less attractive in younger and fertile patients due to the 
potentially higher risk of secondary malignancies. Today after several papers indicating no risk of 
cancer after 131I-iodide therapy, young people and even children are more likely to receive the 
therapy. A higher risk for thyroid cancer has been seen in children after the Chernobyl accident and 
the increase of thyroid cancer is seen in the children that were born or in the fetal stage at the time of 
the accident [121].  For childhood leukemia, no such increase has been seen [122].  
In 1962   twenty six institutions, 25 in the United States and one in the United Kingdom performed 
prospective follow up of the hyperthyroid patients treated with radioiodine with activity (from 70 to 600 
MBq). Reports of the first results were based on follow up of approximately 22, 000 patients treated 
with radioiodine and 14.000 patients treated with antithyroid drugs. The results revealed a small 
increase in leukemia in 131I subjects when compared to age matched U.S rates, but the rates in the 
131I- treated patients were less than those observed in the surgically treated patients [106, 107]. A 
high rate of hypothyroidism was seen in all groups of treated subjects, regardless of therapy; there 
was a strong relationship between the amount of 131I activity and the frequency of hypothyroidism. 
The study clearly demonstrated the importance of inclusion of an appropriate comparison group; 
because without it a small leukemia increase observed would have been attributed to the then 
estimated 50 to 100 mGy, marrow dose from 131I rather than to thyrotoxicosis. Additional information 
was gathered on the frequency of benign and malignant thyroid neoplasm [108]. No evidence of an 
increase in malignant thyroid tumors was observed when disease observed in the first 5 years of 
follow – up was excluded. By excluding these 5 years, the co-occurrence of already present thyroid 
cancer, was not attributed to the 131I therapy. In 1974, 497 nodules were present when the paper by 
Dobyns et al. was published [108]. The charts of these patients were reviewed in the mid -1980s by 
the physicians at the four largest centers, and more than 95% of the cases were instances in which 
one reviewer noted a nodule, which was not subsequently noted in the patient’s chart. As a result to 
limited information on the biological turnover of 131I in the subjects in the original thyrotoxicosis 
therapy study, organ doses could not be estimated, and therefore administered activity, was used as 
a measure of exposure. The amount of activity administered in single doses ranged from <185 MBq to 
>555 MBq. Assuming 25-50% uptake in adults and given a mean activity of 330 MBq of 131I 
administered to the patients who developed leukemia. The bone marrow dose is estimated using 
ICRP data to lie between 13 and 67 mGy. A later follow-up of cancer mortality was conducted on this 
same patient population [109]. The study showed that the total number of cancer deaths was close to 
that expected based on mortality rates in the general population (2950 compared to 2857), but there 
was a small excess of mortality from cancers of the lung, breast, kidney and thyroid. A deficit of 
deaths was noted for cancers of the uterus and the prostate gland. Radioactive iodine was not linked 
to total cancer deaths or to any specific cancer with the exception of thyroid cancer, however, thyroid 
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cancer risk was not elevated when the first 5 years of follow-up were excluded. While this study does 
not provide compelling evidence for an association between 131I therapy given to adult patients and 
thyroid cancer mortality, it should be noted that because thyroid cancer is rarely fatal, mortality is not 
good measure of effects of 131I on the thyroid gland [107]. 
While a British study of hyperthyroid patients found a small but significant increased risk of thyroid 
cancer incidence and mortality among 131I treated patients [110], another Swedish study reported that 
the risk of thyroid cancer was not significantly elevated 10 or more years after treatment [111, 112]. 
Thyroid cancer risk also has been examined in cohorts of patients treated with iodine for diagnostic 
purposes. No significant excess risk of thyroid cancer were examined for reasons other than a 
suspected thyroid tumor, even the mean doses at thyroid are about 0.9 -1 Gy [113, 114, 115, 116]. In 
most recent follow-ups of hyperthyroid patients, neither leukemia risk nor other malignancies have 
been significantly linked to 131I therapy and the doses to organs other than thyroid are quite low. 
The thyroid doses for cancer therapy are extremely high with the aim of killing all of the cells in thyroid 
tissue. The doses to other organs are generally small. In a follow up of Swedish thyroid cancer 
patients treated with 131I the red bone marrow dose was estimated to be about 251 mGy. Cohort study 
in three European countries (Sweden, France and Italy) was conducted. The meanly administered 
activity was 6 (0.2-56) GBq. The risk of leukemia was elevated, but it didn’t reach statistical 
significance (RR= 1.9; 95% CI=0.8-3.6) GBq. There was also suggestive evidence of an increased 
risk of cancers of the salivary gland, bone and soft tissue and uterus. No evidence of genetic effects 
in the offspring of women treated with 131I for thyroid cancer has been detected, but the 
recommendation that conception is delayed for 1 year after therapy is still advocated.  
It is generally agreed that no evidence of significant germ cell damage has been noted among 
subsequently conceived offspring of treated hyperthyroid patients. Gonad damage and transiently 
impaired fertility may occur occasionally among thyroid cancer patients treated with much larger 
amounts of iodine 131I. 
 
4.6.2 Future work 
Although this research involved the use of actual thyroid therapy cases, they do not necessarily 
represent the exact doses the patients are receiving due to geometric factors and distances and sizes 
of the organs. Because of these factors, there is a recommendation for future work. Patient monitoring 
during first twenty four hours of administering radioiodine is very important, because most of the 
administered radioiodine is excreted during this period. Calculation of individual doses should be 
established. Collecting data about external exposure rate using GM counter is very well established 
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and recognized method of measuring distribution and tracer uptake inside body, and it should be 
continued and implemented in routine. 
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4.7 Results of external TLD measurements on the surface of the skin above gastric region 
The measurements over the skin above gastric region were performed by using TLD. In the Table 36 
are presented results from the measurements. The measurements were performed for a limited time 
of fifteen minutes and the period of stay in hospital of 3 and 4 days. All patients were female, aged (17 
up to 67) mean 47.6. 
 
Pat. 
No 
MBq 15 min 
(mSv) 
Hp(0.07) 
3 days 
(mSv) 
Hp(0.07) 
Type f/m age 
1 3589 3.55 76.45 pap F 50 
2 3552 3.72 83.23 pap F 17 
3 3145 2.61 60.96 pap F 45 
4 2960 2.1 91.42 pap F 43 
5 5550 4.93 157 (4day) pap F 17 
6 1850 0.95 39.4 (24h) pap F 48 
7 3700 4.11 95.33 pap F 55 
8 3711 4.32 94.25 pap F 60 
9 3700 2.60 82.8 pap F 45 
10 3552 11.98 195 pap F 56 
11 3700 4.24 92.5 pap F 62 
12 3589 3.20 93.34 pap F 54 
13 3552 3.80 94.87 pap F 67 
14 3700 4.64 97.34 pap F 50 
15 3700 4.57 94.32 pap F 46 
Mean 3570 4.36 96.54  pap F 47.6 
Table 36. External TLD measurements 
 
The meanly administered activity was 3570 MBq. Estimated value of Hp (0.07) for fifteen minutes was 
4.36 mSv, and for all period during the hospitalization of patients was 96.54 mSv. These results give 
useful information about the values of effective doses measured over gastric and total effective dose 
during the hospitalization of the patients. The minimum value of effective dose was estimated at 
patient who was treated with 1850 MBq and the patient was hospitalized only for one day, while the 
maximum was estimated at 195 mSv. These investigations from radiation protection of view are of 
great importance. From gained results, we could conclude and confirm that thyroid cancer patients 
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after receiving radiotherapy should stay hospitalized for several days. Otherwise, they could deliver 
high effective dose if someone is in their close proximity.  
Collecting data about external exposure rate using GM counter is very well established and 
recognized method of measuring distribution and tracer uptake inside body, and it should be 
continued and implemented in routine practice. 
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4.8 Results from environmental measurements of released concentration of iodine in sewage 
system 
Patients, when treated with ablation doses of 131I, are confined in a hospital for a few days to allow 
external radiation levels to decline to acceptable levels before release. The relatively rapid decline in 
activity is due primarily to the biological elimination of 131I from the body. Elevated concentration of 131I 
has been observed in the air nearby waste water following the application of therapy doses [95, 96]. 
The release limit for radioactive waste liquid according EU rules is 1 Bq/ml or 1000 Bq/l. The 
authorized limit dose air concentration is 400 Bq/m3. The measurements were performed in case one 
when only one patient was hospitalized and the case two when in the room were treated two patients. 
The result from the probe was taken for the period of three days during their stay at hospital. Elevated 
concentrations of 131I have been observed in air for the period of three days after administration of the 
therapy. The higher concentration was registered during first 24 hours. That is the time that 80% of 
activity is released in this period. The estimated doses are below the limit proposed by EU regulative. 
  
 
 
 
 
 
Table 37. Results from environmental measurements 
 
 
Graph 34. Energy spectrum of detected radionuclide by probe 
  
Case MBq 1 day  
Bq/m3 
2 day 
Bq/m3 
3 day 
Bq/m3 
Without patient 0 15 - - 
One patient 3700 150 95 25 
Two patients 2 X 3700 320 170 43 
  126 
Chapter 5 
5. CONCLUSIONS 
The development and use of radioactive isotopes of iodine have improved medical care substantially. 
Many clinical applications were an outgrowth of the development of the technology and the biological 
knowledge it engendered. Concern regarding the safe and effective use of radiation in medicine led to 
the development of standardized procedures and methods for calibrating the amount of activity 
administered to patients. This included much attention to quality control of the radionuclides 
administered, their chemical and radionuclide purity, and their stability in the body. 
131I is well used radionuclide for the treatment of both hyperthyroidism and differentiated thyroid 
cancer. It is well tolerated, simple to administer and has been proved in multiple follow up studies to 
be safe and effective. Regulations for the use of radioiodine remain extremely variable throughout the 
world, although there is a general acceptance of the basis radiation protection measures. 
In latest years, there are developed dosimetry systems for intake of radionuclides. These systems 
evolved from simple mathematical models to complex computer based systems that provide high 
accuracy. These methods are in routine use, in all major medical centers. With these tools, many 
investigations have led to the publication of high – quality data on radiation dose to patients, to 
workers and to the public from environmental releases of many radionuclides. 131I has received the 
greatest emphasis because of its unique applications in medicine [107]. 
In this study were performed external dose rate measurements of sixty patients and based on the 
gained results we can conclude the following: 
1. The hyperthyroid patients are discharged from hospital with higher dose rate than the thyroid 
cancer patients, especially the group of patients treated for autonomous functioning thyroid 
adenoma. They should continue to be treated on out - patient basis, because it has several 
advantages: lower health costs, lower doses to nursing staff and psychologic benefits for 
patients and family members. Emphasizing adherence to the new written instructions for 
radiation protection is very important. 
2. The thyroid cancer patients were released according dose rate measurements at third day 
with dose rate less than 8 µSv/h, at a distance of 2.0 m. During the three day stay in the 
hospital room, it is considered that the distance of 2.0 m from the patient could reduce the 
occupational exposure to nurse, physicist and physician who enter the room to visit treated 
patients. Also reducing the time of stay near the radioactive patient will reduce the effective 
doses to the other person and will improve better radiation protection. 
3. Radiation dosimetry deals with the determination of the amount and the spatial and temporal 
distribution of energy deposited in matter by ionizing radiation. Internal radionuclide radiation 
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dosimetry specifically deals with the deposition of radiation energy in tissue to a radionuclide 
within the body. However unlike external radiation dose which can be often measured, 
internal radiation dose must be calculated. These procedures have evolved over more than 
60 years from relatively simple approaches to those with a high level sophistication. Internal 
dosimetry has been applied to the determination of tissue doses and related quantities for 
occupational exposures in radiation protection, and diagnostic and therapeutic exposures in 
nuclear medicine. In this study by using MCNP 4b method were determined internal effective 
doses of several internal organs.  
From the current investigation, the most exposed organ in this created model was stomach. 
The value of extra effective dose due to 1 minute solution and to 15 minutes Na131I 
therapeutic capsules staying in the stomach from the current official radiation protection point 
of view is significant. This warrants long term follow up of such patients. 
The Monte Carlo method is considered to be the most accurate method presently available 
for solving radiation transport problems. It is very useful and unique method for the dosimetry 
of internal organs which is impossible to be calculated with any other method. It is extremely 
expensive computationally, because this method should simulate individual particles and 
simulating the average behavior of the particles in the system. For complex problems that the 
probability is small that a particle will contribute to the interest region, some form of variance 
reduction must be applied to reduce required computer time to obtain the results with 
sufficient precision 
From the gained results, the effective dose equivalent is intended to be directly proportional to the risk 
from the exposure. The investigations were started with the assumption that the values of additional 
effective doses of risks during 15 minutes of 131I capsules retaining in the stomach before their 
absorption are not negligible. Application of the solution has some advantages as the absorption in 
stomach wall is immediate but also has a lot of disadvantages. Capsules containing Na131I are widely 
used as they are more comfortable for administration and there is less possibility for local 
contamination of the patient and medical staff. During that time a large amount of radioactivity 
needlessly expose a part of a stomach and several surrounding organs. The significant uptake of 
radioiodine by stomach and urinary bladder of thyroid cancer patients carries additional risks of 
probabilistic fatal occurrences in them as compare to other organs. This fact was the main reason for 
our predication about the necessity of additional risk estimation. This warrants long term follow – up of 
such patients. Availability of risk estimates will help reduce psycho emotional distress for a patient. 
4. According to the obtained results we recommended some corrections of the traditional 
concept of risk estimation in our hospitals and we emphasized the necessity to create the 
concept which is able to cover the higher risks under presented circumstances. We strongly 
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recommend the estimation of additional risks for each type of the procedure as a part of QA 
programs for Na131I capsules application. This investigation will become actual and important 
for the case of high doses administrated during radiotherapy treatments. We expect that 
estimated risks will be higher and therefore more significant for patient protection as well as 
for radiation protection in general. Risk assessment and effective dose estimation for wide 
range of administered activities of 131I based radiopharmaceutical will give us a good basis for 
creation of suitable quality assurance and quality control programs in clinical practice. It also 
will enable design of appropriate programs for manufacturers and distributors of 
radiopharmaceuticals. Designed quality programs will be useful also for regulatory and 
accreditation bodies in the process of accreditation and radiation protection strategy. 
We hope that the results of our investigation will improve safety culture in our health care system and 
also among authorities who make regulatory decision. 
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5.1 Team collaboration between patient, physician and physicist 
The patient-physician relationship is a special one, involving trust, weighing and balancing of very 
significant decisions exposure of highly personal information. Decision about medical procedures and 
follow-up, use of medications, planning and lifestyle are very personal and often difficult. The role of 
physicist, who provide just one piece of information that physician must weigh and convey to his 
patient, is very peripheral, but nonetheless pivotal in the case of therapeutic use of radiation. These 
three individuals must work closely, however in this ongoing process to provide the highest quality 
medical care possible in every circumstance. Ultimately, the patient makes the final decisions about 
the progress of medical care and must be given the high quality information, clearly and 
unambiguously communicated by the physician and/or physicist.  
It is very important that radiopharmaceutical therapy begin to involve the physicist more than it has in 
the past, as is modeled in external beam radiotherapy. 
 
 
 
 
 
 
  
  130 
Chapter 6 
REFERENCES 
 
1. B.Karanfilski, D.Arsov, I.Tadzer; Iskustva vo lekuvanjeto na hipertireozata so radiojod 131, Godisen 
zbornik na Medicinski fakultet, VI.1959,113-115, Interna klinika i Institut za patofiziologija – Medicinski 
fakultet Skopje. 
2. Briesmeister J: “MCNP – A general Monte Carlo N-Particle Transport Code, Version 4B”, Report 
LA-12625-M. Los Alamos, NM; 1997. 
3. Stabin MG. Fundamentals of nuclear medicine dosimetry, Springer, New York, 2008. 
4. Dendy.P.P & Heaton. B.:(1999). Physics for Diagnostic Radilogy. 2nd edition Bristol 
Philadelphia:U.S.A: Institute of physics (IOP) Publishing. ISBN: 0-7503-0591-6  
5. Klevenhagen, S.C.: (1993). Physics and Dosimetry of Therapy Electron Beams. Madison 
Wisconsin: Medical  Physics (IOP) Publisher. ISBN: 0-944838-36-7.1993. 
6. Friedell, H.L., Thomas, C.I.& Krohmer, J.S.: “Beta-Ray Applicationto the Eye woith the 
Descriptionof an Applicator Utilizing Sr90 and its Clinical use”. Am. J. Ophtalmol. 33:525-535. 
7. Donnald, T.G.;(1996) Principles of Radiological Physics. 3rd edition, New York;Churchill Living 
Stone. ISBN:0-4430-4816-9. 
8. Johns, H.E. & Cunningham, J.R.: (1983) The Physics of Radiology. 4th edition. Springfield U.S.A: 
Chareles C Thomas, Chapter 3,5,13. ISBN: 0-398-04669-7. 
9. Khan. F.M.:(2003). The Physics of Radiation Therapy. 3rd edition. Philadelphia U.S.A.: Lippincott 
Williams & Wilkonsin. ISBN: 0-7817-3065-1. 
10.Podgorsak, E.B.; (2006). Radiation Physics for medical Physicists. Berlin Heilderberg New York: 
Springer. ISBN: 3-540-25041-7. 
11. James, E.M.: (2006). Physics for Radiation Protection 2nd edition. Germany: Weinheim Wiley-
VCH. ISBN: 3-527-40611-5. 
12. IAEA: (2003). Review of Radiation Oncology Physics: AHandbook for Teachers and Students. 
Vienna Austria. 
13. Cherry.S.R.,Sorenson. J.A.& Phelps, M.E.; (2003). Physics in Nuclear Medicine.3rd edition. 
Philadelphia U.S.A.; Saunders, ISBN: 0-7216-8341-X. 
14. International Commission on Radiation Protection Publication: Release of patients after therapy 
with unsealed radionuclides. ICRP 94.pp.80, 2005, Elsevier, Oxford. 
15. International Atomic Energy Agency, Safety Reports Series N0. 63 Release of Patients after 
Radionuclide Therapy, Vienna,2009. 
16.H.R. Maxon, S.R. Thomas, R.C. Samaratunga, “Dosimetric considerations in the radioiodine 
treatment of macrometastases and micrometastases from differentiated thyroid cancer”, Thyroid, 
7(2):183-187,(1997). 
  131 
17. C. Kobe, W. eschner, F. Sudbrock, I. Weber, k. Marx, M. Dietlein, H. Schicha. “Graves’ disease 
and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy” 
Nuklearmedizin,47:14,(2007). 
18. Maboe, D.P.A,: (2001). Radiation Detector Modelling with Monte Carlo N-Particle Code. Msc. 
Thesis, University of Limpopo (MEDUNSA).3-23. 
19.International Commisssion on Radiological Protection. Radionuclide transformations-Energy and 
Intensity of Emissions. ICRP 38. Pergamon Press, Oxford, 1983. 
20. Young, M.E.J; (1983). Radiological Physics. 3th edition. London;H.K. Lewis&CoLtd. ISBN:0-7186-
0452-0. 
21. Hamilton, J. Seaborg,G. (1939), Studies in iodine metabolism by use of a new radioactive isotope 
of iodine, Am J Physiol 127,557,1939. 
22.Early PJ, landa ER. Use of therapeutic radionuclides in medicine. Health Phys 1995; 69(5):677-
694. 
23. Seidlin S, Oshry E, Yallow A. Spontaneous and experimentally induced uptake of radioactive 
iodine in metastases from thyroid carcinoma, J. Clin Endocrinol Metab. 1948;8:423-425. 
24. B. Karanfilski, I. tadzer; Iskustva u testiranju tiroidne funkcije radijodom. Med. Glasnik XIV, 
2a,1960, 126-131. 
25. Nystrom E, Berg G,  Jansson S, Lindstedt G, Torring O, Valdemarsson S, Warin B. Thyrotoxokos 
hos vuxna. ISBN: 91-630-7674-8, Ljungbergs Teyckeri AB, Klippan, Sweden, 1999. 
26. Felliciano DV. Everything you wanted to know about Grave’s disease. Am J Surg 1992; 164(5): 
404-411. 
27. Reinwein D, Benker G, Konig MP, Pinchera Q, Schatz H, Schleusene A. The different types of 
hyperthyroidism in Europe. Results of prospective survey of 924 patients. J Endocrinol Invest 1988; 
11(30:193-200. 
28. Ingbar S.H. Braerman, L.E., Werner’s The Thyroid – A Fundamental and clinical Text, J.B. 
Lippincot Company, Philadelphia, 1986. 
29.International Commisssion on Radiological Protection.Publication 30, Part 1, Limits for Intakes of 
radionuclides by Workers. Pergamon Prewss, Oxford, 1979.  
30. G. Saha, Basic of PET Imaging – Physics, Chemistry and Regulation; Springer, 2004. 
31. Kowalsky R. Perry J., Radiopharmaceuticals in nuclear medicine practice Appleton & Lange, 
Prentice Hall, Connecticut, USA, 1987. 
32. Bernier D., Christian P., Langan J., Nuclear Medicine – technology and techniques; Mosby, 1993. 
33. Kocher, David C., Radioctive Decay data tables, Springfield: National Technical Information 
Service, 1981 DOE/TIC-11026. 
34. Kaplan, Irving, Nuclear Physics, New York: Addison-Wesley, 1964. 
  132 
35. Ernest Mazzaferri, Clive Harmer, Ujjal K. Mallian Pat Kendall Taylor editors; Practical 
management of Thyroid Cancer. 
36. International Commisssion on Radiological Protection. Publication 94: release of patients after 
therapy with unsealed radionuclides. ICRP.pp.80, 2005, Oxford. 
37. International Atomic Energy Agency, Safety reports Series No. 63 release of Patients after 
Radionuclide Therapy, Vienna, 2009. 
38. International Atomic Energy Agency,  Basic Safety Standards for Protection against Ionizing 
Radiation and for the Safety of Radiation Sources, 1996. 
39. Murray, I.P.C. Ell. P.J., Nuclear medicine clinical diagnosis and treatment, Edinburgh: Churchill 
Livingstone, 1994. 
40. V. Spasic Jokic, M. Orlic, Monte Carlo Estimation of Patient Effective Dose in Diagnostic 
Procedures Using 131I; Journal of Physics: Conference Series 238 (2010) 012054. 
41. S. Mattsson and C. Hoechen (eds.), Radiation Protection in Nuclear Medicine, DOI 10.1007/978-
3-642-31167-3_2, Springer – Verlag Berlin Heidelberg 2013. 
42. Bergonie J, Tribondeau L. De quelques resultants de la Radiotherapie, et esaie de fixation d’une 
technique rationelle. Comptes Rendu des Seances de l’Academie des Sciences 143:983-985, 1906. 
43. Luckey TD. Radiation Hormesis. CRC Press.Boca Raton, FL, 1991. 
44. Humm JL, Howell RW, Rao DV. AAPM Report No. 49, Dosimetry of Auger-Electron-Emitting 
Radionuclides, Med Phys 21(12), 1994. 
45. Brooks AL. Evidence for “bystander effects” in vivo. Human Exp Toxicol 23:67-70, 2004. 
46. Hall EJ. The bystander effect, Health Phys 85:31-35, 2003. 
47. National academy of sciences, Health Risks from Exposure to Low Levels of Ionizing Radiation: 
BEIR VII Phase 2. The National Academies Press, Washington DC, 2006. 
48. NCRP. The Relative Biological Effectiveness of Radiations of a different Quality. NCRP Report No 
104. National Council on radiation Protection and Measurements, Bethseda, MD, 1990. 
49. G. Saha., Springer-Verlag: Physics and radiobiology of nuclear medicine, 1993. 
50. International Commission on Radiation Units and Measurements (2011) Fundamental Quantities 
and Units for Ionizing Radiation (Revised). ICRU report 85a. J ICRU 11 (1a). 
51. International Commission on Radiation Units, Quantities and Units in radiation Protection 
Dosimetry, ICRU, Report 51, 1993 
52.  International Commission on Radiation Units. 1971 Radiation quantities and units ICRU Report 
19 (Bethesda, MD: ICRU 1973 Dose equivalent Supplement to Report 19 (Bethesda, MD, USA: 
ICRU). 
53. Rames Chandra; Nuclear medicine Physics: Basics, 7th edition, Lippincott & Wilkins,2011, ISBN 
1451109415. 
  133 
54. International Commission on Radiological Protection. 2007 The Recommendations of the 
International Commission on Radiological Protection. ICRP Publication 103 (2007). 
55. International Commission on Radiological Protection. Basic anatomical and physiological data for 
use in radiological protection: reference values. ICRP Publication 89. Ann ICRP32(3-40 (2002). 
56. International Commission on Radiological Protection. 1990. Recommendations of the International 
Commission on radiological Protection  ICRP Publication 60. Ann. ICRP 21 (1-3) (Oxford: Pergamon 
Press) (1991). 
57. International Commission on Radiation Units and Measurements, 2002, “Absorbed-dose 
specification in medicine nuclear”, Oxford: Pergamon Press: ICRU Publication 67. 
58. G. Sgouros, K.S. Kolbert, A. sheikh, K.S. Pentlow, E.F.Mun, A. barth, R.J. Robbins, S.M. Larson. 
Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124iPET and 3-Dimensional-
Internal Dosimetry (3D-ID) Software. J Nucl Med 45:1366-1372,(2004). 
59. Zanzonico  PB. Radiation dose to patients and relatives incident to 131I THERAPY. Thyroid 
1997;7(2):199-204. 
60. Lima, F.F. DE,2002, Otimizacao da dose terapeutica com 131I para carcinoma diferenciado da 
tiroide. Tese de D.Sc, Universidade Federal de Pernambuco, PE,Brasil. 
61.Intermational Commission on Radiation Units and Measurements, 1998, “Fundamental quantities 
and units for ionizing radiation”, Oxford: Pergamon Press: ICRU Publication 60. 
62. M. C.Cantone, C. Hoeschen; Radiation Physics for Nuclear Medicine, Springer,2011. 
63. Andreo, P., 1991, “Monte Carlo techniques in medical radiation physics”, Phys. Med. Biol., 
v.36,n.7,pp.861-920. 
64. National Radiological Protection Board. Board Statement on Diagnostic Medical Exposures to 
Ionising Radiation During Pregnancy, Documents of the NRPB 4(4). London:HMSO, 1993.) 
65. Mountford P.J., Risk assessment of the nuclear medicine patient, The British Journal of 
Radiology, July 1997. 
66. Mettler FA, Chrisitie JH, Williams  JG, et al. Population characteristics and absorbed dose to the 
population from nuclear medicine:united States-1982. Health Phys 1986; 50: 619-28.) 
67. Cohen BL. Catalog of risks extended and updated. Health Phys 1991; 61; 317-35. 
68. Donald J. Peck, Ehsan samei,; How to understand and communicate Radiation Risk, Image 
Wisely,www.imagewisely.org. 
69. Overbeek F, Pauwels EKJ, Broerse JJ. Carcinogeniic risk in diagnostic nuclear medicine: 
biological and epidemiological considerations. Eur J Nucl Med 1994;21:997-1012. 
70. Stabin M, Stubbs J, Watson E. Recent controversy in radiation dosimetry. Eur J Nucl Med 
1993;20:371-2. 
71. Loevinger R, Budinger Tf, Watson EE(eds). MIRD primer for absorbed dose calculations. New 
York: Society of Nuclear medicine, 1989. 
  134 
72. International Commission on Radiological Protection. Radiation Dose to Patients from 
Radiopharmaceuticals (including Addendum 1), ICRP Publication 53 Oxford: Pergamon Press, 1994. 
73. Mountford PJ, Green S, Jones K, et al. Variation of dose rate with distance from extended sources 
of 99mTc. J Radiol Prot 1996;16:51-5. 
74. Harding LK, Mostafa AB, Thomson WH. Staff radiation doses associated with nuclear medicine 
procedures – a review of some recent measurements. Nucl Med Commun 1990;11:271-7. 
75. Mountford PJ,O’Doherty MJ, Forge NI. Radiationdose rates from adult patients undergoing 
nuclear medicine investigations. Nucl Med Commun 1991;12:767-77. 
76. Harding LK, Mostafa AB, Roden L, et al. Dose rates from patients having nuclear medicine 
investigations. Nucl Med Commun 1985;6:191-4. 
77. Mountford PJ, O’Doherty MJ, Harding LK, et al. Radiation dose rates from paediatric patients 
undergoing 99mTc investigations. Nucl Med Commun 1991;12:709-18. 
78. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data 
quantitative analysis and recommendations. Nucl Med Commun 1989;10:15-27. 
79. Marcuse HR, Van der Steen J, Maessen HJM, et al. Radiation exposure to parents nursing their 
child during treatment with I-131-metaiodobenzylguanidine for neuroblastoma. In:Schlafke-Stelson 
AT,Watson EE, editors. Fourth International Radiopharmaceutical Dosimetry Symposium, CONF-
851113. Oak Ridge, TN: Office of Science and Technological Information, 1986:181-5. 
80. International Commission on radiological Protection. ICRP 74, Conversion coefficients for use in 
Radiological Protection against External Radiation, Annals of the ICRP 26,1997. 
81. V. Spasic Jokic, M.Orlic, Monte Carlo estimation of patients effective dose in diagnostic 
procedures ising 131I, J.Phys:Conf.Ser. 238(1) (2010)1-6. 
82. International Commission on radiological Protection.Radiation dose to patients from 
radiopharmaceuticals. ICRP Publication 53.Ann ICRp 18(1-40 (1987). 
83. I.G.Zubal, C.R. Harrell, E.O. Smith, Z. Rattner, G. Gindi, P.B. Hofer, Computerized 3-dimensional 
segmented human anatomy, Med. Phys. 21 (1994) 299-302. 
84. W.P. Segears, D.S.Lalush, B.M.W. Tsui, Modeling respiratory mechanics in the MCAT and spleen 
–based MCAT phantoms, IEEE Trans. Nucl. Sci. 48 (2001) 89-97. 
85. K.F.Eckerman, M.Cristy, J.C.Ryman, The ORNL Mathematical phantoms Series, Oak Ridge 
National Labaratory, 1996. 
86. International Commission on radiological Protection.ICRP 70, Basic Anatomical & Physiological 
Data for use in Radiological Protection., Annals of the ICRP 26, 1996. 
87. International Commission on Radiological Protection. ICRP 89, Basic Anatomical & Physiological 
Data for use in Radiological Protection., Annals of the ICRP 32 (3-4), 2002. 
88. International Commission on Radiation Units and Measurements, ICRU Report 46, Photon, 
Electron, Proton and Neutron Interaction data for body tissues, Bethesda, MD, 1992. 
  135 
89. H. Behrens, L. Szybisz, Physics Data 6-1, zetralstelle Fur Atomkernenergie- Dokumentation, 
Germany, 1976. 
90. Evaluated Nuclear Structure data File (ENSDF) database at the Brookhaven National Laboratory, 
2002. 
91. J.F. Briesmeister, A General Monte Carlo N-particle transport Code, Version 4B, LA-12625-M 
Report, Los Alamos national laboratory, Los Alamos., N.Mex., USA, 1977. 
92. Hunt, J.G, Da Silva, F.C.A. Dos Santos, D.S, malatova, I., Dantas B.M, Azerdo A., 2000, “Visual 
Monte Carlo for Rdaiation Physics, particle Transport Simulation and Applications, Proceedings of the 
Monte Carlo 200 Conference, Lisbon, October 23-26, 2000, edited by A. Kling, F. Barao, M. 
Nakagawa, L. tavora, and P. Vaz. Springer-Verlag, Berlin, pp. 345-350. 
93. Sherbini, S.S. and Decicco, J.E., 2005, “The use of radiation surveys to estimate the radiation 
effective dose to visitors of hospitalized patients – A theoretical study”, Health Phys., v. 89, n.3, 
pp.216-223. 
94. Yi, Y.; Stabin, M.G.; McKaskle, M.H.; Shone, M.D.; Johnson,A.B.”Comparison of Measured and 
Calculated Dose Rates Near Nuclear Medicine Patients”, Health Physics Society, March, 2013. 
95. Larsen. I.L., E.A. Stetar and K.D. Glass, “In-House screening for Radioactive Sludge at a 
municipal Wastewater Treatment Plant”, Radiation Protection Management, 12(4):29-38,1995. 
96. Larsen. I.L., E.A. Stetar, B.G.Giles, and B.Garrison “Concentration of Iodine -131 Released from a 
Hospital Into a Municipal Sewer”, RSO Magazine January/February 2001, Vol6, No1. 
97. Tzavara I, Vlassopoulou B, Alevizaki C, Koukoulis G, Tzanela M, Koumoussi P, Sotsiou F, 
Thalassinos N, “Differentiated thyroid cancer: a retrospective analysis of 832 cases from 
Greece.;PMID 10468931, Pubmed – indexed foe MEDLINE. 
98. R. Sciuto, L. Romano, S. Rea, F. Marandino, I. Sperdurti, and C.L. Maini;’’Natural history and 
clinical outcome of differentiated thyroid carcinoma: aretrospective analysis of 1503 patients treated at 
a single institution., Annals of Oncology (2009) 20 (10) 1728-1735, Oxford Journals. 
99. Brig SS Anand, V Sood, Lt Col PG. Kumar, Lt Col I. Sinha, Lt Col A. Kotwal, “Retrospective 
Analysis of Thyroid Cancer Patients”, MJAFI, Vol 64, No1, 2008. 
100. L. Johansson, S. Leide-Svegborn, S. Mattsson, B. Nosslin, Biokinetics of iodide in 
man:refinement of current ICRP dosimetry models, Cancer Biother. Radiopharrm. 18(2003) 445-450. 
101. International Commission on Radiological Protection, ICRP 88 Doses to the Embryo and Fetus 
from Intakes of Radionuclides by the mother, International Commission on Radiological Protection, 
Pergamon Press, Oxford, 2001. 
102. Vesna Spasic Jokic, Marina Zdraveska Kocovska,”New technique for effective dose estimation 
using Monte Carlo simulation for the patients undergoing radioiodine therapy”, Measurement 
46(2013) 795-802. 
  136 
103. Brincker H. Hansen HS, Andersen AP. Induction of leukaemia by I131 treatment of thyroid 
carcinoma. Br J Cancer 1973:28:232-237. 
104. Jall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 
64:159-163. 
105. Sobels FH. Estimation of the genetic risk resulting from the treatment of women with 
I131.Strahlentherapie 1968:138:172-177 
106. E. L. Saenger, G. E. Thoma and E. A. Tompkins, Incidence of leukemia following treatment of 
hyperthyroidism: Preliminary report of the cooperative thyrotoxicosis therapy follow-up study. 
J.Am.Med.Assoc.205.855-862 (1968). 
107. A.B.Brill, M.Stabin, A. Bouville, and E. Ron,”Normal Organ Radiation Doseimetry and Associated 
Uncertainties in Nuclear medicine, with Emphasis on Iodine-131.Radiation Research, 16691): 128-
140.2006. 
108. B. M. Doybyns, G. E. Sheline, J.B. Workman, E. A. Tompkins, W. M. McConahey and D. V. 
Becker, Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: A 
report of the cooperative thyrotoxicosis therapy follow up studyJ. Clin. Endocrinol. Metab. 38, 976-998 
(1974). 
109. E. Ron, M. M. Doody, D. V. Becker, A. B. Brill, R. E. Curtis, M. B. Goldman, B. S. H. Harris, D. A. 
Hoffman, W. M. McConahey and J. D. Boice, Cancer mortality following treatment for adult 
hyperthyroidism. J. AM. Med. Assoc. 280, 347-355 (1998). 
110. J. A. Franklyn, P. Maiaonneuve, M. C. Sheppard, J. Betteridge and P. Boyle, Mortality after the 
treatment of hyperthyroidism with radioactive iodine. New Engl. J. Med. 338, 712-718 (1998). 
111. L. E. Holm, P. Hall, K. Wiklund, G. Lundell, G. Berg, G. Bjelkengren, E. Cederquist, U. B. 
Ericsson, A. Hallquist and L. G. Larsson, Cancer risk after iodine-131 therapy for hyperthyroidism, J. 
Natl. Cancer Inst. 83, 1072-1077 (1991).  
112. P. Hall, G. Berg, G. Bjelkengren, J. D. Boice, Jr., U. B. Ericsson, A. Hallquist, M. Lindberg, G. 
Lundell, J. Tennvall and L. E. Holm, Cancer mortality after iodine 131 therapy for hyperthyroidism. Int. 
J.Cancer 50,886-890 (1992).                                                                                                                                                                                                                          
113. P. W. Dickman, L. E. Holm, G. Lundell, J. D. Boice, Jr. and P. Hall, Thyroid cancer risk after 
thyroid examination with I131: A population based cohort study in Sweden. Int. J. cancer 106, 580-
587 (2003). 
114. K. Hahn, p. Schnell-Inderst, B. Grosche and L.E. Holm, Thyroid cancer after diagnostic 
administration of iodine in childhood. Radiat. Res. 156,61-70 (2001). 
115. L. E. Holm, K. E. Wiklund, G. E. Lundell, N. A. Bergman, G. Bjelkengren, E. S. Cederquist, U. B. 
Ericsson, L. G. Larsson, M. E. Lidberg and R. S. Lindberg, Thyroid cancer after diagnostic doses of 
iodine 131: A retrospective cohort study, J. Natl. cancer Inst. 80, 1132-1138 (1998). 
  137 
116. B. Globel, H. Globel, and E. Oberhausen, Epidemiologic studies on patients with iodine-131 
diagnostic and therapy. In Radiation - Risk – Protection, Vol,II, pp. 565-568. Fcahhverband fur 
Strahlenschutz e. V., Koln, 1984. 
117. Clark OH, Dah QY. Thyroid Cancer. Med Clin North Am 1991;75:211-34. 
118. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and 
mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 
1999; 353:2111-2115. 
119.  Wartofsky L, Glinoer D, Solomon B, Lagasse R. differences and similarities in the treatment of 
diffuse goiter in Europe and the ibnited states. Exp Clin End 1991; 97:243-251. 
120. Monsieurs MA, Thierens HM, Van de Wiele C, Vrasl AM, Mierlaen IA, De winter HA, de Sadeleer 
CJ, De ridder I, Kaufman JM, Dierckx RA. Estimation of risk based on biological dosimetry for patients 
treated with radioiodine. Nucl Med Comm 1999;20:911-917. 
121. Astakhova LN, Anspaugh LR, Beebe GW, Bouville A, Drozdovitch VV, Garber V, Gavrilin YI, 
Khrouch VT, Kuvshinnikov AV, Kuzmenkov YN, Minenko VP, Moschik KV, Nalivko AS, Robbins J, 
Shemiakina EV, Shinkarev S, Toschitskaya SI, Waclawiw MA. Chernobil-related thyroid cancer in 
children of Belarus :a case control study. Radiat Res 1998; 150(3):349-356. 
122. Gapanovich VN, Laroshevich RF, Shuvaeva LP, Becker SI, Nekolla EA, Kellerer AM. Childhood 
leukemia in Belarus before and after the Chernobyl accident: continued follow up. Radiat environ 
Biophys 2001; 40(4):259-267. 
123. Chandra,R., (1992), Introductory physics of nuclear medicine, 4th edition, Lea Febiger, 
Philadelphia,1992. 
124. Edwards,M.S., 1977,”Dose Estimate Techniques”, In:ROLLO, F.D., Nuclear Medicine Physics, 
Instrumentation, and agents, Chapter 14,Ed.Mosby Company. 
125. Ahmed S, Jahan QM, Demir M, Zalaria GA, Study on Radioiodine distribution over several 
organs of the Thyroid cancer patients to determine the effective dose equivalent that relates to fatal 
occurrences: A clinical perspective. World J Nucl Med 2004;3: 131-136. 
 
  
  138 
LIST OF FIGURES 
 
Figure 1. Photoefect 
Figure 2. Compton effect 
Figure 3. Thyroid Gland 
Figure 4. Examples of scintigrams after administration of 131I 
Figure 5. Decay Scheme of 131I 
Figure 6. Capsule form 131I 
Figure 7. Gastric 
Figure 8. Isolation ward for patients 
Figure 9. Relationship between physical protection and operational quantities 
Figure 10. Representation of source and target volume 
Figure 11. Visualization of absorbed fraction per different radiation 
Figure 12. Differences between a mathematical simulator and a simulator voxel 
Figure 13. The adult human phantom external dimensions  
Figure 14. The adult human phantom: GI tract 
Figure 15. Voxel based phantoms 
Figure 16. MIRD software 
Figure 17. Activity in breast feeding woman 
Figure 18. Form of the package with radioiodine 131I 
Figure 19. Survey meter ”minirad” series 1000 
Figure 20. Process of thermoluminiscence 
Figure 21. TLD 
Figure 22. TLD Reader Thermo Harshaw 6600 
Figure 23. Monitoring system 
Figure 24. Dose calibrator Atom lab 100 
Figure 25. Lead container and vial for capsule 
Figure 26. Elipsoid gastric model 
 
 
 
 
 
 
 
 
  139 
LIST OF TABLES 
 
Table 1. 131I decay data 
Table 2. Physical, biological and effective half life of 131I 
Table 3. Formulation information of therapeutic sodium iodide 
Table 4. Dose threshold for deterministic effects 
Table 5. Excess cancer mortality life time risk 
Table 6. ICRP recommended radiation weighting factors  
Table 7. ICRP recommended tissue weighting tissue factors, ICRP 2007 
Table 8. Values of coefficients of variation provided by Briesmeister 
Table 9. Risk associated with procedure 
Table 10. Examples of occupational, personal and recreational activities carrying a fatal risk 
Table 11. Nominal risk for cancer effects 
Table 12. Evolution of risk estimates for fatal cancer 
Table 13. Detriment 
Table 14. TTP 
Table 15. ICRP conversion coefficient 
Table 16. Hyperthyroid patients 
Table 17. Carcinoma patients 
Table 18. Distribution of malignant thyroid tumors 
Table 19. Dose rate test 
Table 20. Inverse square dose rate validation 
Table 21. Measured dose rates for hyperthyroid patients 
Table 22. Coefficients at distances 
Table 23. Dose rate vs. distances for hyperthyroid patients at time of treatment 
Table 24. Inverse square law validation 
Table 25. Dose rate results 
Table 26. Coefficients 
Table 27. Coefficients 
Table 28. Day 1 
Table 29. Day 2 
Table 30. Day 3 
Table 31. Inverse square law 
Table 32. Imparted energy per transformation for different organs 
Table 33. Calculated values of dose equivalents 
Table 34. Total risk 
  140 
Table 35. Risk coefficient 
Table 36. External TLD measurements 
Table 37. Released concentration of iodine 
 
 
 
 
 
 
 
  141 
LIST OF GRAPHS 
 
Graph 1. Possible dose response curve describing the excess risk of stochastic health effects at low 
doses of radiation 
Graph 2. Tissue weighting factors according ICRP 26, ICRP 60 and ICRP 103 
Graph 3. Time activity curve 
Graph 4. The main elements of the radiation protection 
Graph 5. Heating cycle 
Graph 6. Beta spectra of 131I 
Graph 7. Treated patients for 5 years 
Graph 8. Treated patients by sex 
Graph 9. Administered activity per years 
Graph 10. Papillary cancer per age 
Graph 11. Number of patients 
Graph 12. Inverse square dose rate validation 
Graph 13. Patients by diagnose 
Graph 14. Patients by sex 
Graph 15. Patients by administered activity 
Graph 16. Dose rate of hyperthyroid patient 
Graph 17. Coefficients at distance 
Graph 18. Standard deviation 
Graph 19. Patients vs. standard deviation 
Graph 20. Inverse square law validation for hyperthyroid patients 
Graph 21. Patients by diagnose 
Graph 22. Patients by sex 
Graph 23. Patients by administered activity 
Graph 24. Dose rate of thyroid cancer patients 
Graph 25. Standard deviation 
Graph 26. Inverse square law validation 
Graph 27. Effective doses 
Graph 28. Comparison of effective doses 
Graph 29. Effective doses for skin, lung and liver 
Graph 30. Effective doses for ovary, gonads, bladder and colon 
Graph 31. Stomach 
Graph 32. Stomach for 1 and 15 minutes 
Graph 33. Risk estimation 
  142 
Graph 34. Energy spectrum  
  143 
Annex 1 
 
Central Limit theorem 
Define sets of a discrete random variable ξ, 
MãÄ	 	xZ
[
ZÄ?
pZ 
And continuous ξ random variable at interval (a, b) 
MãÄ	äxpxdx
,
+
 
The variance of a discrete random variable ξ is defined by the number 
Dξ = M[ξ − Mξ8] 
And continuous random variable ξ at an interval (a, b) 
Dξ = 	ä x8
,
+
pxdx − äxpxdx
,
+
8
 
If ξ1,ξ2,v..ξN is a long sequence of values assumed by ξ the average of this will be the next 
Mƚ, 
Mξ	 ≈ 	 1N		ξ? +	ξ8 +	… . . ξ/ = 	
1
NξZ
/
ZÄ?
 
SN =	AZ©,ê©,4©…
 = A¨
/
?
 
Considering ξ1, ξ2, ξ3vv.N, independent random variables equally distributed. The 
distribution of the variables is the same as their variances. Thus we can write  
Mξ1 = Mξ2 = vvMξN = m 
Dξ1 = Dξ2 = vv..DξN = b
2  
Knowing that for any random variable ξ and η and take place 
M (ξ + η) = Mξ + Mη 
D (ξ + η) = Dξ + Dη 
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If we denote with ρN the sum of the variables 
ρN = ξ1 + ξ2 + vv+ξN    follows  
Mρ/ = Mξ? + ξ8………… + ξ/ = Nm 
Dρ/ = Dξ? + ξ8………… + ξ/ = Nb8 
Assuming	ξ/, denotes a normal random variable by individual parameters  
a = Nm	and	σ8 = Nb8 
The Central Limit Theorem states that for any range (a’ b’) and N sufficiently large it. 
PëaE < ρ/ < bEì ≈ 	 ä Pξ/
,E
+E
xdx 
Thus the sum of a large number of independent variables also is approximately normal 
distributed  
Pρ/x ≈ Pξ/(x)) 
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Annex 2 – tables with results  
     
 
MBq Skin Lungs Liver 
 
185 0,007 0,016 0,031 
 
370 0,014 0,033 0,062 
 
555 0,022 0,050 0,096 
 
1110 0,044 0,102 0,192 
 
1813 0,065 0,149 0,282 
 
2423 0,087 0,199 0,377 
 
2516 0,090 0,206 0,391 
 
2756 0,099 0,226 0,428 
 
3009 0,108 0,247 0,468 
 
3145 0,113 0,258 0,489 
 
3237 0,115 0,262 0,497 
 
3349 0,117 0,268 0,501 
 
3441 0,121 0,278 0,536 
 
3515 0,126 0,288 0,546 
 
3614 0,130 0,296 0,562 
 
3737 0,134 0,306 0,581 
 
3838 0,138 0,314 0,596 
 
3959 0,142 0,324 0,615 
 
4033 0,145 0,330 0,627 
 
4440 0,160 0,364 0,690 
 
5106 0,188 0,400 0,731 
 
5476 0,200 0,405 0,803 
 
5550 0,220 0,455 0,863 
 
6105 0,220 0,500 0,949 
 
Table A2-1. Results of organ effective dose for given activity 
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MBq Ovary, gonads Bladder Colon 
185 24,040 27,429 47,028 
370 48,079 54,858 94,061 
555 72,121 82,288 141,084 
1110 144,244 164,581 282,100 
1813 235,690 244,020 461,060 
2423 315,060 326,190 616,360 
2516 327,080 338,640 639,880 
2756 358,350 371,010 701,050 
3009 391,250 405,070 765,410 
3145 408,850 423,300 799,850 
3237 416,100 433,100 801,900 
3349 426,100 443,100 819,900 
3441 437,100 463,100 836,900 
3515 457,050 473,200 894,140 
3614 469,840 486,450 919,170 
3737 485,810 502,980 950,410 
3838 498,890 516,530 976,010 
3959 514,670 532,860 1006,870 
4033 524,290 542,820 1025,690 
4440 577,200 597,600 1129,200 
5106 632,200 650,600 1289,200 
5476 700,030 709,880 1399,500 
5550 721,500 747,000 1411,500 
6105 793,650 821,700 1552,650 
 
Table A2-2. Effective doses for ovary, bladder and colon  
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MBq Stomach 
185 3713,514 
370 7427,062 
555 11140,544 
1110 22281,091 
1813 36407,000 
2423 48666,500 
2516 50524,000 
2756 55353,500 
3009 60435,620 
3145 63155,000 
3237 65740,640 
3349 68727,500 
3441 69099,000 
3515 70599,900 
3614 72576,240 
3737 75043,000 
3838 77063,960 
3959 79501,000 
4033 80987,000 
4440 89160,000 
5106 102534,000 
5476 109964,000 
5550 111450,000 
6105 122595,000 
 
Table A2-3. Effective doses for different activity for stomach 
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Annex 3 
 
Administrated activity: 185 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 0.555 0.04 1.84 1.00 x10
-9
 
Colon 0.435 0.03 3.22 0.90 x10
-7
 
Ovary, gonads  0.133 0.01 1.62 0.80 x10
-8
 
Stomach   247.76 0.024 x10
-3
 
 
Administrated activity: 555 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 1.665 0.11 5.61 3.01 x10
-9
 
Colon 1.306 0.09 9.56 2.64 x10
-7
 
Ovary, gonads  0.400 0.02 4.83 2.43 x10
-8
 
Stomach   743 0.08 x10
-3
 
 
Administrated activity: 1813 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 5.439 0.33 16.56 1.007 x10
-8
 
Colon 4.268 0.27 31.01 7.54 x10
-7
 
Ovary, gonads  1.308 0.09 15.87 7.92 x10
-8
 
Stomach   2502 0.24 x10
-3
 
 
Administrated activity: 2423.5 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 7.271 0,48 22.02 0.14 x10
-7
 
Colon 5.705 0.36 42.07 0.11 x10
-5
 
Ovary, gonads  1.749 0,14 21,67 0.11 x10
-6
 
Stomach   3254.44 0.31 x10
-3
 
 
Administrated activity: 2516 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 7.548 0.46 22.66 0.14 x10
-7
 
Colon 5.923 0.37 43.27 0.11 x10
-5
 
Ovary, gonads  1.816 0.11 21.08 0.12 x10
-6
 
Stomach   3371.08 0.32 x10
-3
 
 
Administrated activity: 3515.7 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 10.547 0.64 32.05 0.21 x10
-7
 
Colon 8.276 0.51 60.09 0.16 x10
-5
 
Ovary, gonads  2.537 0.16 30.88 0.16 x10
-6
 
Stomach   4710.61 0.46 x10
-3
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Administrated activity: 4440 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 13.320 0.81 41.02 0.25 x10
-7
 
Colon 10.452 0.64 76.28 0.19 x10
-5
 
Ovary, gonads  3.142 0.21 39.82 0.25x10
-6
 
Stomach   5951 0.58 x10
-3
 
 
Administrated activity: 5476 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 16.050 1.01 48.34 0.31 x10
-7
 
Colon 13.009 0.78 94.34 0.23 x10
-5
 
Ovary, gonads  3.995 0.25 48.03 0.24 x10
-6
 
Stomach   7343.67 0.74 x10
-3
 
 
Administrated activity: 6105 MBq 
Organ H[µSv/s] H[mSv/1 min] E[µSv] Risk  
Bladder 18.315 1.12 55.08 0.34 x10
-7
 
Colon 14.372 0.87 103.61 0.26 x10
-5
 
Ovary, gonads  4.406 0.27 53.01 0.27 x10
-6
 
Stomach   8200 0.76 x10
-3
 
 
Administrated activity: 185 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 0.555 0.497 27.429 0.149 x10
-7
 
Bone surface 0.031 0.013 27.789x10
-5 
0.139 x10
-10
 
Colon 0.435 0.392 47.028 0.131 x10
-5
 
Liver 0.007 0.004 0.031 0.865 x10
-8
 
Lungs 0.001 0.001 0.016 1.007 x10
-8
 
Ovary, gonads  0.133 0.120 24.040 0.120 x10
-6
 
Skin 0.007 0.007 0.007 0.132 x10
-8
 
Stomach   3713.514 0.340 x10
-3
 
TOTAL    0.346 x10
-3
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Administrated activity: 370 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 1.110 0.994 54.858 0.298 x10
-7
 
Bone surface 0.062 0.026 55.601x10
-5 
0.278 x10
-10
 
Colon 0.871 0.800 94.061 0.262 x10
-5
 
Liver 0.014 0.008 0.062 1.736 x10
-8
 
Lungs 0.002 0.002 0.033 2.015 x10
-8
 
Ovary, gonads  0.267 0.241 48.079 0.241 x10
-6
 
Skin 0.014 0.014 0.014 0.265 x10
-8
 
Stomach   7427.062 0.681 x10
-3
 
TOTAL    0.693 x10
-3
 
 
Administrated activity: 555 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 1.665 1.492 82.288 0.448 x10
-7
 
Bone surface 0.094 0.040 83.367x10
-5 
0.418 x10
-10
 
Colon 1.306 1.176 141.084 0.396 x10
-5
 
Liver 0.022 0.013 0.096 2.596 x10
-8
 
Lungs 0.003 0.003 0.050 3.022x10
-8
 
Ovary, gonads  0.400 0.361 72.121 0.362 x10
-6
 
Skin 0.022 0.022 0.022 0.397 x10
-8
 
Stomach   11140.544 1.022 x10
-3
 
TOTAL    1.0384 x10
-3
 
 
Administrated activity: 1110 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 3.331 2.983 164.581 0.898 x10
-7
 
Bone surface 0.189 0.080 166.720x10
-5 
0.837 x10
-10
 
Colon 2.613 2.354 282.100 0.800 x10
-5
 
Liver 0.044 0.026 0.192 5.194 x10
-8
 
Lungs 0.006 0.006 0.102 6.046x10
-8
 
Ovary, gonads  0.794 0.724 144.244 0.724 x10
-6
 
Skin 0.044 0.044 0.044 0.800 x10
-8
 
Stomach   22281.091 2.045 x10
-3
 
TOTAL    2.0770 x10
-3
 
 
 
 
 
 
 
 
 
 
  151 
Administrated activity: 1813 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 5.439 4.876 244.02 1.465 x10
-7
 
Bone surface 0.302 0.124 272.44x10
-5 
1.362 x10
-10
 
Colon 4.268 3.842 461.06 1.112 x10
-5
 
Liver 0.063 0.036 0.282 8.477 x10
-8
 
Lungs 0.014 0.012 0.149 9.874 x10
-8
 
Ovary, gonads  1.308 1.176 235.69 1.176 x10
-6
 
Skin 0.072 0.065 0.065 1.299 x10
-8
 
Stomach   36407 3.337 x10
-3
 
TOTAL    3.389 x10
-3
 
 
Administrated activity: 2423.5 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 7.271 6.517 326.19 1.959 x10
-7
 
Bone surface 0.404 0.364 364.18x10
-5 
1.821 x10
-10
 
Colon 5.705 5.135 616.36 1.487 x10
-5
 
Liver 0.084 0.075 0.377 11.332 x10
-8
 
Lungs 0.018 0.017 0.199 13.198 x10
-8
 
Ovary, gonads  1.749 1.572 315.06 1.572 x10
-6
 
Skin 0.096 0.087 0.087 1.736 x10
-8
 
Stomach   48666.5 4.461 x10
-3
 
TOTAL    4.531 x10
-3
 
 
Administrated activity: 2516 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 7.548 6.766 338.64 2.033 x10
-7
 
Bone surface 0.420 0.378 378.08x10
-5 
1.890 x10
-10
 
Colon 5.923 5.331 639.88 1.544 x10
-5
 
Liver 0.087 0.078 0.391 11.764 x10
-8
 
Lungs 0.019 0.017 0.206 13.702 x10
-8
 
Ovary, gonads  1.816 1.632 327.08 1.632 x10
-6
 
Skin 0.100 0.091 0.090 1.802 x10
-8
 
Stomach   50524 4.631 x10
-3
 
TOTAL    4.704 x10
-3
 
 
 
 
 
 
 
 
 
 
  152 
Administrated activity: 2756.5 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 8.270 7.413 371.01 2.228 x10
-7
 
Bone surface 0.460 0.414 414.22x10
-5 
2.071 x10
-10
 
Colon 6.489 5.841 701.05 1.691 x10
-5
 
Liver 0.095 0.086 0.428 12.889 x10
-8
 
Lungs 0.021 0.019 0.226 15.012 x10
-8
 
Ovary, gonads  1.989 1.788 358.35 1.788 x10
-6
 
Skin 0.110 0.099 0.099 1.974 x10
-8
 
Stomach   55353.5 5.073 x10
-3
 
TOTAL    5.153 x10
-3
 
 
Administrated activity: 3009.3MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 9.029 8.093 405.07 2.432 x10
-7
 
Bone surface 0.509 0.452 452.25x10
-5 
2.261 x10
-10
 
Colon 7.085 6.377 765.41 1.846 x10
-5
 
Liver 0.104 0.094 0.468 14.072 x10
-8
 
Lungs 0.023 0.020 0.247 16.390 x10
-8
 
Ovary, gonads  2.172 1.952 391.25 1.952 x10
-6
 
Skin 0.120 0.108 0.108 2.156 x10
-8
 
Stomach   60435.62 5.539 x10
-3
 
TOTAL    5.626 x10
-3
 
 
Administrated activity: 3145 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 9.435 8.458 423.30 2.542 x10
-7
 
Bone surface 0.525 0.473 472.60x10
-5 
2.363 x10
-10
 
Colon 7.404 6.664 799.85 1.930 x10
-5
 
Liver 0.109 0.098 0.489 14.705 x10
-8
 
Lungs 0.024 0.021 0.258 17.128 x10
-8
 
Ovary, gonads  2.270 2.040 408.85 2.040 x10
-6
 
Skin 0.125 0.113 0.113 2.253 x10
-8
 
Stomach   63155 5.789 x10
-3
 
TOTAL    5.880 x10
-3
 
 
 
 
 
 
 
 
 
 
  153 
Administrated activity: 3237.5 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 9.599 8.5007 433.10 2.547 x10
-7
 
Bone surface 0.536 0.461 479.10x10
-5 
2.391 x10
-10
 
Colon 7.596 6.903 801.90 1.957 x10
-5
 
Liver 0.111 0.099 0.497 15.001 x10
-8
 
Lungs 0.025 0.022 0.262 17.773 x10
-8
 
Ovary, gonads  2.300 2.080 416.10 2.088 x10
-6
 
Skin 0.129 0.113 0.115 2.408 x10
-8
 
Stomach   65740.64 6.026 x10
-3
 
TOTAL    6.120 x10
-3
 
 
Administrated activity: 3349.25 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 9.885 8.856 443.10 2.550 x10
-7
 
Bone surface 0.546 0.406 489.10x10
-5 
2.441 x10
-10
 
Colon 7.896 7.001 819.90 1.977 x10
-5
 
Liver 0.115 0.100 0.501 15.409 x10
-8
 
Lungs 0.025 0.022 0.268 18.003 x10
-8
 
Ovary, gonads  2.398 2.101 426.10 2.100 x10
-6
 
Skin 0.135 0.113 0.117 2.318 x10
-8
 
Stomach   68727.5 6.163 x10
-3
 
TOTAL    6.260 x10
-3
 
 
Administrated activity: 3441 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 10.107 9.156 463.10 2.554 x10
-7
 
Bone surface 0.561 0.508 503.10x10
-5 
2.541 x10
-10
 
Colon 8.176 7.260 836.90 2.001 x10
-5
 
Liver 0.118 0.101 0.536 16.409 x10
-8
 
Lungs 0.026 0.023 0.278 18.669 x10
-8
 
Ovary, gonads  2.458 2.201 437.10 2.179 x10
-6
 
Skin 0.135 0.113 0.121 2.488 x10
-8
 
Stomach   69099 6.333 x10
-3
 
TOTAL    6.433 x10
-3
 
 
 
 
 
 
 
 
 
 
  154 
Administrated activity: 3515.7 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 10.547 9.454 473.20 2.841 x10
-7
 
Bone surface 0.586 0.528 528.31x10
-5 
2.642 x10
-10
 
Colon 8.276 7.450 894.14 2.157 x10
-5
 
Liver 0.122 0.109 0.546 16.439 x10
-8
 
Lungs 0.027 0.024 0.288 19.147 x10
-8
 
Ovary, gonads  2.537 2.281 457.05 2.281 x10
-6
 
Skin 0.140 0.126 0.126 2.518 x10
-8
 
Stomach   70599.9 6.471 x10
-3
 
TOTAL    6.573 x10
-3
 
 
Administrated activity: 3614.2 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 10.842 9.719 486.45 2.921 x10
-7
 
Bone surface 0.603 0.543 603.93x10
-5 
2.716 x10
-10
 
Colon 8.508 7.658 919.17 2.217 x10
-5
 
Liver 0.125 0.112 0.562 16.899 x10
-8
 
Lungs 0.027 0.025 0.296 19.683 x10
-8
 
Ovary, gonads  2.608 2.344 469.84 2.344 x10
-6
 
Skin 0.144 0.130 0.130 2.589x10
-8
 
Stomach   72576.24 6.652 x10
-3
 
TOTAL    6.757 x10
-3
 
 
Administrated activity: 3737 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 11.211 10.050 502.98 3.020 x10
-7
 
Bone surface 0.623 0.562 561.56x10
-5 
2.808 x10
-10
 
Colon 8.797 7.918 950.41 2.293 x10
-5
 
Liver 0.129 0.116 0.581 17.473 x10
-8
 
Lungs 0.028 0.026 0.306 20.352 x10
-8
 
Ovary, gonads  2.697 2.424 485.81 2.424 x10
-6
 
Skin 0.149 0.134 0.134 2.677x10
-8
 
Stomach   75043 6.878 x10
-3
 
TOTAL    6.986 x10
-3
 
 
 
 
 
 
 
 
 
 
  155 
Administrated activity: 3838 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 11.513 10.320 516.53 3.101 x10
-7
 
Bone surface 0.640 0.577 576.68x10
-5 
2.883 x10
-10
 
Colon 9.034 8.132 976.01 2.354 x10
-5
 
Liver 0.133 0.119 0.596 17.944 x10
-8
 
Lungs 0.029 0.026 0.314 20.900 x10
-8
 
Ovary, gonads  2.769 2.489 498.89 2.489 x10
-6
 
Skin 0.153 0.138 0.138 2.749x10
-8
 
Stomach   77063.96 7.063 x10
-3
 
TOTAL    7.174 x10
-3
 
 
Administrated activity: 3959MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 11.872 10.647 532.86 3.199 x10
-7
 
Bone surface 0.660 0.595 594.92x10
-5 
2.975 x10
-10
 
Colon 9.320 8.389 1006.87 2.429 x10
-5
 
Liver 0.137 0.123 0.615 18.511 x10
-8
 
Lungs 0.030 0.027 0.324 21.561 x10
-8
 
Ovary, gonads  2.857 2.568 514.67 2.568 x10
-6
 
Skin 0.157 0.142 0.142 2.836x10
-8
 
Stomach   79501 7.287 x10
-3
 
TOTAL    7.401 x10
-3
 
 
Administrated activity: 4033 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 12.099 10.846 542.82 3.259 x10
-7
 
Bone surface 0.673 0.606 606.04x10
-5 
3.030 x10
-10
 
Colon 9.494 8.546 1025.69 2.474x10
-5
 
Liver 0.140 0.125 0.627 18.857 x10
-8
 
Lungs 0.031 0.028 0.330 21.964 x10
-8
 
Ovary, gonads  2.910 2.616 524.29 2.616 x10
-6
 
Skin 0.160 0.145 0.145 2.889x10
-8
 
Stomach   80987 7.423 x10
-3
 
TOTAL    7.540 x10
-3
 
 
 
 
 
 
 
 
 
 
  156 
Administrated activity: 4440 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 13.320 11.940 597.6 3.588 x10
-7
 
Bone surface 0.740 0.667 667.20x10
-5 
3.336 x10
-10
 
Colon 10.452 9.408 1129.20 2.724 x10
-5
 
Liver 0.154 0.138 0.690 20.760 x10
-8
 
Lungs 0.034 0.030 0.364 24.180 x10
-8
 
Ovary, gonads  3.142 2.880 577.2 2.880x10
-6
 
Skin 0.176 0.160 0.160 3.180x10
-8
 
Stomach   89160 8.172 x10
-3
 
TOTAL    8.300 x10
-3
 
 
Administrated activity: 5106 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 15.620 14.004 650.60 4.004 x10
-7
 
Bone surface 0.856 0.767 767.20x10
-5 
3.836 x10
-10
 
Colon 12.452 10.408 1289.20 3.104 x10
-5
 
Liver 0.184 0.157 0.731 23.760 x10
-8
 
Lungs 0.040 0.032 0.400 28.180 x10
-8
 
Ovary, gonads  3.801 3.199 632.2 3.190x10
-6
 
Skin 0.204 0.182 0.188 3.378x10
-8
 
Stomach   102534 9.398 x10
-3
 
TOTAL    9.545 x10
-3
 
 
Administrated activity: 5476 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 16.050 14.825 709.88 4.385 x10
-7
 
Bone surface 0.920 0.809 799.00x10
-5 
4.00 x10
-10
 
Colon 13.009 11.260 1399.5 3.309 x10
-5
 
Liver 0.190 0.165 0.803 25.050 x10
-8
 
Lungs 0.041 0.036 0.405 29.625 x10
-8
 
Ovary, gonads  3.995 3.501 700.03 3.470 x10
-6
 
Skin 0.218 0.193 0.200 3.598x10
-8
 
Stomach   109964 10.079 x10
-3
 
TOTAL    10.237 x10
-3
 
 
 
 
 
 
 
 
 
 
  157 
Administrated activity: 5550 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 16.650 14.925 747.00 4.485 x10
-7
 
Bone surface 0.926 0.834 834.00x10
-5 
4.170 x10
-10
 
Colon 13.065 11.760 1411.5 3.405 x10
-5
 
Liver 0.192 0.173 0.863 25.950 x10
-8
 
Lungs 0.042 0.038 0.455 30.225 x10
-8
 
Ovary, gonads  4.005 3.600 721.5 3.600 x10
-6
 
Skin 0.221 0.200 0.220 3.975x10
-8
 
Stomach   111450 10.215 x10
-3
 
TOTAL    10.376 x10
-3
 
 
Administrated activity: 6105 MBq 
Organ H[µSv/s] H[mSv/15min] E[µSv] Risk  
Bladder 18.315 16.418 821.70 4.934 x10
-7
 
Bone surface 1.018 0.918 917.40x10
-5 
4.587 x10
-10
 
Colon 14.372 12.936 1552.65 3.746 x10
-5
 
Liver 0.211 0.190 0.949 28.545 x10
-8
 
Lungs 0.046 0.042 0.500 33.248 x10
-8
 
Ovary, gonads  4.406 3.960 793.65 3.960 x10
-6
 
Skin 0.243 0.220 0.220 4.373x10
-8
 
Stomach   122595 11.237 x10
-3
 
 
 
 
 
